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General introduction
The immune system can form a powerful defense mechanism against cancer. 
Besides protecting us from pathogens like viruses, bacteria, fungi and parasites, it also 
recognizes altered malignant cells from the own body. For an effective host immune 
defense, immunological recognition of the pathogen or malignant cell by immune 
effector systems is required. Additionally, immunological memory allows strong responses 
during subsequent exposure, and immune regulation is important to keep the 
immune system under control and prevent autoimmunity. However, in cancer patients 
the immune system is not capable to eliminate uncontrolled growth of malignant 
cells. This occurs when immune cells do not efficiently recognize altered tumor cells, 
and even when they do, tumor cells can suppress the immune systems effector 
functions by various means. Therefore, cancer immunotherapy aims to enhance 
existing and/or provoke new anti-tumor immune responses in order to destroy tumor 
cells more effectively. In this thesis, we aim to develop novel ways to improve anti- 
tumor T cell immunity via two different and possibly complementary strategies. First, 
by temporary inhibition of the AKT-pathway we aim to improve the efficacy of adoptive 
T cell-based immunotherapy. Secondly, by targeting a major immune-escape mechanism 
of tumor cells we aim to enhance tumor antigen-specific T cell responses in the local 
tumor microenvironment.
Cancer
Cancer is a group of neoplastic diseases characterized by unregulated cell growth 
and tumor cell invasion and metastasis, which forms the major cause of cancer deaths. 
Malignant cells require the trait of sustained proliferative signaling as a consequence 
of genetic mutations. For example, acquired mutations in growth factor pathways 
result in growth factor independence.1 Also, the capacity to modify cellular metabolism 
may enhance neoplastic proliferation. Additionally, cancer cells no longer respond to 
growth inhibitory signals and do not undergo apoptosis in response to DNA damage. 
The last characteristic is often associated with a loss of the tumor suppressor gene 
TP53, which normally senses DNA damage and induces apoptosis.2 Another hallmark 
of cancer is replicative immortality. Normal cells have a limited number of cell growth- 
and-division-cycles, regulated by telomers which are shortened with every cell cycle. 
In contrast, cancer cells maintain the length of their telomers resulting in unlimited 
replicative potential.1 Especially in solid tumors, the capacity of cancer cells to induce 
angiogenesis is crucial for sustained nutrient supply. And last but not least, the immune 
system may play a role in at least two ways. Malignant cells can be supported by 
innate immune cell induced inflammation and secondly, malignant cells develop 
many ways to evade immune destruction by T and B lymphocytes, macrophages and 
natural killer (NK) cells.1,3-5
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Tumor resection via surgery, chemotherapy, radiation therapy, targeted therapy, or a 
combination of these, form in most cases the first line treatment for cancer patients. 
Chemotherapy induces extensive DNA damage which triggers apoptosis or blocks 
DNA synthesis in rapidly dividing cancer cells. Radiation therapy also induces DNA 
damage by generating reactive oxygen species in the irradiated cells. Additionally, 
targeted therapies interact with particular proteins associated with tumor development 
and progression, for example tyrosine kinase inhibitors for the treatment of chronic 
myeloid leukemia (CML) and FLT3 or IDH inhibitors for the treatment of acute myeloid 
leukemia (AML).6,7 These conventional therapies can be very effective, but when cells 
acquire drug resistance, additional therapies are needed. In the last decade, 
immunotherapy has taken its place in cancer therapy by demonstrating that it can be 
a powerful strategy to eradicate remaining and conventional therapy refractory tumor 
cells.
Allogeneic stem cell transplantation
One of the oldest successful forms of cellular immunotherapy for the treatment of 
patients with hematological cancers is allogeneic stem cell transplantation (allo-SCT). 
This therapy was originally developed to make high dose chemo- and radiation 
therapy possible as this almost completely eradicates the patient’s hematopoietic 
system. Allo-SCT after high intensity chemo- and/or radiation therapy substitutes the 
patient’s immune system with healthy donor hematopoietic stem cells. These stem 
cells form a new hematopoietic system including the immune system and prevent 
long term bone marrow aplasia. Later, additional treatment benefits were observed 
by donor lymphocyte infusions, consisting of both T cells and NK cells originating 
from the same stem cell donor. The allogeneic immune effector cells recognize 
remaining malignant cells of the patient’s hematopoietic system as non-self, resulting 
in eradication of these cells.8-10 On the other hand, there is also risk to develop life 
threatening graft-versus-host disease (GVHD) when donor lymphocytes develop 
immune responses against healthy tissues of the patient.11 
 To minimize risks of GVHD or graft rejection, it is important that the human 
leukocyte antigen (HLA) genotype of donor and patient are matched. HLA molecules 
are encoded by the major histocompatibility complex (MHC) class I and II genes 
located at chromosome 6. MHC class I (HLA-A, HLA-B, HLA-C) molecules are 
expressed on all nucleated cells of the body, while MHC class II (HLA-DR, HLA-DP, 
HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ) molecules are expressed mainly on 
antigen presenting cells of the hematopoietic system including dendritic cells (DCs), 
macrophages and B cells. Intracellular cytoplasm-derived peptides are presented by 
MHC class I and recognized by CD8+ T cells, while endocytosed extracellular 
peptides are presented by MHC class II and recognized by CD4+ T cells. Antigen 
presenting cells also have the capacity to cross-present endocytosed peptides on 
11
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MHC class I to facilitate CD8+ T cell cross-priming towards for example tumor-
antigens.12-14 Matching HLA genotype between donor and recipient limits the risk to 
evoke CD8+ cytotoxic T cell immune responses against allogeneic MHC class I on 
healthy tissues. However, in a full HLA-matched setting still differences in minor 
 histocompatibility antigens (MiHAs) can be present that evoke donor T cell responses. 
These MiHAs are derived from polymorphic genes that differ between patient and 
donor.15,16 Some of the known MiHAs are restricted to the hematopoietic system and 
form a powerful tool for the induction of selective graft-versus-tumor (GVT) responses 
by the donor immune system. The best characterized hemato-restricted MiHAs 
include HA-1, HA-2, LRH-1, ARHGDIB and UTA2-1.17 Detection of MiHA-specific T cell 
responses after allo-SCT, as a consequence of a MiHA-mismatch between donor 
and patient, has been associated with improved relapse-free survival.18 This provided 
the rationale for further boosting of MiHA-specific T cell responses by additional 
 immunotherapeutic strategies, such as vaccination or adoptive T cell approaches.
 While allo-SCT can be curative, the GVT response is still in many cases not 
effective enough to eliminate all tumor cells causing relapse. Furthermore, also 
partially matched HLA haplo-identical transplantations are performed in combination 
with allo-reactive T cell depletion in vivo.19 Especially, T cell depletion is necessary to 
prevent severe GVHD in this partially-matched setting, but this will also diminish the 
potentially curative GVT immunity. Therefore, additional immunotherapies are 
developed to boost specifically GVT immunity in the post-SCT setting. Furthermore, 
bridge-to-transplant immunotherapy approaches are being developed to eradicate 
chemotherapy-refractory disease and reduce tumor load before allogeneic SCT in 
high-risk patients.
Adoptive T cell therapy
One of the strategies to enhance anti-tumor immune responses is to infuse ex vivo 
expanded tumor-targeting T cells. CD8+ cytotoxic T lymphocytes (CTL) are effective 
immune cells that target and kill tumor cells directly upon recognition of antigenic 
peptides presented by tumor cells. Activated antigen-specific CD8+ CTL form an 
immunological synapse with their target cells and release perforin and granzyme 
molecules inducing tumor cell death. Furthermore, TNF-related apoptosis-inducing 
ligand (TRAIL) and FAS ligands on these CTL interact with receptors of the tumor 
cells inducing apoptosis. In addition, cytokines such as interferon gamma (IFNγ), 
interleukin (IL)2 and tumor-necrosis factor alpha (TNFα) are secreted enhancing 
tumor cell killing and other immune effector mechanisms.20
 Adoptive T cell therapy in the form of donor lymphocyte infusion (DLI) is used 
already for some time in the post allo-SCT setting.21,22 DLI consists of uncultured and 
unselected leukocytes from the donor, containing only a limited number of tumor- 
reactive T cells that can evoke anti-tumor responses and thereby boost GVT immunity. 
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Furthermore, because not only tumor-reactive T cells are infused, there is a high risk 
to induce GVHD. While, post-transplantation DLI has been associated with increased 
overall survival without initiating GVHD in patients with CML it was less effective in 
acute leukemia and non-hodgkin lymphoma.23,24 Because of limited efficacy and 
reasonable high chances to induce GVHD, it is important to develop adoptive T cell 
therapy consisting of primarily tumor-reactive T cells. Different strategies can be used 
for the generation of tumor-targeting T cells including expanded endogenous T cells, 
T cell receptor (TCR) or chimeric antigen receptor (CAR) engineered T cells or tumor 
infiltrating lymphocyte (TIL) therapy (Figure 1).
Expanded endogenous T cells
In case of post-allo-SCT adoptive T cell therapy, a mismatch in hematopoietic- 
restricted MiHA can be used to direct selective anti-tumor immunity. MiHA-specific 
CD8+ T cells can be efficiently expanded from the naïve repertoire by culturing donor 
T cells with MiHA-peptide loaded autologous antigen presenting cells (e.g. DCs). 
After a period of ex vivo expansion, the MiHA-specific T cells can be given to the 
patient where they can boost the GVT response post-allo-SCT. Besides expansion of 
MiHA-specific T cells, this strategy can also be used to expand T cells specific for 
tumor-associated antigenic peptides derived from selectively (over)expressed 
proteins. This makes it also possible to treat patients outside the post-allo-SCT 
setting or with non-hematological malignancies.25,26 For example, tumor-antigen 
Wilms Tumor 1 (WT-1) reactive CD8+ T cells have shown to be effective in leukemia 
patients and Melanoma Antigen Recognized by T cells 1 (MART1)-reactive T cells for 
melanoma.27,28 Furthermore, endogenous T cell therapy has also shown efficacy in 
clinical trials for patients with refractory metastatic melanoma and other solid 
tumors.29 
 Besides priming from the naïve repertoire, another strategy for expanded endogenous 
T cell therapy is ex vivo culturing of circulating or infiltrated CTL-clones from the 
patient’s tumor environment and subsequent reinfusion.30 For this, patient-derived T 
cells are plated in a limiting dilution assay, followed by screening of tumor-antigen 
reactivity. These specific clones are subsequently expanded thousands fold in 2-4 
weeks by stimulation with irradiated feeder cells, a TCR trigger like anti-CD3 and 
cytokine support by IL2. Adoptive transfer of CTL clones specific for MiHAs, and 
melanoma-associated antigens MART-1 or gp100 showed tumor regression and 
persistence of tumor-specific T cells beyond day 42.31,32 The advantage of ‘naturally’ 
occurring antigen-specific T cells might be lower risk to develop autoimmune 
diseases as compared to engineered T cells with enhanced affinities.33 However, 
applicability of endogenous T cell therapy may be limited because of the required 
expertise, time-consuming manufacturing procedures and limited success rate for 
the production of patient- and  tumor-specific T cell products for each patient.20
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Chapter 1
TCR- and CAR-engineered T cell therapy
Another strategy is genetic modification of T cells with a T cell receptor (TCR) of 
interest. This can be a TCR specifically recognizing the MiHAs on patient’s 
hematopoietic cells, or other tumor-associated antigens for the treatment of patients 
outside the allo-SCT setting. To generate these cells, TCRα and β chains of interest 
can be sequenced, cloned and packaged in viral vectors to transduce T cells of the 
patient or donor.34 Additionally, also receptors from innate-like immune cells including 
γδT cells and NK cells can be cloned and transduced, which can recognize malignant 
cells via different mechanisms.35,36 Initially, only retroviral vectors were used but later 
also lentiviruses were applied to allow efficient delivery in slowly or non-dividing T 
cells. Additionally, transposon-based technology is developed which circumvents 
the use of viral vectors.33 One of the challenges in the TCR-transduced T cell field is 
preventing mispairing of the α and β chains with endogenous TCRs, as this can result 
in new specificities potentially targeting and destructing healthy cells.37,38 Unwanted 
pairing can be prevented by modifying the TCR sequence or knockdown of 
endogenous TCRs with siRNAs.39-41 Another challenge is increasing the binding 
properties of TCR:MHC complex without inducing cross-reactivity.29,42 Naturally 
occurring TCRs specific for self-antigens have often low avidity because high avidity 
T cells are deleted during thymic selection to avoid autoimmunity (also described in 
Chapter 2). Specific mutations may increase TCR affinity, as well as induction of 
 antigen-specific T cells from an allogeneic donor, however this increases also the 
chance to be deleted in the thymus and/or might induce autoimmune toxicities.43-46 
 Importantly, some good initial responses have been found for the treatment of 
patients with TCR-transduced T cells. WT1 TCR-transduced T cells showed tumor-re-
activity in patients with AML and myelodysplastic syndrome (MDS).47 Furthermore, 
MAGE-A4 and NY-ESO-1 TCR-transduced T cells showed clinical efficacy and T cell 
persistence.48-50 Nevertheless, adoptive transfer with TCR-transduced T cells is often 
associated with tumor relapses within some months after therapy.48,50,51 One study 
described a change in cytokine secretion profile of TCR- transduced T cells, whereby 
a Th2-type profile and therefore lack of cytotoxic functions were observed at time of 
tumor relapse.52 
 Besides genetically engineering the TCR, another successful strategy is 
transduction of T cells with a chimeric antigen receptor (CAR). These antibody-based 
receptors recognize surface antigens on tumor cells independent of antigen-presen-
tation in MHC molecules. This can be an advantage as one of the tumor escape 
mechanisms of tumor cells from the T cell mediated attack is the downregulation of 
MHC molecules.53 A CAR consists of a single chain variable fragment (scFv), derived 
from the VH and VL sequences of a monoclonal antibody. This is fused via a 
transmembrane domain to a CD3ζ intracellular signaling domain resulting T cell 
activation upon antibody binding. With the second and third generation CAR T cells, 
more signaling domains are included like CD28, 4-1BB, OX-40 and/or CD27 to 
enhance T cell activation and persistence.34,54 Additionally, to improve safety of CAR 
15
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T cell therapies, suicide genes may be incorporated in the form of inducible caspase 
9 fused to a binding protein (FKBP). A small molecule pharmaceutical (AP1903) 
induces dimerization and activation of caspase 9, resulting in selective apoptosis of 
the CAR T cells.55,56 This is important, because commonly seen toxicities in CAR T 
cell therapy are cytokine release syndrome and neurotoxicity, which can be life 
threatening. Nevertheless, steroid and IL6-receptor antibody treatment (tocilizumab) 
are often sufficient to treat the cytokine release syndrome.57 
 The development of T cells engineered with a CAR specific for CD19 showed 
impressive complete remissions and durable long-term remission and survival in 
patients with B cell malignancies.58-62 This therapy has rapidly evolved and led to 
FDA and EMA approval for the treatment of pediatric B cell acute leukemia in 
2016-2017, and for relapsed/refractory diffuse large cell B cell lymphoma in 2018. 
Furthermore, CAR T cells targeting B cell maturation antigen (BCMA) have shown 
promising clinical responses in multiple myeloma (MM).63,64 CAR T cell therapy for 
solid tumors has shown to be more challenging, in the first place because of 
difficulties to define candidate surface molecules on tumor cells that do not cause 
severe toxicity to normal tissues. For instance, αGD2-CAR T cells have been 
developed for the treatment of neuroblastoma, and although antitumor efficacy was 
observed, this was also associated with severe toxicities towards the central nervous 
system.65,66 Also HER2 CAR T cells have shown promising pre-clinical results, and 
clinical benefit in a phase I trial for patients with progressive glioblastoma.67-69 
Besides difficulties in finding tumor-selective antigens, another difficulty is successful 
trafficking of T cells into solid tumor sides, as well as effective T cell function in a 
hostile tumor microenvironment. 
TIL therapy
Interestingly, in immunogenic solid tumors, tumor-targeting T cells are often infiltrated 
in the tumor, though not capable to fully eliminate all malignant cells. Immunogenicity 
of a tumor type is dependent on the ability to stimulate immune responses. When 
mutations or oncolytic viruses that change peptide sequences result in presentation 
of new (neo)antigens, tumors become immunogenic to the adaptive immune system. 
The neoantigens can activate T cells and induce T cell infiltration.70 After surgical 
removal of the tumor, tumor infiltrating lymphocytes (TILs) can be isolated, ex vivo 
expanded and given back to the patient as adoptive cell therapy.71 Additionally, also 
the isolation and ex vivo expansion of bone marrow-infiltrating lymphocytes (MILs) is 
investigated for the treatment of MM.72 The first approach of TIL therapy has been 
developed 30 years ago for the treatment of metastatic melanoma.73 Tumor fragments 
were digested and cultured ex vivo with high dose IL2 (6,000U/ml) for 7-8 weeks. 
Additionally, TILs were infused together with high-dose IL2. While tumor reduction 
was observed, it was often accompanied with severe IL2- and other effector cyto-
kine-related toxicities.73,74 To reduce IL2-related toxicities, lymphodepletion was 
incorporated in some studies prior to TIL infusion. Besides depleting patient’s 
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lymphocytes, a combination of cyclophosphamide and fludarabine (Cy/Flu) also led 
to homeostatic bioavailability of IL7 and IL15 that supports growth and persistence of 
the infused TILs.75 A downside of Cy/Flu conditioning is the reduction of the normal 
immune repertoire and number of granulocytes, which increases the risk of infections. 
Therefore, also autologous SCT is sometimes included to repopulate the normal 
immune repertoire. Lymphodepletion followed by TIL and high-dose IL2 therapy 
resulted in response rates in 50-70% of the melanoma patients.75 Unfortunately, 
in this study only 40% of all TIL products met the requirements of expansion and 
reactivity ex vivo and could be adoptively transferred to the patient. Therefore, 
a shorter culture protocol was developed in which TIL were expanded for a shorter 
duration of 4-5 weeks. Furthermore, exclusion criteria of in vitro activity were eliminated, 
resulting in successful expansion and infusion in more than 70% of cases.76,77 
This TIL therapy showed durable and complete responses for cutaneous and uveal 
melanoma, breast, ovarian, colorectal cancer, and human papillomavirus (HPV)- 
associated cancers.29,78-80 However, a main restriction in TIL therapy is formed by 
the necessity to have relatively large tumors, which are infiltrated with TILs. 
 While adoptive T cell therapy can be generated via different strategies, their efficacy 
is in all cases associated with specific T cell characteristics. To get more insight in 
the most effective T cell traits for the induction of anti-tumor responses, first basic 
concepts in T cell activation and differentiation are introduced.
T cell activation and differentiation
T cells develop in the thymus, were they subsequently undergo positive and negative 
selection resulting in (mainly) single-positive CD4+ and CD8+ T cells and absence of 
high-affinity interactions with self-antigens (see Chapter 2). Thereafter, T cells are 
released in the bloodstream and circulate through blood and lymphoid tissues as 
naïve T cells (TN), until they encounter a T cell-activating antigen with their TCR. T cell 
activation and subsequent proliferation and differentiation requires peptide:MHC 
complexes presented on APCs, either MHC class I or class II complexes to activate 
CD8+ or CD4+ T cells, respectively (Figure 2). Additionally, T cell activation requires 
co-stimulatory signaling induced by interaction of co-stimulatory molecules on antigen 
presenting cells with its receptors on T cells. A third signal required for adequate T 
cell activation is stimulation via supporting cytokines. Moreover, these cytokines also 
control the differentiation into specific T cell subsets.  
 Interaction of T cells and DCs, the most important APC, takes place in peripheral 
lymphoid tissues including lymph node and spleen but also in tissues. TN cells highly 
express L-selectin (CD62L) and CCR7 which are required for migration from the 
bloodstream into lymphoid tissues. CD28 on TN facilitates co-stimulation via 
interaction with B7 molecules (B7.1; CD80 and B7.2; CD86) expressed by APCs. In 
addition, co-stimulation can also occur via CD27, 4-1BB (CD137) or OX40 expression 
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on T cells, interacting with CD70, 4-1BBL and OX40L on APCs, respectively. T cell 
activation by peptide:MHC complexes in absence of co-stimulatory signaling results 
in T cell tolerance or anergy. This is an important mechanism to prevent autoimmune 
responses to self-peptides presented by MHC-molecules on healthy cells. 
 Upon activation, CD8+ TN and CD4+ TN cells differentiate into stem cell memory 
(TSCM), central memory T (TCM) cells, effector memory T (TEM) cells and effector T 
(TEFF) cells (Figure 2).81,82 These different effector/memory subsets have differential 
functional traits. Additionally, CD4+ T cell can be subdivided in T helper (TH)1, TH2, 
TH9, TH17, TH22, follicular helper (TFH) and regulatory T cells (Treg), and CD8+ T cells 
in cytotoxic T (TC)1, TC2, TC9, TC17 and CD8+ Tregs. These subdivisions are based on 
expression of extracellular markers, intracellular transcription profiles and the cytokine 
production profile (described in more detail in Chapter 2). CD8+ cytotoxic T cells are 
crucial to kill cells infected with intracellular pathogens like viruses, as well as cells 
that present altered-self tumor/neo antigens in MHC class I complexes. While CD8+ 
T cells are the main effectors of adaptive anti-tumor responses, CD4+ T cells can 
provide important help by secretion of cytokines and interaction with antigen presenting 
cells resulting in enhanced T cell priming.83 It has been described that combined 
adoptive transfer of CD4+ TN or TCM improves CD8+ CAR T cell efficacy in mice.84
 Memory T cells are known for their capacity to induce fast immune responses 
after antigen re-exposure. Upon antigen recall, memory T cells show high proliferative 
capacity and can differentiate into effector cells. However, with acquiring effector 
functions, antigen experienced T cells loose proliferative capacity (Figure 2). The 
specific subset of TSCM cells is known to have stem cell properties including 
self-renewal capacity, meaning that they can replicate while preserving their TSCM 
phenotype. Furthermore, TSCM cells have an increased proliferative capacity and 
superior anti-tumor efficacy compared to TCM and TEM subsets.85 Importantly, 
specifically  TSCM cells are known to persist long term in the host.86
Figure 2 | T cell activation and differentiation. CD4+ and CD8+ T cells are activated by 
interaction of the T cell receptor with MHC class I or II complexes, together with co-stimulatory 
molecule signaling and cytokine stimulation. After activation naïve T cells (TN) differentiate in 
stem cell memory (TSCM), central memory (TCM), effector memory (TEM) and effector T cells (TEFF). 
Upon differentiation, cells acquire effector functions but loose proliferative and self-renewal 
capacity.
TN TSCM TCM TEM TEFF
Proliferation
Self-renewal
Eector function
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Importance of early memory T cells
While adoptive T cell therapy can be generated via many different strategies, similar 
determinants are found to be important for clinical efficacy. In endogenous T cell 
therapy as well as CAR-transduced and TIL therapy, clinical responses correlate with 
the early memory characteristics of adoptively transferred tumor-reactive T cells. 87,88 
This early memory phenotype is associated with better in vivo persistence of 
transferred T cells, where the duration of T cell persistence is correlated with clinical 
responses.65,76,88 In animal studies, a direct comparison of adoptive T cell transfer of 
TCM versus further differentiated TEM revealed that TCM cells are indeed responsible 
for persistent T cell memory.89 Furthermore, treatment with TSCM and TCM cells results 
in better anti-tumor efficacy in vivo compared to TEM cells.85 
 In patients, adoptive therapy with CTLs showed that persistent T cells are derived 
from a very low frequency clonotype with survival advantages, most likely form the 
naïve repertoire.90 Additionally, persistent CTLs can also acquire a TCM phenotype 
expressing CD28, CD127, CD62L and CCR7.32 These clones can persist up to 2 years 
and induced tumor regression, and even continuous clinical remission in one patient. 
Also in neuroblastoma patients treated with anti-GD2 CAR T cells, persistence was 
associated with the presence of TCM CD8+ T cells.65 Furthermore, in TIL therapy 
CD28+ T cells showed better in vivo persistence compared to CD28- T cells.91 
 Together this shows that early memory T cell characteristics were associated 
with better persistence and treatment outcome. As a consequence, different strategies 
have been developed to limit T cell differentiation during the ex vivo T cell expansion 
prior to infusion. Different strategies can be used to preserve T cell differentiation, for 
example by reducing the activation stimulus, by changing the supporting cytokines 
in the culture or by inhibition of specific pathways involved in T cell differentiation. For 
example in a study generating CAR T cells, anti-CD3/28 beads induced less T cell 
differentiation as compared to anti-CD3 (OKT3).92 By using specific cytokine cocktails 
like a combination of IL7 and IL15 instead of high dose IL2, more tumor-specific TSCM 
cells were obtained, which showed superior in vivo expansion and possibly 
self-renewal characteristics.93 Also, addition of IL-21 to the ex vivo culture procedure 
resulted in TCM cells and extended persistence in vivo.27,94 In other studies, cytokines 
IL12, IL7 and IL21 were combined and associated with preserved T cell differentia-
tion.95 Another strategy is modification of T cell metabolism with antioxidants which 
hindered terminal differentiation while allowing expansion and generation of TSCM 
cells.96 Furthermore, pharmacological inhibition of the Wnt-signaling pathway has 
shown to arrest effector T cell differentiation, though limits ex vivo proliferation.97 
Alternatively, we and others showed that inhibition of AKT signaling facilitates the 
generation of CD8+ TSCM-like cells with polyfunctional characteristics (see Chapter 3 
and 4).98-100 Furthermore, AKT-inhibition preserved CD4+ T cell effector memory 
differentiation as well as influenced T-helper subset differentiation (Chapter 4).
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AKT signaling-pathway
The phosphatidylinositol-3-kinase(PI3K)/AKT-pathway plays a pivotal role in several 
cellular processes including cell survival and proliferation. Furthermore, TCR and 
cytokine stimulation activates the PI3K/AKT signaling pathway in T cells.101 PI3Ks are 
heterodimers composed of a catalytic subunit (p110) and an adaptor/regulatory 
subunit (p85) (Figure 3). Upon activation, PI3K phosphorylates phosphatidylinosi-
tol-4,5-biphosphate (PIP2) into PIP3, and this can be reversed by tumor suppressor 
gene PTEN. Additionally, the AKT phosphorylation can be induced via activation of 
one of the isoforms of AKT, also known as (Protein Kinase B (PKB)): AKT1/PKBα, 
AKT2/PKBβ and AKT3/PKBγ. AKT has a N-terminal pleckstrin-homology (PH) domain 
which interacts directly with PIP3 resulting in recruitment of AKT to the plasma 
membrane. Additionally, kinase domain Threonine 308 (Thr308) and Serine 473 
(Ser473) can be phosphorylated by phosphoinositide-dependent kinase 1 (PDK1) 
and mammalian target of rapamycin complex (mTOR)C2, respectively.102-105 
 Phosphorylation of AKT on Thr308 is necessary and also sufficient for AKT activation, 
but additional phosphorylation at Ser473 maximizes AKT activation.106,107 Activated 
AKT eventually induces downstream mTORC1 phosphorylation.
Figure 3 | PI3K-AKT-mTOR signaling in cells. T cell activation induces PI3K/AKT-signaling. 
First, PIP2 is phosphorylated (resulting in PIP3), followed by PH-domain directed recruitment of 
AKT  to the plasma membrane and subsequent phosphorylation of the Thr308 phosphorylation 
side. Additionally, mTORC2 phosphorylates the Ser473 domain. Phosphorylated, and thereby 
activated AKT induces phosphorylation of mTORC1 which has a negative feedback interaction 
with PI3K to balance AKT-signaling. Furthermore, tumor-suppressor PTEN dephosphorylates 
PIP3 to inhibit AKT-signaling. Pharmacological inhibition of the pathway can amongst others be 
obtained by allosteric AKT-inhibitors which prevent interaction of the PH-domain with the 
plasma membrane, by ATP-competitive AKT-inhibitors which bind the phosphorylation side of 
AKT, or by rapamycin which inhibits downstream signaling of mTORC1.
PI3K
PIP2 PIP3
PTEN
AKT
mTORC1
mTORC2
Proliferation
T cell dierentiation
Glucose metabolism
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In T cells, AKT-signaling is directly involved in T cell differentiation via AKT1 and 
AKT2.108 The strength of TCR signaling in combination with costimulatory molecule 
and cytokine receptor signaling determines the magnitude of AKT activation, resulting 
in more or less effector T cell differentiation.109. AKT signaling promotes downstream 
mTORC1 phosphorylation and reduces expression of early memory associated 
transcription factors, while increasing effector T cell associated factors.110 AKT- 
signaling regulated differentiation of TN towards TEM/EFF T cells is associated with a 
reduction of transcription factor levels for T cell factor 7 (TCF7), lymphoid enhancer- 
binding factor 1 (LEF1), Kruppel-like factor (KLF) family members, Forkhead box P1 
(FOXP1) and inhibitor of DNA-binding (ID)3. Other transcription factors are up 
regulated, including ID2, eomesodermin (EOMES), T-box 21 (TBX21, also known 
T-BET), PR domain-containing 1 with ZF domain (PRDM1, also known as BLIMP-1) 
and zinc finger E-box binding homeobox 2 (ZEB2) (Chapter 2).111  Furthermore, AKT 
signaling directly promotes effector cytokines like IFNγ, and reduces the expression 
of early-memory associated cytokine receptors like IL7Rα.112 Moreover, deletion of 
PTEN has shown to strongly suppress the development and survival of memory 
CD8+ T cells by repressing IL7 and IL15 receptor expression.113 Besides differentiation, 
also CD8+ T cell metabolism is regulated via Akt-related kinases like PDK1.114 
Furthermore, AKT is described to be a signal integrator that links other involved 
pathways including FOXO, mTOR and Wnt/β-catenin, emphasizing the important role 
of AKT-signaling in activated T cells.109 
AKT-inhibitors
Because the PI3K/AKT/mTOR signaling pathway is upregulated in some cancers, 
resulting in enhanced proliferation and survival, AKT-inhibitors are under clinical 
development as anti-cancer drug. The PI3K/AKT/mTOR signaling pathway is 
connected to several other pathways and controlled by multiple feedback loops. As 
a consequence, for example inhibition of the AKT downstream target mTORC1 by 
Rapamycin results in less inhibition of PI3K by mTOR, and thereby possibly more 
PI3K/AKT signaling (Figure 3).115,116 Direct inhibition of AKT is also possible with 
either allosteric or ATP-competitive AKT-inhibitors. Allosteric AKT-inhibitors bind the 
PH domain of AKT and prevent its binding to PIP3 and subsequent phosphorylation 
of Thr308 and Ser473. ATP-competitive inhibitors bind the ATP binding side to prevent 
AKT phosphorylation in a more direct way.117,118 Table 1 gives an overview of the 
clinical development of both type of AKT-inhibitors suitable for good manufacturing 
practices (GMP)-grade manufacturing of adoptive T cell immunotherapy products. 
Specific characteristics of each inhibitor are described in Chapter 3 in more detail, 
where these AKT-inhibitors were investigated for their capacity to preserve effector 
memory differentiation.
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Chapter 1
Allosteric AKT-inhibitor MK-2206 is one of the AKT-inhibitors which has been 
extensively studied for its direct anti-tumor effects. Clinical studies showed that while 
it was well tolerated, patient benefit was minimal.132,133 In a Phase II study with PIK3CA 
mutant breast cancer patients, reduced AKT phosphorylation was observed after 
treatment with MK-2206. However, no suppression of proliferation or induction of 
apoptosis of tumor cells was found.119 On the other hand, a phase I/II trial, treatment 
with MK-2206 in combination with chemoimmunotherapy (bendamustine and 
rituximab) was associated with clinical remission in 38% of treated refractory chronic 
lymphocytic leukemia patients.120 They did however not compare this effect to 
treatment with chemoimmunotherapy alone, hence the effect cannot be subscribed 
to MK-2206 yet. Additionally, a phase II trial of Oki et al. (2015) showed modest activity 
in patients with Hodgkin lymphoma, with a overall response rate of 20%.121 The other 
allosteric AKT-inhibitor Triciribine has so far only been investigated in phase I trials, 
where it was well tolerated and associated with reduced phosphorylation of AKT.123,124 
Treatment with AZD5363 or GDC-0068 was also found to be safe, and showed 
important preliminary evidence of antitumor activity in patients with solid 
tumors.125,126,128 Also GSK2110183 showed tolerability with an intermittent dose 
schedule, and importantly one partial response and some stable diseases were 
observed.129 On the other hand, a recent phase II trial with GSK2141795 did not yield 
clinical benefit in NRAS-mutant or wild-type melanoma in combination with trametinib 
treatment (MEK inhibitor).131 Because most AKT-inhibitors are still in phase I/II trials, 
clinical efficacy and direct anti-tumor effects have yet to be proven. 
 Noteworthy, while AKT signaling is known to affect T cell differentiation and T 
cells are an important player in anti-tumor immunity, effects of in vivo AKT-inhibition 
on T cells are not reported in clinical studies so far. In mouse studies, in vivo mTORC1 
and PI3K-inhibition has been associated with increased number of memory T cells, 
improved expansion upon antigen recall and diminished tumor growth.134-137 Since 
multiple AKT-inhibitors are under clinical development, this may provide possibilities 
for in vivo enhancement of T cell mediated anti-tumor responses. Therefore, we 
explored in Chapter 5 the possibility to improve T cell functionality by in vivo 
AKT-inhibition in mice.
Adaptive T cell resistance
Besides effector memory differentiation, also other factors affect the functional traits 
of T cells in vivo. This can be caused by T cell intrinsic factors but also by extrinsic 
factors in the tumor microenvironment. Here, both natural occurring tumor-specific T 
cells, as well as adoptively transferred T cells can acquire adaptive T cell resistance, 
as they are subject to endogenous immune suppression in the host tumor microen-
vironment. The tumor microenvironment can contain many immunosuppressive 
factors that can limit effective anti-tumor immune responses.138-140 Especially in solid 
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tumors, different factors limit the accessibility of tumor cells for T cells. Changed 
chemokine expression results in impaired T cell trafficking towards tumor sites and 
additionally, collagen deposits and abnormal vasculature can form a physical barrier. 
Furthermore, the anaerobic glucose-poor environment in a tumor makes T cells less 
functional, since effector T cells largely depend on glucose.141 Additionally, 
suppressive immune cells like CD4+ Tregs cells are attracted to suppress anti-tumor 
immune responses.142 These Tregs inhibit anti-tumor efficacy by secreting inhibitory 
cytokines such as IL10, IL35, and TGFβ or by direct cell contact.143 Besides Tregs 
also specific recruitment of neutrophils and myeloid derived suppressor cells in the 
tumor microenvironment suppresses CD8-mediated anti-tumor immunity.4,144 
 Furthermore, T cells balance their own immune responses by upregulation of 
co-inhibitory receptors.  CTLA-4 is upregulated on T cells upon activation to regulate 
contraction of the expanded population. When CTLA-4 on T cells binds co-stimulatory 
molecules CD80 or CD86 on APCs, this triggers signaling inhibition resulting in T cell 
inactivation.145 T cell activation also induces PD1 expression on T cells and when this 
receptor interacts with PD-L1 or PD-L2 on tumor cells or APCs, this suppresses T cell 
responses. High expression of these co-inhibitory ligands has been associated with 
poor prognosis.146 Besides PD1, tumor reactive CD8+ T cells of relapsed patients 
after allo-SCT co-expressed also increased levels of the co-inhibitory receptor TIGIT 
which interacts with CD122 and CD115 on APCs, T cells and tumor cells.147,148
 Lymphodepletion by using Cy/Flu based regimens pre-T cell infusion is one 
approach to reduce the immune suppressive environment and to facilitate in vivo 
expansion of T cells after adoptive transfer. Additional administration of IL2 and/or 
IL15 can further promote expansion and persistence of T cells.20 Furthermore, 
specific targeting of co-inhibitory receptors and/or ligands to allow further T cell 
expansion with so-called immune checkpoint inhibitors has demonstrated to be very 
effective in improving T cell functionality.145,149,150 
Immune checkpoint inhibitors
Blocking of co-inhibitory receptors on T cells can be very effective in patients with 
immunogenic types of cancer. In these patients, tumor antigen-specific T cells are 
already present in the tumor, but not effective because of co-inhibitory receptor 
expression. Here, the administration of immune checkpoint inhibitors recovered 
anti-tumor activity and even resulted in complete cures.151-153 CTLA4 antibodies 
(Ipilimumab; Yervoy) improved survival of patients with metastatic melanoma.145 
Anti-PD1 (Nivolumab; Opdivo, Pembrolizumab; Keytruda) and anti-PDL1 
(Atezolizumab; Tecentriq, Avelumab; Bavencio) showed significant survival benefits 
in the treatment of melanoma and non-small cell lung cancer respectively.154,155 
Additionally, also impressive treatment efficacy was observed in urothelial carcinoma, 
head and neck cancer and Hodgkin lymphoma.150,156,157 This led to FDA and EMA 
approval of these immune checkpoint inhibitors for the treatment of a wide variety of 
malignancies. Furthermore, the combination of anti-CTLA4 and anti-PD1 showed 
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improved clinical responses in melanoma but also increased the frequency of 
toxicities.158 A 4-year multicentre randomized phase III trial for Nivolumab and 
Ipilimumab combined or Nivolumab alone has shown that both treatment protocols 
give a sustained survival benefit in patients with advanced melanoma.159
 Anti-CTLA4, anti-PD1 alone or combination treatment result in different immuno - 
logic effects in vivo.160 CTLA4 antibodies enhance antigen spreading resulting in 
induction of more endogenous T cell responses to different tumor- associated 
antigens.161 Anti-PD1 and anti-PDL1 antibodies abolish PDL1-PD1 interactions 
between tumor and T cells and thereby enhance the anti-tumor functionality of 
already existing tumor-specific T cells.162 Interestingly, antibodies against CTLA-4, 
PD-1 and PD-L1 restored also glucose in the tumor microenvironment. In addition, 
PD-L1 blocking inhibited mTOR activity in tumor cells, resulting in decreased 
glycolysis.141 This permitted T cell glycolysis and increased IFNγ production. 
 Systemic blockade of the PD1 receptor on T cells showed impressive results, 
however can result in severe toxicities in combination with allo-SCT.163 Besides 
enhancing GVT immunity also life-threatening GVHD can be induced.164 Therefore, 
we investigated the efficacy of small interfering (si)RNA-mediated PD-L1 silencing in 
AML in Chapter 6 to ultimately induce local instead of systemic checkpoint blockade.
Outline of this thesis
T cell-based immunotherapy has great potential for the treatment of patients with 
various malignancies. Adoptive T cell transfer of tumor-reactive T cells can boost 
anti-tumor responses, especially when infused T cells have early-memory character-
istics.65,87,165,166 Therefore, strategies are developed which allow ex vivo generation 
of tumor-specific T cells, while preserving their early-memory phenotype, to improve 
efficacy in cancer patients.
 In Chapter 2 we describe comprehensive phenotyping analysis of T cell subsets. 
We describe how to characterize CD4+ T-αβ cells (TH1, TH2, TH9, TH17, TH22, TFH and 
Treg), and CD8+ T (TC1, TC2, TC9, TC17 and Tregs) and their additional effector memory 
status (TN, TSCM, TCM, TEM, and TEFF) by using flow cytometry. Furthermore, 
identification of antigen-specific T cells subsets is described as well as technical 
considerations for the usage of flow cytometry. 
 In Chapter 3, we explored the strategy to apply AKT-inhibition for the generation 
of early-memory tumor-specific CD8+ T cells. A panel of clinically applicable allosteric 
and ATP-competitive AKT-inhibitors were tested for their capacity to preserve differ-
entiation while allowing ex vivo proliferation of CD8+ T cells. We demonstrated via 
transcriptome profiling that these AKT-inhibited T cells were closely related to the 
naturally occurring stem cell memory-like CD8+ T cells. In line with these findings, 
AKT-inhibited T cells showed enhanced expansion capacity upon antigen recall. 
Surprisingly, human AKT-inhibited T cells cultured by the established protocol 
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showed enhanced glycolytic function, while this is generally as an effector T cell 
characteristic. Finally, we demonstrated that AKT-inhibition facilitated effective 
expansion of MiHA-specific CD8+ T cells with a stem cell memory-like phenotype 
and enhanced polyfunctionality with co-secretion of IFNγ and IL2. Because of these 
promising findings when applying AKT-inhibition in MiHA-specific CD8+ T cell 
expansion, we further explored the possibility to improve other adoptive T cell 
therapies like TCR/CAR-transduced and TIL therapy. Because these therapies are 
most often generated from total CD3+ T cells, we investigated the effect of 
AKT-inhibition on CD4+ T cells in Chapter 4. We show that both CD4+ T effector 
memory and helper-subset differentiation is changed in presence of either an 
allosteric or ATP-competitive AKT-inhibitor, resulting in preserved early memory T 
cells, less TH1 and more TH2 cells. Additionally, we found that the presence of CD4+ 
T cells did not interfere with preservation of memory differentiation in CD8+ T cells. 
Moreover, while CD4+ T cell help improved expansion of CD8+ T cells upon antigen 
recall as well as production of IFNγ, IL2 and TNFα in the absence of AKT-inhibition, 
the preferred polyfunctional characteristics of AKT-inhibited CD8+ T cells were less 
pronounced in presence of AKT-inhibited CD4+ T cells. This indicates that for the 
most optimal generation of TCR/CAR-transduced T cells or TIL therapy it is 
recommended to separate CD4+ and CD8+ T cell cultures and add the AKT-inhibitor 
only to the ex vivo CD8+ T cell culture, and subsequently combine cultured non-Akt-in-
hibited CD4+ and Akt-inhibited CD8+ T cell products for adoptive transfer.  
 Another interest to improve T cell functions is to explore the in vivo treatment with 
AKT-inhibitor. Because AKT-inhibition is also known to target specific tumor types 
directly, this approach can potentially improve anti-tumor effects two-directionally. To 
investigate the possibility of (tumor-antigen) vaccination in combination with in vivo 
AKT-inhibition, we exploited the OT-1 mouse model. In Chapter 5, we first describe 
the effect of AKT-inhibition on murine OVA-specific CD8+ T cells ex vivo. We explored 
the effects on T cell differentiation, metabolism and functionality. Moreover, we 
performed in vivo mouse experiments, were adoptive transfer of OVA-specific T cells 
is combined with OVA-peptide vaccination under in vivo AKT-inhibition. This showed 
temporarily preserved early memory CD8+ OT-1 T cells. 
 Next to AKT-inhibition, we aimed to improve the anti-tumor effect of T cells by 
targeting of the PD-L1 immune-escape mechanism in Chapter 6 by using the siRNA 
silencing techonology. We showed that siRNA-directed PD-L1 silencing leads to 
efficient downregulation of PD-L1 in AML. Importantly, this leads to an improved T cell 
functionality. This study shows rationale for the development of siRNA loaded 
particles which migrate to the tumor side and deliver the siRNA locally, and hereby 
provides another strategy to improve anti-tumor T cell immunity.
All findings are summarized in Chapter 7, and further discussed in regard to future 
perspectives in Chapter 8.
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Abstract
The T cell compartment can form a powerful defense against extrinsic (e.g. pathogens) 
and intrinsic danger (e.g. malignant cells). At the same time, specific subsets of 
T cells control this process to keep the immune system in check and prevent 
autoimmunity. A wide variety in T cell functionalities exists, which is dependent on the 
differentiation and maturation state of the T cells. In this review, we report an overview 
for the identification of CD4+ T-αβ cells (T-helper (Th)1, Th2, Th9, Th17, Th22 and CD4+ 
regulatory T cells), CD8+ T-αβ cells (cytotoxic T lymphocyte (Tc)1, Tc2, Tc9, Tc17, 
CD8+ regulatory T cells) and their additional effector memory status (naïve, stem cell 
memory, central memory, effector memory (TEM), effector) using flow cytometry. 
These different subsets can be discriminated based on selective extracellular 
markers, in combination with intracellular transcription factor and/or cytokine stainings. 
Additionally, identification of very small subsets, including antigen-specific T cells, 
and important technical considerations of flow cytometry are discussed. Together, 
this overview can be used for comprehensive phenotyping of a T cell subset of interest. 
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Main text
T cells appear in different sorts and flavors, with distinct characteristics that can be 
visualized through flow cytometry. T cells originate from lymphoid progenitors and 
have the capacity to traffic from the bone marrow to the thymus. Here T-cell 
development takes place comprising T-cell receptor (TCR)-mediated selection and 
maturation into naive T cells (Figure 1).1,2 Lymphopoiesis starts with progenitor cells 
expressing CD2, CD5, CD7, and cytoplasmic CD3, which have the capacity to enter 
the cortex of the thymus.3,4 At this point, TCRs are formed after rearrangements of α, 
β, γ and δ chains resulting in  T cells with γδ-chains (T-γδ)  and T cells with αβ- chains 
(T-αβ). These T-γδ and T-αβ cells can be characterized by flowcytometric gating for 
CD3 and the γδ-TCR or αβ-TCR respectively.5-8 At this stage, NK-T cells originate 
from the CD3-expressing precursor T cells by expressing a specific α-chain (Vα14-Jα18) 
which pairs via a β-chain interaction with glycolipid-CD1d. Upon development NK-T 
cells acquire expression of the neural cell adhesion molecule (NCAM, CD56).9 
A CD1d tetramer together with CD56 antibody, can be used to study NK-T cells.10 
Meanwhile, precursor T cells express CD3 at low levels on their surface and go through 
a rapid transition, where first CD8 and then CD4 expression is acquired. As expression 
of CD8 can occur prior to or after rearrangement of the TCRs, T-γδ cells can also 
separate from the αβ-path after up-regulation of CD8, which results in approximately 
30% the T-γδ cells being CD8+.8 The CD4+CD8+ double positive (DP) T-αβ cells 
continue their development by undergoing positive selection via interaction with either 
peptide:MHC class I complexes resulting in single expression of CD8 or peptide: 
MHC class II complexes resulting in single expression of CD4.11 Thereafter, T-αβ 
migrate from the thymic cortex to the medulla, where they undergo negative clonal 
selection to remove T cells that have a high affinity interaction for self-antigens. Finally, 
mature single-positive CD4+ and CD8+ T-αβ cells are released into the blood.12-15 
A small percentage (~1%) of the peripheral blood T-αβ cells does not express CD4 
nor CD8, and are known as double negative (DN) T-αβ cells.16-18 
 Mature T-αβ cell subsets can be further characterized by comprehensive pheno - 
typing, keeping in mind that differentiation often shows gradual changes in expression 
patterns, and molecules previously described as subset specific (e.g. CD56), are 
also expressed by other immune cells.19 In this review we provide an overview of 
extracellular proteins, intracellular transcription factors, and effector molecules that 
can be used to characterize different populations of T-αβ cells. 
T-αβ cell subsets can be defined by extracellular proteins,  
transcription factors and cytokine profiles
The most common strategy to segregate CD4+ T-αβ helper (Th) cell subsets (i.e. Th1, 
Th2, Th9, Th17, Th22 and regulatory T cells (Tregs)) is based on their functionality. In 
the last decade, new research highlighted that this segregation can be applied to 
CD8+ T-αβ cells as well, separating cytotoxic T lymphocytes (Tc)1, Tc2, Tc9, Tc17 and 
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CD8+ Tregs. The division is mainly based on extracellular markers, selective intra cellular 
transcription profiles and the cytokine production profile of the T cells. To define the 
various T-αβ subpopulations, a phenotype based on TCR-αβ, CD4, and CD8 staining 
should be combined with CD183 (CXCR3; Th1 and Tc1), CD194 (CCR4) and CD294 
(CRTH2; both for Th2 and Tc2), CD196 (CCR6) or CD161 (KLRB1; both for Th17 and 
Tc17), CCR10 (Th22), and CD25 (IL-2Rα), and CD152 (CTLA4; both for CD4+ and 
CD8+ Tregs) (Table 1 and Figure 2).20-31 However, so far no distinct extracellular 
marker for Th9 and Tc9 cells has been identified. For better discrimination, subsequent 
intracellular transcription factor profiling can be performed. These include T-bet 
(Th/c1), GATA3 (Th/c2), PU.1 (Th9), RORγt (Th/c17), AHR and/or FOXO4 (Th22) and 
Figure 1 | Discriminating T-αβ cells from their relatives. T-αβ cells arise from CD34+ hemato - 
poietic stem cells which acquire CD2, CD5, and CD7 expression during lymphopoiesis. After 
migration from the bone marrow to the thymus, CD3 is expressed and T-γδ cells and NK-T cells 
deviate from the T-αβ-path. T-γδ cells express the γδ-TCR and NK-T cells express a specific 
αβ-TCR which pairs with glycolipid-CD1d and they express CD56. The T-αβ cells gain both CD4 
and CD8 and subsequent to positive and negative clonal selection, single positive CD4+, and 
CD8+ T-αβ cells are released into the blood. Double negative (DN) T-αβ cells are negative for 
both CD4 and CD8.
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FoxP3 (CD4/CD8+ Tregs).20-30 Selective transcription factors for Tc9 have not yet 
been found. Nevertheless, the best method to distinguish between the subsets is 
based on their cytokine secretion profile upon stimulation in the presence of a Golgi 
system inhibitor, like Brefeldin A or Monensin, to prevent cytokine release. Following 
subsequent fixation and permeabilization, cells can be stained for intracellular IFNγ 
and IL2 (Th1/Tc1), IL4 and IL5 (Th2/Tc2), IL9 (Th9/Tc9), IL10 (CD4+/CD8+ Treg), IL17 
(Th17/Tc17), and IL22 (Th22).20-30
Characterization of effector memory differentiation
T-αβ cell subsets can be further characterized based on their effector memory differ-
entiation status. Either via a linear or partly progressive model, stem cell memory 
(TSCM), central memory (TCM), effector memory (TEM) and effector T cells (TEFF) 
develop from the naive (TN) repertoire upon activation.32-37 Effective T cell activation 
requires interaction of the TCR-CD3 complex with the peptide:MHC complex on anti-
gen-presenting cells, co-stimulatory signaling and cytokine support. Every effector/
memory subset has unique characteristics which provide them with differential 
migratory capacity, longevity and functionality. While CD197+CD62L+ TN, TSCM and 
TCM home to lymphoid tissues in search of their specific antigen being presented by 
antigen-presenting cells, CD197-CD62L- TEM and TEFF patrol peripheral tissues and 
blood and efficiently produce effector molecules upon antigen encounter.36-38 
Notably, early memory T cells (TSCM and TCM) are known for their longevity and high 
proliferative capacity, which gradually decreases upon differentiation.36 Although the 
expression of various extracellular markers changes during activation and differentiation 
(Table 2), one can already discriminate the different CD4+ and CD8+ effector memory 
T cell subsets using a small set of markers, including CD45RA or CD45RO in 
combination with CD197 (CCR7) and CD95 (Figure 3A). Additionally, often the cell 
adhesion molecule and homing receptor L-selectin (CD62L, Figure 2B), co-stimulatory 
molecules CD27 and CD28, and cytokine receptors IL2Rβ (CD122) and IL-7Rα 
(CD127) are included in effector memory differentiation analyses. Upon stimulation, 
besides expression of co-stimulatory markers, activated T-αβ cells can also start to 
express co-inhibitory receptors upon stimulation, including CTLA-4, PD-1, TIGIT and 
TIM-3.39,40 While this prevents sustained T cell activation via a natural feedback loop, it can 
also hamper immune responses in patients with chronic viral infections or cancer.41 
The analysis of all the described subsets should be always preceded by a proper 
gating strategy which includes the exclusion of doublets using a single cell gate42 
(Figure 3C), dead cells with a life/dead stain (Figure 3D), and, when necessary, auto-
fluorescent cells using an empty fluorescence channel. This is especially important 
when small (low frequent) populations including TSCM and antigen-specific T cells are 
analyzed. Antigen-specific CD8+ T-αβ cells can be visualized using single or double 
(combinatorial encoding) tetramer or pentamer stainings (Figure 3E). Tetramers and 
pentamers consist of respectively 4 or 5 biotinylated peptide-MHC complexes linked 
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Table 1   A comprehensive phenotype of cytokine-based subsets within CD4+  
and CD8+ T-αβ cells.
CD4 CD8
Th1 Th2 Th9 Th17 Th22 Treg Tc1 Tc2 Tc9 Tc17 Treg
Extracellular 
CCR10 +
CD25 (IL-2Rα) + +
CD127 (IL-7Rα) +/-
CD152 (CTLA4) + +
CD161 + +
CD183 (CXCR3) + +
CD194 (CCR4) + + + + -
CD196 (CCR6) - - + + + +
CD294 (CRTH2) + +
IL23R + +
Intracellular
AHR +
Foxp3 + +
FOXO4 +
GATA3 + +
IRF4 + + + + + +
PU.1 +
RORγT + +
T-bet + + -
Intracellular upon cell stimulation
IFNγ + - - - + -
IL2 + +
IL4 - + - - + - +/-
IL5 + - +
IL9 + + + - +
IL10 + - + + +
IL13 + +
IL17 + - +
IL21 + +
IL22 + +
TNF-α + + +
TGF-β + +
References 20-22,24 20-23,30 30 8,21,22,28 21,25 22,26,31 29 23,29 29 27-29 29
Boxes marked negative (-) indicate antigens, transcription factors or cytokines which are not expressed or 
produced by the corresponding subset. An empty box indicates that this is not used for the discrimination 
of a specific subset.
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to a fluorescent label. The use of double tetramer staining with two different fluorescent 
labels eliminates the chance of false positive results, thereby increasing the analysis 
specificity. Combinatorial staining with 6 different fluorochromes results in 15 unique 
color combinations, and makes it possible to identify up to 15 different epitopes with 
a high specificity.43 Additionally, in particular when performing deep multiparametric 
phenotypes, also Fluorescence Minus One (FMO) controls should be taken into 
consideration. An FMO control includes cells stained with all fluorochromes of the 
panel except one, and can be used to verify the cut-off point of background 
fluorescence and thereby the positive population (Figure 3F) after optimum 
concentrations have been established via an antibody titration assay. Finally, single 
stains on the cells of interest should be performed to set the appropriate 
Figure 2 | Identification of CD4+ and CD8+ T-αβ subsets. A combination of both surface 
and intracytoplasmic stainings for cytokines and transcription factors should be used for the 
correct identification of CD4+ T-αβ helper (Th) cell subsets Th1, Th2, Th9, Th17, Th22, and Treg, 
and CD8+ cytotoxic T-αβ (Tc) cell subsets Tc1, Tc2, Tc9, Tc17, and CD8+ Tregs. Discriminative 
surface proteins are visualized on the cell surface, cytokines intracellular as circles and 
transcription factors intracellular as squares.
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compensations followed by a check of compensation settings when using the 
complete panel. It is essential to synchronize flowcytometer settings over time and 
also harmonize your analyzers to acquire identical data on different machines. The 
right settings, together with accurate gating and a complete flow cytometry panel can 
be used for comprehensive phenotyping of your T-cell subset of interest.
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Figure 3 | Gating for flow cytometry. Peripheral blood mononuclear cells were resuspended 
in PBS containing 0.5% bovine serum albumin followed by extracellular staining for 30 min at 
4°C in the dark. (A) Gating strategy to discriminate CD4+ and CD8+ T cell memory populations 
within single, live, CD56–TCR–γδ–CD3+ cells. TN-like cells are CD45RO–CCR7+, TCM cells are 
CD45RO+CCR7+ and TEM/EFF cells are CD45RO+CCR7–. The discrimination between TN 
and TSCM within TN-like was based on the CD197-differentiation pattern of total CD4+ or CD8+ 
T cells (− ->). (B) Gating strategy to discriminate CD4+ and CD8+ T cell memory populations 
with CD45RO, CD62L, and CD27 within single, live, CD56–TCR-αβ+CD3+cells. TN-like cells are 
CD45RO–CD62L+CD27+, TCM cells are CD45RO+CD26L+CD27+ and TEM/EFF cells are 
CD45RO+CD62L-CD27+/−. (C) Discrimination of single cells by plotting forward scatter width 
(FS-W) against forward scatter area (FS-A) as well as plotting side scatter width (SS-W) against 
side scatter area (SS-A). Events deviating from the linear cell population are called doublets. 
(D) Live cells can be evaluated by gating on viability dye-negative cells. (E) Antigen-specific 
CD8+ T cells are analyzed by using antigen-specific tetramers, labeled with two different 
fluorescent labels. (F) Fluorescence minus one (FMO) control for CD45RO expression within 
FL3 contains all antibodies except CD45RO-ECD. This is used to determine the position of 
CD45RO+ cells.
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Abstract
Adoptive T cell therapy has shown clinical potential for patients with cancer, though 
effective treatment is dependent on longevity and potency of the exploited tumor- 
reactive T cells. Previously, we showed that ex vivo inhibition of AKT using the research 
compound Akt-inhibitor VIII retained differentiation and improved functionality of 
minor histocompatibility antigen (MiHA)-specific CD8+ T cells. Here, we compared a 
panel of clinically applicable AKT-inhibitors with an allosteric or adenosine triphosphate- 
competitive mode of action. We analyzed phenotype, functionality, metabolism and 
transcriptome of AKT-inhibited CD8+ T cells using different T cell activation models. 
Most inhibitors facilitated T cell expansion while preserving an early memory phenotype, 
reflected by maintenance of CD62L, CCR7 and CXCR4 expression. Moreover, 
transcriptome profiling revealed that AKT-inhibited CD8+ T cells clustered closely to 
naturally occurring stem cell-memory CD8+ T cells, while control T cells resembled 
effector-memory T cells. Interestingly, AKT-inhibited CD8+ T cells showed enrichment 
of hypoxia-associated genes, which was consistent with enhanced glycolytic 
function. Notably, AKT-inhibition during MiHA-specific CD8+ T cell priming uncoupled 
preservation of early memory differentiation from ex vivo expansion. Furthermore, 
AKT-inhibited MiHA-specific CD8+ T cells showed increased polyfunctionality with 
co-secretion of IFN-γ and IL-2 upon antigen recall. Together, these data demonstrate 
that AKT-inhibitors with different modality of action promote the ex vivo generation 
of stem cell memory-like CD8+ T cells with a unique metabolic profile and retained 
polyfunctionality. Akt-inhibitor VIII and GDC-0068 outperformed other inhibitors, and 
are therefore promising candidates for ex vivo generation of superior tumor-reactive 
T cells for adoptive immunotherapy in cancer patients. 
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Introduction
Adoptive cell therapy exploiting tumor-reactive CD8+ T cells can be an effective 
strategy to treat advanced cancers.1-4 Different strategies are applied to generate 
T cells for infusion, including the expansion of tumor-infiltrating lymphocytes (TIL), 
genetic modification of T cells with a tumor-reactive T cell receptor (TCR) or chimeric 
antigen receptor (CAR), or expansion of tumor-reactive T cells from the naïve repertoire. 
Since the success of adoptive T cell therapy is associated with infusion of a high cell 
number,5 all strategies include ex vivo activation and expansion. Additionally, in vivo 
proliferative capacity, persistence, homing to lymphoid organs, and presence of 
central memory T (TCM) and stem cell memory T (TSCM) cells have shown to be of 
critical importance for clinical efficacy.1-3,5-9 
 It has become evident that the differentiation status of an expanded T cell product is 
of crucial importance for clinical efficacy. However, T cell expansion and differentiation has 
been shown to be a tightly coupled processes initiated by signaling via the TCR, 
co-stimulatory molecules and cytokine receptors.6,10,11 These joined signals activate 
the PI3K/AKT/mTOR-pathway that has been shown to play a pivotal role in regulating 
CD8+ T cell differentiation and memory formation.12,13 Interestingly however, 
interference of PI3K/AKT signaling does not severely impair the proliferation of murine 
CD8+ T cells.14 Therefore, we and others exploited pharmacological AKT-inhibition to 
generate early memory TSCM/CM-like CD8+ T cells for ex vivo adoptive cell therapy.15-19 
Previously, we demonstrated that minor histocompatability antigen (MiHA)-specific 
CD8+ T cells with early memory traits can be efficiently expanded ex vivo from the 
naïve repertoire in the presence of the allosteric Akt-inhibitor VIII (AktiVIII).15 
Importantly, these AKT-inhibited MiHA-specific CD8+ T cells displayed improved 
proliferation capacity upon antigen re-encounter after withdrawal of the AKT-inhibitor. 
Furthermore, they exerted a superior anti-tumor effect in multiple myeloma-bearing 
mice. Taken together, our results demonstrated that the effect of AKT-inhibition on ex 
vivo generation of tumor-reactive CD8+ T cells is highly promising for improving 
adoptive therapy. This uncoupling of T cell differentiation from expansion using 
AKT-inhibitors has been confirmed in other models, including melanoma-derived 
tumor- infiltrating lymphocytes and CD19 CAR T cells, as well as by modulation of up- 
and down-stream targets of the AKT-pathway, including mTORC2 and PI3K-δ.16-18,20,21
 Here, we compared and mechanistically studied a panel of AKT-inhibitors that 
are in clinical development and have either an allosteric or an adenosine triphosphate 
(ATP)-competitive mode of action. The allosteric inhibitors bind the AKT protein in the 
pleckstrin-homology (PH) domain, thereby preventing localization of AKT to the plasma 
membrane and its subsequent phosphorylation.22,23 In contrast, ATP-competitive 
inhibitors bind the ATP-binding pocket directly, thereby preventing the catalytic 
effects of ATP during phosphorylation.23 In order to select the most optimal AKT- 
inhibitor, we compared phenotype, expansion potential, metabolism, transcriptome 
and cytokine production of AKT-inhibited CD8+ T cells upon polyclonal or anti-
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gen-specific activation. Notably, most of the examined AKT-inhibitors preserved an 
early memory CD8+ T cell phenotype, facilitated superior T cell expansion potential 
upon re-challenge, and induced a transcriptome profile resembling the TSCM subset. 
Importantly, the allosteric AktiVIII and ATP-competitive GDC-0068 (GDC) outperformed 
other AKT-inhibitors and allowed robust expansion of CD62L-expressing MiHA-specific 
CD8+ T cells with superior polyfunctionality. Together, our findings demonstrate that 
pharmaceutical AKT inhibition by AktiVIII and GDC is a highly promising strategy for 
the ex vivo generation of superior early memory T cell products for adoptive immuno - 
therapy in cancer patients.
Results
AKT-inhibition preserves early memory CD8+ T cells, while allowing 
proliferation and improving expansion capacity upon antigen recall
To develop superior AKT-inhibited T cells for adoptive T cell therapy, we evaluated 
various AKT-inhibitors that are in clinical development in comparison with the 
previously studied research-grade AktiVIII compound (Table 1). To exclude effects of 
the solvent DMSO, proliferation and differentiation were first evaluated following 
exposure to increasing dosages of DMSO. These assays revealed that DMSO levels 
≤0.5% did not influence our read-out parameters (Supplemental Figure 1). Next, 
based on extensive pre-screening of different concentrations (data not shown), 
titrations were performed with increasing dosages of the different AKT-inhibitors 
during polyclonal stimulation of CD8+ TN cells. The concentration of AktiVIII was 
already optimized in our previous study,15 and further pre-screenings (data not 
shown). Generally, AKT-inhibition had minimal effect on T cell viability, as only cells 
cultured with TCN or the highest dose of GSK2 showed reduced viability (Figure 1A). 
Proliferation, based on the dilution of cell proliferation dye, was only inhibited at the 
higher dosages of MK-, AZD- and GSK1 (Figure 1B and Supplemental Figure 2). 
 Next, polyclonally expanded CD8+ T cells were analyzed for their differentiation 
status based on expression of CD62L, CCR7 and CXCR4. While CD62L expression 
was mostly lost on proliferated DMSO-treated control T cells, its expression was 
retained in AKT-inhibited conditions (Figure 1C). We observed higher CD62L, CCR7, 
and CXCR4 expression with increasing dosages of all inhibitors, independent of the 
action mode of the inhibitor (Figure 1D). This indicates an inverse correlation between 
T cell differentiation and AKT-inhibition. Notably, T cells exposed to the highest 
concentrations of AKT-inhibitor showed a less prominent, or even lacked inhibition of 
differentiation, possibly due to a toxic effect as proliferation and viability were also 
affected at these dosages (Figure 1B and Supplemental Figure 2). Together, these 
data demonstrate that CD8+ T cells cultured in the presence of different AKT-inhibitors 
at optimal concentrations exhibit a less differentiated phenotype, with good viability 
and expansion. The AKT-inhibitor TCN was excluded from further evaluations 
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because of its toxic effects and lack of inhibition on T cell differentiation at low 
dosages.
 Subsequently, the different AKT-inhibitors were applied during allogeneic stimulated 
CD8+ TN cells. AKT-inhibited T cells were evaluated for activation, differentiation and 
expansion profile. Here, T cell expansion was inhibited in a dose-dependent manner 
(Figure 2A), but lower dosing of all inhibitors allowed good T cell expansion. 
Corresponding phenotype analysis revealed that DMSO-treated control T cells lost 
CD62L and CCR7 expression upon proliferation, while high expression of these 
markers was retained on all AKT-inhibited CD8+ T cells, independent of the applied 
dosage (Figure 2B-C). Especially CD62L was 3-6 fold higher expressed by all 
AKT-inhibited CD8+ T cells compared to control T cells. Chemokine receptor CXCR4, 
normally expressed on naïve T cells and lost upon differentiation, was preserved at T 
cells treated with the higher dosages of AZD, GDC and GSK1. For MK and GSK2, 
which were evaluated in different donors, these effects were not found. Importantly, 
both IL7Rα and co-stimulatory receptor CD28 were higher in all Akt-inhibited 
conditions (Figure 2C). Moreover, as superior proliferative capacity is one of the 
major advantages of early memory CD8+ T cells,15,24 we investigated the secondary 
expansion capacity upon allogeneic restimulation in the absence of AKT-inhibition. 
Notably, all AKT-inhibited T cells expanded 2 to 10-fold better as compared to control 
T cells (Figure 2D, p<0.05). Altogether, these data show that all evaluated 
AKT-inhibitors allow the generation of increased numbers of early memory CD8+ T 
cells with superior expansion capacity. 
AKT-inhibited CD8+ T cells have a transcriptome profile resembling 
TSCM cells with unique metabolic attributes
To compare AKT-inhibited allogeneic stimulated CD8+ TN cells with naturally occurring 
T cell subsets, transcriptome profiling was performed. First, AKT-inhibited T cells 
were compared to control T cells. We identified 2713, 3736, 3375, 3559, and 3244 
differentially expressed genes in AktiVIII, MK, GDC, GSK1 and GSK2 respectively. 
Analysis in a Venn diagram shows that AKT-inhibited T cells share 1107 genes which 
were significantly up- or down-regulated compared to control cells (Figure 3A). 
Nevertheless, a unique transcriptome profile for each AKT-inhibitor was found, 
ranging from 561 to 816 unique transcripts. To determine whether both allosteric and 
ATP-competitive AKT-inhibitors show similarities with any of the natural T cell subsets, 
a principal component analysis was performed. This was based on a set of 900 
transcripts which are differentially expressed in the T cell subsets TN, TSCM, TCM and 
effector memory T cells (TEM) as previously described by Gattinoni et al.24 This 
analysis revealed that despite their unique transcriptome profiles, both allosteric 
AKT-inhibitors (left panel) as well as ATP-competitive AKT-inhibitors (right panel) 
resembled the naturally occurring TSCM subset (Figure 3B). In contrast, DMSO-treated 
control T cells clustered more closely with the natural occurring TEM cells. Accordingly, 
unsupervised hierarchical clustering of AktiVIII- and GDC-treated T cells showed a 
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Figure 1 | AKT-inhibition preserves early memory CD8+ T cells with minimal effect on 
viability and proliferation. CD8+ TN cells were stimulated with CD3/CD28 Dynabeads® in 
presence of DMSO (Ctrl) or AktiVIII (12 µM), MK (10-5-2.5-1.25 µM), TCN (80-40-20-10 µM), 
AZD (40-20-10-5 µM), GDC (40-20-10-5 µM), GSK1 (20-10-5-2.5 µM) or GSK2 (40-20-10-5 µM). 
Viability, proliferation and phenotype were analyzed in 2 independent donors. (A) Percentage 
viable cells and (B) median fluorescence intensity (MFI) of cell proliferation dye. (C) 
Representative plots (donor 2) of CD62L expression and cell proliferation dye dilution of Ctrl, 
12µM AktiVIII, 5 µM MK, 40 µM TCN, 20 µM AZD, 20 µM GDC, 10 µM GSK1 and 20 µM 
GSK2-treated T cells, gated on viable CD8+ T cells. Numbers indicate MFI of CD62L. (D) 
CD62L, CCR7 and CXCR4 expression of CD8+ T cells (Mean+SD, n=2). Statistical analysis 
was performed using One-way ANOVA followed by Bonferroni’s Multiple Comparison Test of 
AKT-inhibited versus Ctrl T cells. ND=no determined, ‡p<0.001, #p<0.01, *p<0.05.
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Figure 2 | Allogeneic stimulated AKT-inhibited CD8+ T cells retain an early memory 
phenotype and superior expansion capacity. CD8+ TN cells were stimulated with allogeneic 
mDCs in presence of DMSO (Ctrl) or AktiVIII (12µM), AZD (12-8-4 µM), GDC (40-30-20 µM), 
GSK1 (7.5-5-2.5 µM), MK (10-5-2.5 µM) and GSK2 (30-20-10 µM). MK and GSK2 were evaluated 
in different donors. (A) Relative cell number of AKT-inhibited CD8+ T cells compared to Ctrl T 
cells. (B) Representative plots of CD62L and CCR7 expression during proliferation of Ctrl, 12 
µM AktiVIII, 8 µM AZD, 20 µM GDC, 5 µM GSK1, 5 µM MK and 20 µM GSK2-treated T cells, 
gated on viable CD8+ T cells. (C) Relative expression of CD62L, CCR7, CXCR4, IL7Rα and CD28 
within proliferated CD8+ T cells. (D) Relative expansion of AktiVIII (12 µM), AZD (12-8 µM), GDC 
(40-30 µM), GSK1 (7.5-5 µM), GSK2 (20-10 µM) or MK (10-5 µM) treated cells during 
re-stimulation with allo-mDCs for 7 days after removal of AKT-inhibitor. Mean+SD of one 
representative donor out of 2-5 donors, n=3 per experiment. Statistical analysis was performed 
using One-way ANOVA followed by Bonferroni’s Multiple Comparison Test of AKT-inhibited 
versus Ctrl T cells within donors, ‡p<0.001, #p<0.01, *p<0.05.
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Figure 3 | AKT-inhibited CD8+ T cells cluster with TSCM cells and are enriched for hypoxia 
related- and Hif1α target genes. CD8+ TN cells of 3 independent donors were stimulated with 
allo-mDCs in presence of DMSO (Ctrl) or AktiVIII (12 µM), MK (5 µM), GDC (10 µM), GSK1 (2.5 
µM) or GSK2 (10 µM), followed by gene analysis. (A) Venn diagram with numbers of differentially 
regulated genes compared with Ctrl T cells. (B) Principle component analysis (PCA) of gene 
expression in Ctrl, AKT-inhibited and naturally occurring CD8+ T cell subsets. (C) Hierarchical 
clustering of AktiVIII- or GDC-cultured cells and naturally occuring T cell subsets. (D) Gene set 
enrichment analysis of AktiVIII- and GDC-treated cells compared to Ctrl cells for hypoxia 
associated-, Hif1α target, and hematopoietic stem cell associated genes.
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strong association with TSCM and TCM cells, while control T cells clustered with the 
more differentiated TEM cells (Figure 3C). Importantly, transcriptome profiling 
confirmed the retained expression of genes expressed by early memory T cells 
including BCL6, CD28, ICOS, and the FOXO1 targets IL7R, S1PR1 and SELL 
(Supplemental Figure 3). The effector associated genes EOMES, ID2, KLRG1 and the 
chemokine ligands XCL1 and XCL2 were found to be lower expressed in AKT-inhibited 
cells. Additionally, lower expression was observed of genes associated with 
acquisition of T cell effector functions, including FASLG, GZMA, GZMB, and apoptosis 
associated genes TRAIL and BAD in AKT-inhibited T cells. Interestingly, the effector 
associated TBX21 was solely down-regulated in GDC cultured cells. As reported 
previously,15 the effector associated transcription factor PRDM1, encoding BLIMP1, 
was highly expressed in AKT-inhibited T cells. Furthermore, naïve and memory 
associated genes LEF1, SATB1 and TCF7 were surprisingly down-regulated in 
AKT-inhibited T cells, highlighting unique characteristics of these cells. Further 
analysis of AktiVIII- and GDC-treated T cells showed enrichment of hematopoietic 
stem cell associated genes (Figure 3D), emphasizing the existence of a conserved 
molecular network regulating self-renewal and differentiation in stem cells and early 
memory T lymphocytes.25 Interestingly, AKT-inhibited T cells were also enriched with 
hypoxia pathway genes and Hif1α targets compared to control cells (Figure 3D). 
Together, the transcriptome analysis demonstrates unique profiles for all AKT-inhibited 
T cell products, which exhibit close resemblance with TSCM cells and enrichment of 
specific pathways and effector characteristics, independent of the mode of inhibition.
 Given the positive correlation between AKT-inhibition and hypoxia/HIF1a-induced 
transcripts, we next investigated whether AKT-inhibition modulated the metabolic 
characteristics of the expanded CD8+ T cells. For this, allogeneic expanded 
Akt-inhibited T cells were subjected to metabolic- and glycolytic stress tests. While 
CD62L expression was significantly higher for all AKT-inhibited T cell conditions 
compared to DMSO-treated control T cells, no significant finding along different 
donors in mitochondrial respiration was observed (Figure 4A and Supplementary 
Figure 4A-B). Although reduced glycolytic metabolism is associated with CD8+ T cell 
memory,26,27 we observed a trend towards increased glycolytic function in 
AKT-inhibited T cells (Figure 4A-B). The increase in glycolysis was most prominent for 
AktiVIII-treated T cells (Figure 4A-B), while other inhibitors showed only moderate 
effects. No change in glycolytic capacity and glycolytic reserve were found for 
AKT-inhibited T cells (Supplemental Figure 4C). Interestingly, a positive association 
was found between CD62L expression and glycolysis upon combining data of all 
inhibitors (Figure 4C, p=0.02). These observations were confirmed by enhanced 
expression of glycolysis-associated PFKM and lower expression oxidative phosphor-
ylation-associated CPT1A (Figure 4D). Combined, these data indicate that inhibition 
of AKT-signaling preserves a TSCM-like gene expression profile but simultaneously 
favors enhanced glycolytic function.
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Figure 4 | AKT-inhibition is associated with increased glycolysis. CD8+ TN cells were 
stimulated with allo-mDCs in presence of DMSO (Ctrl) or AktiVIII (12 µM), MK (5 µM), GDC (10 
µM), GSK1 (2.5 µM) or GSK2 (10 µM) and (A-C) challenged in different metabolic assays or (D) 
followed by gene analysis. (A) Mitochondrial respiration and glycolytic function of one 
representative out of 4 donors, n=4-6. (B) Glycolysis in 4 independent donor, different symbols 
depict different donors. (C) Association between glycolysis and CD62L expression (Median 
Fluorescence Intensity, MFI). Data of all Ctrl and AKT-inhibited conditions included. (D) Fold 
change of PFKM and CPT1A expression compared to Ctrl cells. Statistical analysis was 
performed using (B) a two-tailed paired t-tests or (C) linear regression with 95% confidence 
interval, Median Fluorescence Intensity (MFI), ‡p<0.001, #p<0.01, *p<0.05.
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AKT-inhibition permits expansion of MiHA-specific CD8+ T cells 
with an early memory phenotype and superior polyfunctionality
Allogeneic stem cell transplantation (allo-SCT) is a potentially curative treatment for 
patients with hematological malignancies. Nevertheless, high relapse rates remain a 
problem. Here, adoptive T cell therapy could be given as adjunctive therapy to boost 
graft-versus-tumor responses. For that purpose, MiHA-specific CD8+ T cells can be 
ex vivo expanded from the naive repertoire using two rounds of stimulation with 
peptide-loaded mDCs. The MK compound was omitted based on the experimental 
variability observed in these experiments (data not shown). AKT-inhibition limited the 
expansion of total CD8+ T cells in all conditions, except for AktiVIII- and AZD-treated 
cells (Figure 5A). This effect occurred especially during the first week of culture, and 
was most pronounced in GDC- (p<0.01), GSK1- (p<0.001) and GSK2-treated cells 
(p<0.01). Importantly, the expansion of MiHA-specific CD8+ T cells was not hampered 
by AKT-inhibition, and even resulted in higher percentages and increased expansion 
for AKT-inhibited compared with control MiHA-specific CD8+ T cells (Figure 5B-D). 
Consistent with our results using polyclonal and allo-MLR stimulations, AKT-inhibited 
MiHA-specific CD8+ T cells showed increased CD62L expression compared to 
controls (Figure 5E-F), with the most pronounced effect for the AktiVIII and GDC 
compounds (both p<0.01).
 Since effector T (TEFF) cells can accelerate the differentiation of naïve T cells28 
and the frequency of TEFF differs per donor, we aimed to increase the robustness of 
our culture protocol by starting the culture with CD8+ TN cells instead of total CD8+ T 
cells. Here, we selected the most effective AKT-inhibitors of the allosteric and 
ATP-competitive group: AktiVIII and GDC, respectively. Starting from TN cells, the 
effect of AKT-inhibition on total CD8+ T cell expansion was less prominent (Figure 
6A), and frequencies and expansion of MiHA-specific CD8+ T cells were similar 
among conditions (Figure 6B-C). Notably, both AktiVIII and GDC effectively retained 
CD62L expression, though levels strongly varied (Figure 6D). In case of AktiVIII, this 
variation could be explained by the expansion of MiHA-specific CD8+ T cells (Figure 
6E, p<0.04), showing that enhanced expansion of MiHA-specific CD8+ T cells was 
associated with less effective inhibition of differentiation. This correlation was not 
found for DMSO-treated control or GDC-inhibited T cells (Supplementary Figure 5A). 
For clinical efficacy and effective targeting of malignant cells, it is essential that in vivo 
progeny of infused AKT-inhibited T cells possess superior functionality. To investigate 
this, AKT-inhibited CD8+ T cells were expanded for another 7 days in the absence of 
inhibitors, followed by analyses of their antigen-specific cytokine profile. In both 
control and AKT-inhibited conditions, increased IFN-γ production was observed 
compared to non-stimulated T cells (Supplementary Figure 5B). Importantly, further 
characterization revealed that only within AktiVIII- and GDC-cultured T cells, these 
IFN-γ producing cells co-produced IL-2 (Figure 6F). These data demonstrate that 
AKT-inhibited early memory CD8+ T cells can differentiate into superior polyfunctional 
effector cells.
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Figure 5 | AKT-inhibition preserves CD62L expression while promoting expansion of 
antigen-specific CD8+ T cells. CD8+ T cells were stimulated with peptide-loaded mDCs for 
12 days in the absence (Ctrl) or presence of AktiVIII (12 µM), AZD (4 µM), GDC (10 µM), GSK1 
(2.5 µM), or GSK2 (10 µM). (A) Expansion of total CD8+ T cells. (B) Representative tetramer 
staining and (C) percentages of MiHA-specific CD8+ T cells on day 12 of culture. (D) Expansion 
of MiHA-specific CD8+ T cells calculated from an estimated precursor frequency of 1:107. (E) 
Overlays of representative CD62L staining gated on Ctrl or AKT-inhibited MiHA-specific CD8+ 
T cells. Numbers represent Median Fluorescence Intensity of CD62L. (F) Relative CD62L 
expression of AKT-inhibited compared to Ctrl MiHA-specific CD8+ T cells on day 12 of culture. 
(C&F) Individual donors are depicted with unique symbols. Statistical analysis was performed 
using (A&D) Two-way ANOVA followed by a Bonferroni post-hoc test or a (C&F) one-tailed 
Wilcoxon matched-pairs signed rank test. ‡p<0.001, #p<0.01, *p<0.05 compared to matched 
Ctrl cultures
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Discussion
Adoptive cell therapy is a promising strategy to treat advanced cancer, as demonstrated 
by the impressive anti-tumor responses in patients treated with CAR T cell or TIL 
therapy.1-4 However, long-term immune surveillance can be further improved, as 
sometimes only temporary responses and delayed progression is observed. 
Improved clinical efficacy of adoptive T cell therapy could be reached by generating 
tumor-specific T cell products with an early differentiation state, as they show superior 
longevity and proliferative capacity.1-3,5-9,15-21,24,25,29-35 This could be accomplished 
by inhibition of the AKT pathway, as was previously shown by us and others.15-21 
In this study, we aimed to further optimize AKT-inhibited CD8+ T cells by exploring 
Figure 6 | AKT-inhibited MiHA-specific CD8+ T cells show co-secretion of IFN-γ and IL-2 
upon antigen recall. CD8+ TN cells were stimulated with peptide-loaded mDCs in presence of 
DMSO (Ctrl) or AktiVIII (15 µM) or GDC (12.5 µM). (A) Expansion of total CD8+ T cells. (B) 
Percentage MiHA-specific CD8+ T cells on day 12 and (C) fold expansion of MiHA-specific 
CD8+ T cells, calculated from an estimated precursor frequency of 1:106. (D) Relative CD62L 
expression of AKT-inhibited MiHA-specific CD8+ T cells compared to Ctrl MiHA-specific CD8+ 
T cells at day 12. (E) Association between CD62L expression and expansion of AktiVIII-treated 
MiHA-specific CD8+ T cells. (F) Percentage IL-2 producing cells within IFN-γ+CD8+ T cells 
upon peptide stimulation of re-challenged T cells in the absence of AKT-inhibitor. Mean+SEM 
of 2 independent donors. (B,D&E) Individual donors are depicted with unique symbols. (E) 
Statistical analysis was performed using linear regression with 95% confidence interval or (F) 
Student’s t-test comparing AKT-inhibited T cells with Ctrl T cells, *p<0.05.
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AKT-inhibitors with diverse modality of action, and further characterize these cells for 
their phenotype, transcriptome, metabolism and functionality. Here, we showed that 
both allosteric and ATP-competitive AKT-inhibitors retain T cells in an early memory 
state, do not hamper the expansion of MiHA-specific CD8+ T cells, and facilitate 
generation of polyfunctional T cells for adoptive cell therapy. 
 Although the PI3K-AKT-pathway is known to be involved in cell division and 
survival,10 the inhibitors in the tested concentrations showed minimal effect on viability 
and proliferation. Only AKT-inhibitor TCN hampered viability, which may be attributed 
to its inhibition of DNA synthesis and subsequent cell cycle and apoptosis induction, 
as previously observed in T-ALL cell lines.36 Importantly, proliferation was only 
modestly restrained upon exposure to high dosages of inhibitors. This is in agreement 
with findings of Klebanoff et al., who showed that AKT-inhibition (using low dose 
AktiVIII) uncouples T cell differentiation from expansion.18 Interestingly, while 
expansion was not hampered by inhibiting AKT, generation of early memory cells by 
interference with GSK-3β clearly blocked proliferation of T cells.15,30,33 This makes 
AKT a very potent candidate for the generation of effective adoptive T cell products.
 While proliferation and viability were unaffected, T cells cultured with AKT-inhibitors 
retained an early memory phenotype. Though allosteric and ATP-competitive 
inhibitors have different modes of action to prevent AKT phosphorylation, inhibition 
via either route resulted in T cells with sustained expression of CD62L, CCR7 and 
CXCR4 compared to control T cells. This naïve associated phenotype indicate that 
our T cells are closely related to early memory T cells. Moreover, high expression of 
these homing receptors allows T cell migration to lymphoid organs where they can be 
activated by antigen-presenting cells.37 Additionally, this enables effective migration 
to the bone marrow, which has been associated with improved clinical efficacy of 
donor lymphocyte infusion in leukemia patients.38
 In addition to the phenotypical resemblance to early memory T cells, transcriptome 
analysis revealed clustering of AKT-inhibited cells with the natural TSCM subset. Here, 
we observed upregulated naïve- and memory-associated genes, while expression of 
effector-associated genes was lower compared to control T cells. These data are in 
agreement with previously published data on AKT-inhibited T cells by us and 
others,15-19 and confirms the extensive down-stream analysis by Klebanoff et al., 
which highlights FOXO1 as the key player in this process.18 With the increased 
expression of FOXO1 targets, increased expression of naïve-associated markers, 
and decreased expression of effector and apoptosis molecules, our AKT-inhibited 
cells possess unique and superior characteristics for adoptive cell therapy in cancer 
patients. However, AKT-inhibition did not preserve all naïve associated genes, and 
did elevated specific effector-related factors, including PRDM1, which could be 
involved in triggering effector cell functions. This may be attributed to feedback 
regulations due to close interaction of the transcription factors involved.39 
 Our results on phenotype and transcriptome correspond to previous findings of 
AKT-inhibited T cells. However, the metabolic profiling of our AKT-inhibited T cells 
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differed from previously reported AKT-inhibited and GSK-3β-inhibited TSCM-enriched 
cells.18,33 Instead of an increased oxidative phosphorylation, we observed enhanced 
glycolysis in AKT-inhibited T cells, especially with AktiVIII inhibition. This observation 
was confirmed by the higher expression of glycolysis-associated PFKM and 
decreased expression of OXPHOS-associated CPT1A in our transcriptome analysis. 
Moreover, the enhanced glycolytic function is in accordance with the observed 
increase in the highly entangled hypoxia and HIF1α-related pathways.40 These 
differences may be related to differences in experimental T cell activation models and 
inhibitor dosing. Furthermore, as downstream targets of AKT, including mTORC1, can 
also be regulated via other pathways, this may have contributed to different effects on 
hypoxia, HIF1α targets, and glucose metabolism.40 Moreover, our assays were 
performed using naïve CD8+ T cells only, whereas others mainly used total PBMCs. 
Nevertheless, though also in natural memory subsets, including TSCM cells, oxidative 
metabolism is described to be more dominant,27 a recent publication on autoreactive 
TSCM cells also observed an increased glycolytic profile.41 They showed that their IL-7 
generated TSCM cells were glucose dependent, as a selective GLUT1-inhibitor 
diminished in vitro TSCM differentiation and cell division. Notably, the increased 
glycolysis observed in our AKT-inhibited CD8+ T cells may facilitate quicker immune 
responses and allow effective tumor targeting in low oxygen environments like the 
tumor mass and bone marrow. This has already been described for hematopoietic 
stem cells which, as compared to mature blood cells, rely more on glycolysis than on 
oxidative phosphorylation.42,43 As hematopoietic stem cells reside in stem cell niches 
with low oxygen levels, they are highly dependent on anaerobic metabolism. 
Interestingly, low oxygen levels stabilize and activate HIF,44 which is important for the 
maintenance of hematopoietic stem cells and promotes self-renewal of embryonic 
stem cells.45,46 Therefore, the enrichment of hypoxia-, HIF1α-targets and hematopoietic 
stem cell-associated genes in our AKT-inhibited CD8+ T cells could indicate improved 
self-renewal capacity and good functionality in low oxygen environments. 
 Upon activation, early memory T cells differentiate into effector cells. Confirming 
previously published data,15,16,18 AKT-inhibited T cells showed increased secondary 
expansion capacity after removal of the inhibitor. Moreover, we found that next to 
IFN-γ, AktiVIII and GDC-treated T cells also produced IL-2, which was not observed 
in control T cells. This observation is in line with data published by Abu Eid et al. who 
reported that mouse T cells treated with AKT-inhibitor MK produced higher levels of 
IL-2.19 Normally, terminally differentiated CD8+ T cells show diminished secretion of 
IL-2.47 As our Akt-inhibited T cell products effeciently co-produced IL-2 and IFN-γ, this 
reflects the superior polyfunctionality of our T cells. 
 For clinical implementation and reduction of variability between cultures, 
we developed a culture protocol starting with naïve CD8+ T cells. In this way, late 
memory and effector T cells can no longer stimulate the differentiation of antigen- 
specific T cells.28 Starting with CD8+ TN cells resulted in an elevated CD62L expression 
in all cultures, though variation remained high. This variation between cultures might 
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be explained by basal donor variation in AKT expression and phosphorylation,48 
showing that optimal dosing is important. As too high AKT-inhibition induces cell 
death and blocks proliferation, further research could focus on identification of 
biomarkers for optimal dosing of AKT-inhibitors. 
 Several adoptive T cell therapy studies have shown that persistence of T cells is 
essential for durable clinical responses, and that this is mainly dependent of the 
memory phenotype of the cell product.1-3,5-9,25,29,32,34 This perspective should 
promote further research and clinical translation of adoptive T cell therapy with 
interference of the PI3K/AKT/mTOR or Wnt-signalling pathway.15-19,21,33 Here we 
show that AKT-inhibition can be used for the generation of a unique TSCM-like CD8+ 
T cell product for adoptive transfer. Though this is irrespective of the mode of action 
of the inhibitor, the choice of inhibitor does influence the characteristics and, thereby, 
possibly the clinical potency of the therapeutic product. In conclusion, we show that 
AktiVIII and GDC are excellent candidates for the generation of a superior 
MiHA-specific CD8+ T cell therapy, with an early memory phenotype and excellent 
polyfunctionality. This reaffirms the great potential of AKT-inhibition as a powerful 
strategy for the generation of effective cell products for immunotherapy in the battle 
against cancer. 
Material and Methods
Cell material and isolation
All experiments were performed using peripheral blood mononuclear cells (PBMCs) 
isolated from buffy coats of healthy donors (Sanquin Blood Supply Foundation). For 
antigen-specific experiments, HLA-A2 and/or B7-positive donors were used who lack 
the expression of the MiHA of interest. PBMCs were isolated via Ficoll-paqueTM PLUS 
gradient (cat#17-1440-03, Sigma-Aldrich), followed by selection of CD14+ and/or 
CD8+ cells by magnetic bead isolation, on fresh and cryopreserved material 
respectively (cat#130-050-201 and cat#130-045-201, Miltenyi Biotec). Cryopreserved 
material was frozen using a Mr. FrostyTM (cat#5100-0001, ThermoFisher) in self made 
serum-supplemented medium with 10% DMSO. For polyclonal T cell stimulation or 
allogeneic mixed lymphocyte reactions (allo-MLR), further purification of CD8+ naive 
T (TN) cells was performed via FACS-sorting of CD3+CD8+CCR7+CD45RO- cells 
using the FACS Aria (BD Bioscience). The EasySep™ Human Naïve CD8+ T Cell 
Isolation Kit (cat#19258, Stemcell Technologies) was used to isolate CD8+ TN cells 
from fresh or cryopreserved material for T cell priming experiments. Cell numbers 
were based on trypan blue cell counting, and all isolations resulted in ≥90% purity.
Flow cytometry 
Flowcytometry stainings were performed on cells resuspended in PBS (cat#3623130, 
Braun) containing 0.5% bovine serum albumin (BSA, cat#A9647, Sigma). MiHA-spec-
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ificity of CD8+ T cells was detected via phycoerythrin (PE) and allophycocyanin 
(APC)-labeled tetramers containing the peptide of interest (HA-1.A2, VLHDDLLEA; 
HY.B7, SPSVDKARAEL; provided by Prof. JHF Falkenburg, Leiden University Medical 
Center, Leiden, the Netherlands). Cells were incubated with tetramers for 15 minutes 
at room temperature (RT) in the dark. Surface marker staining was performed for 30 
minutes at 4°C in the dark, using the following antibodies: CD3 (UCHT1 or OKT3, 
Biolegend), CD8 (3B5, Invitrogen), CD28 (CD28.2, Biolegend), CD45RO (UCHL1, 
Beckman Coulter), CD62L (DREG56, Biolegend), IL7Rα (A019D5, Biolegend), CCR7 
(G04H7, Biolegend), or CXCR4 (12G5, Biolegend). Viability was determined via 
staining with Fixable Viability Dye eFluor780 for 30 minutes at 4°C in the dark, or by 
adding SYTOX™ Blue dead cell stain (cat#65-0865-14 and cat#S34857, both 
ThermoFisher) for 5 minutes at RT prior to analysis. To evaluate T cell cytokine 
production, intracellular cytokine staining was performed on T cells after overnight 
peptide rechallenge (5 µM; HA1.A2 (VLHDDLLEA) or HY.B7 (SPSVDKARAEL)) in 
presence of Brefeldin A (cat#555029, GolgiPlug, BD biosciences). Cells were fixated 
with 4% paraformaldehyde (cat#P6148, BOOM) for 10 minutes at RT in the dark, 
followed by permeabilization with 0.1% saponin (cat#47036, Sigma) buffer containing 
10% fetal calf serum (FCS, Integro B.V.) for 10 minutes at RT. Intracellular staining was 
performed using IFN-γ (B27, BD Bioscience) and IL-2 (5.344.111, BD Bioscience) for 
30 min at 4°C in the dark. Cells were measured on the Gallios flowcytometer (Beckman 
Coulter) and analyzed with Kaluza software (Beckman Coulter, version 1.5a). In all 
analysis, gating was performed based on live and single cells using the dead/live 
staining and forward- and side scatter. Subsequently, analysis was performed 
within theCD3+CD8+ T cells. Tetramer-positive CD8+ T cells were defined as double 
tetramer positive, in combination with a not-gate to exclude a specific staining and 
background fluorescence. MiHA-specific CD8+ T cells were further analyzed if a 
homogenous population was found.
In vitro activation and culture of CD8+ T cells
To generate mature monocyte-derived dendritic cells (mDCs) CD14+ cells were 
cultured in manufactory pre-tested X-VIVOTM 15 medium (cat#BE02-061Qor 
cat#BE02-060Q, Lonza), supplemented with 2% human serum (HS, cat#N0398000, 
Sanquin Blood Supply Foundation), 500 IU/ml IL4, and 800 IU/ml GM-CSF 
(cat#11340045 and cat#11343125, ImmunoTools). On day 2 or 3, cells were harvested 
and re-plated at 0.5x106/ml in X-VIVO15 containing 2% HS with 500 IU/ml IL4 and 800 
IU/ml GM-SCF for 3-4 days. To induce maturation, medium was supplemented with 
5 ng/ml IL1β, 15 ng/ml IL6, 20 ng/ml TNFα (cat#11340015, cat#11340064, 
cat#11343015, all ImmunoTools) and 1 µg/ml PGE2 (Prostin E2®, Pfizer) for 2 days. 
 CD8+ TN cells were stimulated with CD3/CD28 Dynabeads® (cat#11131D, 
Thermo Fisher) at a 1:1 ratio, or with allogeneic mDCs at a 1:10 DC:T cell ratio for 6-7 
days. Prior to activation, CD8 TN cells were labeled with 10µM Cell Proliferation Dye 
eFluor450 (cat#65-0842-85, Thermo Fisher). For the expansion of MiHA-specific 
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CD8+ T cells, CD8+ T or TN cells were stimulated with peptide-loaded mDCs (5µM; 
HA1.A2 (VLHDDLLEA) or HY.B7 (SPSVDKARAEL)) at a DC:T cell ratio of 1:10. T cell 
cultures were performed in X-VIVO 15 medium containing 10% HS, supplemented 
with 50 IU/ml IL-2 (Proleukin®, Chiron), 5 ng/ml IL-7 and 5 ng/ml IL-15 (cat#11340075 
and cat#11340155, both Immunotools). When indicated, DMSO (cat#102952, Merck 
millipore)-dissolved Akt-inhibitor VIII (cat#A6730, Sigma), MK-2206, Triciribine, 
AZD5363, GDC0068, GSK2141795 (cat#HY-10358, cat#HY-15457, cat#HY-15431, 
cat#HY-15186, cat#HY-15965, all MedChemExpress), GSK2110183 hydrochloride 
(cat#2460, Axon MedChem) or as control, DMSO alone was added (Table 1). For all 
conditions, not more than 0.5% DMSO was added to the media. Half of the medium, 
including cytokines and inhibitor or DMSO, was refreshed every 2-3 days. Furthermore, 
MiHA-specific CD8+ T cell cultures were restimulated with mDCs at day 7. 
Re-challenge was performed upon restimulation with allogeneic mDCs on day 7 of 
allo-MLR, or with peptide-loaded mDCs or irradiated peptide-loaded 293T.HLA-A2.
CD80.ICAM1 cells on day 12 of the MiHA-specific CD8+ T cell cultures, all in the 
absence of inhibitor and DMSO. 
Microarray analysis
CD8+ T cells were sorted based on Cell Proliferation Dye eFluor450 by FACS-sorting. 
Proliferated cells were isolated at day 7 of allo-MLR, and total RNA was isolated with 
the RNeasy Plus Mini Kit (cat#74134, Qiagen). Microarray analysis of control and 
AKT-inhibited CD8+ T cells was performed as previously described,24 using the 
Whole Transcript Human Gene 1.0 ST arrays (cat#901085, Affymetrix). The raw data 
were imported into the Partek Genomincs Suite, normalized using the Robust 
Multi-array Average (RMA) method and log2 transformed. Principal component 
analysis (PCA) and hierarchical clustering are presented based on Partek visualization 
program, using a 900 gene list from Gattinoni et al.24 Enrichment of up- or 
down-regulated genes was examined with the parametric gene set enrichment 
analysis (GSEA).49 Enriched gene sets were identified using 1000 permutations of 
the phenotype labels.
Metabolic assays
CD8+ T cells were sorted based on Cell Proliferation Dye eFluor450 by FACS-sorting. 
Proliferated cells were isolated at day 7 of allo-MLR, and then rested overnight in 
medium containing 50 IU/ml IL-2, 5 ng/ml IL-7, 5 ng/ml IL-15 and the corresponding 
AKT-inhibitor. Then, extracellular acidification rates (ECAR) and oxygen consumption 
rates (OCR) were measured with the XF96 Extracellular Flux Analyzer (Seahorse, 
Agilent) in basal medium (DMEM (cat#D5030, Sigma), 143 mM NaCl (cat#3624-01, 
Baker), 3 ml/L Phenol Red (cat#P0290, Sigma) supplemented with 2 mM L-glutamine 
(cat#35050-061, Life Technologies) for glycolytic stress tests (GST) and additionally 
25 mM d-glucose (cat#4912-12, VWR) and 1 mM sodium pyruvate (cat#360-070, 
Life Technologies) for mitochondrial stress tests (MST)). GST was measured in 
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response to 80 mM D-glucose, 18 µM oligomycin (cat#75351, Sigma) and 1 M 
2-deoxy- d-glucose (2DG, cat#D6134, Sigma). MST was measured in response to 16 
µM oligomycin, 4.5 µM fluoro-carbonyl cyanide phenylhydrazone (FCCP, cat#C2920, 
Sigma), 10 µM rotenone (cat#R8875, Sigma) and 10 µM antimycin A (cat#A8674, 
Sigma).
Statistics
Statistical analyses were performed with Prism software (GraphPad Software Inc., 
version 5.03) using a Student’s t-test, Wilcoxon rank test or One- or Two-way ANOVA, 
followed by a Bonferroni post-hoc test as indicated in the figure legends. Linear 
regression was calculated with a 95% confidence interval. P values ≤0.05 were 
considered to be significant and were used as predefined response definition.
Additional information regarding Minimal Information About T cell 
Assays (MIATA)
This study was conducted in a laboratory that operates under exploratory research 
principles. Experiments are performed in general research investigative assays 
according to investigative protocols. Raw data can be provided per request. 
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Supplementary Figure 1 | DMSO has no effect on viability, proliferation, and differentiation 
of CD8+ T cells. (A) CD8+ TN cells were stimulated with CD3/CD28 Dynabeads® in the presence 
of DMSO and analyzed for viability, proliferation, activation and differentiation phenotype 
based on expression of CD62L, CCR7 and CXCR4, n=2. Statistical analysis was performed by 
a One-way ANOVA followed by Bonferroni’s Multiple Comparison Test, Median Fluorescence 
Intensity (MFI).
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Supplementary Figure 2 | Minimal effect of AKT-inhibition on viability and proliferation. 
CD8+ TN cells of 2 independent donors were stimulated with CD3/CD28 dynabeads in presence of 
DMSO (Ctrl) or AktiVIII (12µM), MK (10-5-2.5-1.25 µM), TCN (80-40-20-10 µM), AZD (40-20-10-5 µM), 
GDC (40-20-10-5 µM), GSK1 (20-10-5-2.5 µM) or GSK2 (40-20-10-5 µM). Relative number of 
viable cells, n=2. Statistical analysis was performed by One-way ANOVA followed by Bonferroni’s 
Multiple Comparison Test compared to Ctrl cells, ‡p<0.001, #p<0.01, *p<0.05.
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Supplementary Figure 3 | Differentiation-, functionality- and apoptosis-associated genes 
are differently expressed in AKT-inhibited T cells. CD8+ TN cells of 3 independent donors 
were stimulated with allo-mDCs in presence of DMSO (Ctrl) or AktiVIII (12 µM), MK (5 µM), 
GDC (10 µM), GSK1 (2. 5µM) or GSK2 (10 µM). Expression of genes related to AKT activation, 
differentiation, functionality and apoptosis. Gene expression is shown as significant altered 
expression compared to control cells.
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Supplementary Figure 4 | Metabolic activity of AKT-inhibited CD8+ T cells. (A) CD8+ TN 
cells were stimulated with allo-mDCs in presence of DMSO (Ctrl) or AktiVIII (12 µM), MK (5 µM), 
GDC (10 µM), GSK1 (2.5 µM) or GSK2 (10 µM). (A) CD62L expression of proliferated CD8+ T 
cells used in the metabolic assays. Different symbols reflect different donors. (B) Basal 
respiration, maximal respiration and spare respiratory capacity, and (C) glycolytic capacity and 
glycolytic reserve of proliferated CD8+ T cells. Statistical analysis was performed by (A) 
One-way ANOVA followed by Bonferroni’s Multiple Comparison Test of AKT-inhibited compared 
to Ctrl cells, or (B) paired T test, Median Fluorescence Intensity (MFI), ‡p<0.001, #p<0.01, 
*p<0.05.
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Supplementary Figure 5 | Expansion and IFN-y production of AKT-inhibited MiHA-specific 
CD8+ T cells. CD8+ TN cells were stimulated with peptide-loaded mDCs in presence of DMSO 
(Ctrl) or 15 µM AktiVIII or 12.5 µM GDC. (A) Association of CD62L expression and expansion of 
Ctrl and GDC cultured MiHA-specific CD8+ T cells. (B) Percentage IFNγ+CD8+ T cells after 
rechallenge and O/N peptide stimulation. Mean+SEM of 2 independent donors. The mean 
percentage MiHA-specific CD8+ T cells was 0.9% in Ctrl, 0.2% in AktiVIII- and 5.8% in GDC- 
treated cultures. Linear regression was calculated with 95% confidence interval, Median 
Fluorescence Intensity (MFI).
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Abstract
Efficacy of adoptive T cell therapy could be improved by infusion of tumor-reactive 
T cells with early memory characteristics. Previously, we and others showed that 
 pharmacological AKT-inhibition during ex vivo CD8+ T cell expansion facilitates the 
generation of polyfunctional tumor-reactive T cells with stem cell memory-like traits. 
This makes AKT-inhibition an interesting approach to improve T cell therapies 
including chimeric antigen receptor or T cell receptor engineered T cells. However, 
these products are mostly generated from total lymphocytes or CD3+ T cells, 
containing also CD4+ T cells that can affect CD8+ T cells dependent on the helper 
subset. Here, we investigated the effect of AKT-inhibition during CD4+ T cell 
expansion, focusing on memory and T-helper subset differentiation. Akt-inhibitor VIII 
and GDC-0068 were added during activation and expansion of (naïve or total) CD4+, 
CD8+ or CD3+ T cells, whereupon phenotype, transcription factor profile, cytokine 
production, and expansion capacity were analyzed. Interestingly, ex vivo AKT-inhibition 
preserved the early memory phenotype of stimulated CD4+ T cells based on higher 
CD62L, CXCR4 and CCR7 expression. However, in the presence of AKT-inhibition 
T-helper subset differentiation was skewed towards more T-helper 2 at the expense 
of T-helper 1 cells. Additionally, the total percentage cytokine producing CD4+ 
T helper cells was lower in AKT-inhibited cultures. The enhanced induction of T-helper 
2 cells was still observed in total CD3+ T cell cultures and with both dendritic cell and 
polyclonal stimulation. Nevertheless, enhanced rechallenge capacity, degranulation 
and polyfunctionality upon antigen recall of AKT-inhibited CD8+ T cells was only 
observed in dendritic cell stimulated cultures. Importantly, the favorable effect of 
AKT-inhibition on CD8+ T cell polyfunctionality upon dendritic cell stimulation 
diminished in presence of AKT-inhibited CD4+ T cells. These findings indicate that for 
ex vivo generation of superior polyfunctional CD8+ T cells with stem cell memory-like 
characteristics, it is recommended to apply AKT-inhibition in absence of CD4+ T cells. 
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Introduction
Adoptive transfer of tumor-reactive T lymphocytes has the potential to induce 
sustained clinical remission in patients with advanced cancer.(1-3) Clinical efficacy 
seems dependent amongst others on the infusion of tumor-reactive T cells with early 
memory-like characteristics.4-6 Previously, we and others showed that pharmacolog-
ical AKT-inhibition during ex vivo CD8+ T cell expansion facilitates the generation of T 
cells with a stem cell memory (TSCM)-like phenotype.7-11 Interestingly, AKT-inhibition 
during activation of CD8+ T cells allows proliferation, while preserving the early 
memory phenotype with high expression of CD62L, CCR7, CXCR4, CD27 and 
CD28.7-12  Furthermore, the gene expression profile of AKT-inhibited CD8+ T cells 
resembled TSCM cells, which are known for their superior persistence in vivo.11, 13 
Importantly, AKT-inhibited CD8+ T cells showed increased expansion capacity upon 
recall, increased anti-tumor reactivity and enhanced polyfunctionality by co-producing 
IFNγ and IL2.7-11 This makes AKT-inhibition an interesting approach to improve 
adoptive T cell products, including ex vivo expanded tumor infiltrating lymphocytes 
(TILs), chimeric antigen receptor (CAR) T cells and T cell receptor (TCR)-transduced 
T cells.9, 12, 14, 15 However, these products are mostly generated from the total CD3+ 
T cell fraction or total peripheral blood mononuclear cells (PBMCs), containing also 
CD4+ T cells which can influence CD8+ T cells depending on the helper subset.16-18 
Therefore, we investigated the effect of AKT-inhibition on in vitro CD4+ T cell activation, 
focusing on memory and T-helper subset differentiation. 
 Like CD8+ T cells, naïve CD4+ T (TN) cells differentiate into TSCM, central memory 
T (TCM) cells, effector memory T (TEM) cells and effector T (TEFF) cells.19 Besides 
effector/memory differentiation, CD4+ T cells also acquire differential functional traits. 
The most prominent populations are CD4+ T helper 1 cells (Th1), T helper 2 cells 
(Th2), T helper 17 cells (Th17) and regulatory T cells (Tregs). Discrimination is mainly 
based on cytokine production profiles, in combination with expression of extracellular 
markers and transcription factors. The different CD4+ T cell subsets have distinctive 
helper functions, with Th1 cells being described as the most potent to support 
anti-tumor immunity. Th1 cells produce IFNγ and IL-2, thereby promoting priming and 
expansion of CD8+ T cells, and recruitment of NK cells and type I macrophages.20, 
21 In contrast, presence of Tregs is unfavorable for anti-tumor immunity, where high 
Treg:CD8 ratios are correlated with poor patient survival.22, 23 Th2 cells can promote 
anti-tumor effects through IL4 secretion and subsequent eosinophil and macrophage 
infiltration, but intratumoral Th2 cells have also been associated with reduced survival 
in solid tumors like pancreatic cancer.24-26 Th17 cells can favor anti-tumor immunity 
by stimulating T cell priming27, 28 or differentiation into IFNγ-secreting  cells, but they 
have also been reported to exert unfavorable effects by promoting angiogenesis.29-
32 As the CD4+ T helper subset may influence CD8+ T cell functionality when cultured 
together, it is essential to determine the effect of AKT-inhibition during ex vivo 
expansion.
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Previous studies showed that the PI3K/AKT-pathway plays a role in skewing differen-
tiation towards CD4+ T helper subsets. AKT signaling can support Th1 and Th17 dif-
ferentiation via mTORC1, while Th2 differentiation is stimulated via PI3K and 
mTORC2.33-35 Furthermore, inhibition of AKT and mTORC1 can cause induction of 
Tregs.36, 37 Together, this indicates that inhibition of AKT during CD4+ T cell stimulation 
might stimulate Th2 and Treg differentiation, while reducing skewing towards Th1 and 
Th17. Therefore, ex vivo AKT-inhibition might negatively influence CD4+ and CD8+ T 
cell function when applied in the generation of T cell therapy from total CD3+ T cells.
In this study, we investigated the effect of Akt-inhibitor VIII (AktiVIII) and GDC-0068 
(GDC) on CD4+ T cell effector/memory and functional helper subset differentiation. 
AktiVIII and GDC have an allosteric or adenosine triphosphate (ATP)-competitive 
mode of action respectively, and previously showed to be the most promising 
AKT-inhibitors for the generation of TSCM-like CD8+ T cells during T cell expansion by 
dendritic cells (DCs).11 Here, we show that next to CD8, both AKT-inhibitors preserved 
memory differentiation in CD4+ T cells reflected by higher expression of CD62L, 
CXCR4 and CCR7. However, T-helper subset skewing was altered with less Th1, and 
more Th2 cells in AKT-inhibited compared to control cultures. Furthermore, the 
favorable effect of AKT-inhibition on CD8+ T cell polyfunctionality was diminished in 
the presence of AKT-inhibited CD4+ T cells. Together, our findings indicate that for 
the optimal generation of polyfunctional CD8+ T cells with a TSCM-like phenotype it is 
recommended to apply AKT-inhibition in absence of CD4+ T cells.
Methods
Cell material and isolation
PBMCs were isolated from buffy coats of healthy donors (Sanquin Blood Supply 
Foundation) using Ficoll-paqueTM PLUS (Sigma-Aldrich) density gradient 
centrifugation. CD14+ monocytes were isolated from fresh material using anti-CD14 
immunomagnetic beads (Miltenyi Biotec). Peripheral blood lymphocytes (PBLs) were 
cryopreserved in medium containing 10% dimethylsulfoxide (DMSO, Merck Millipore) 
and 10% serum. T cells were isolated from fresh or frozen material via magnetic bead 
isolation using the EasySepTM Human Naïve CD4+ T Cell Isolation Kit (Stemcell 
Technologies) or CD3, CD4 or CD8 microbeads (Miltenyi Biotec). The obtained purity 
was on average 95% (ranging from 91-99%) and CD3, CD4 and CD8 bead-isolated T 
cells contained on average 52% TN cells (ranging from 27-83%).
T cell cultures
To generate mature dendritic cells (mDCs), monocytes were cultured for 2-3 days in 
X-VIVOTM 15 medium (Lonza) supplemented with 2% human serum (HS, Sanquin 
Blood Supply Foundation), 500 IU/ IL4 and 800 IU/ml GM-CSF (both ImmunoTools). 
Subsequently, cells were re-plated at 0.5x106/ml in fresh X-VIVOTM 15 containing 2% 
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HS, 500 IU/ IL4 and 800 IU/ml GM-CSF for another 3-4 days. Next, immature DCs 
were maturated for 2 days by adding X-VIVOTM 15 containing 2% HS and cytokines at 
a final concentration of 5 ng/ml IL1β, 15 ng/ml IL6, 20 ng/ml TNFα (all ImmunoTools) 
and 1 µg/ml PGE2 (Pfizer). 
 CD3+ T cells, CD4+ T cells, CD4+ TN, or CD8+ T cells were stimulated with 
allogeneic mDCs at a 1:10 DC:T cell ratio or with CD3/CD28 Dynabeads (ThermoFisher) 
at a 1:1 bead: T cell ratio for 10 days in Isove’s Modified Dulbecco’s Medium (IMDM, 
Gibco), supplemented with 10% HS, 50 IU/ml IL2 (Chiron), 5 ng/ml IL7, and 5 ng/ml 
IL15 (both ImmunoTools). When indicated, Akt-inhibitor VIII (cat#A6730, Sigma) or 
GDC-0068 (cat#HY-15186, MedChemExpress), dissolved in DMSO (Merck Millipore), 
was added. Control conditions were supplemented with corresponding concentrations 
of DMSO (≤0.1% in all experiments). Half of the culture volume was refreshed with 
medium plus cytokines and AKT-inhibitor or DMSO every 2-3 days. Cells were 
rechallenged with mDCs or CD3/CD28 beads on day 10 and cultured for another 7 
days without AKT-inhibitor or DMSO. To evaluate cytokine production profiles on day 
10 or 17, T cells were restimulated overnight with mDCs (1:10 DC:T cell ratio) or 1µg/
ml PMA plus 40µg/ml ionomycin (both Sigma), in the presence of Brefeldin A or 
Monensin, in absence of AKT-inhibitor or DMSO.   
Flow cytometry
Immunophenotypical analysis was performed by flow cytometry. Cells were washed 
with PBS (Braun) containing 0.5% bovine serum albumin (BSA, Sigma) followed by 
extracellular staining for 30 minutes at 4°C in the dark with antibodies against CD3 
(UCHT1, Biolegend), CD4 (SK3, Biolegend), CD8 (RPA-T8, Biolegend), CD45RO 
(UCHL1, Beckman Coulter) and Fixable Viability Dye eFluor780 (ThermoFisher). 
Additionally, for effector memory phenotyping the following antibodies were used: 
CCR7 (G04H7, Biolegend), CD62L (DREG56, Biolegend) and CXCR4 (12G5, 
Biolegend); and for CD4+ T cell subset skewing: CXCR3 (G025H7, Biolegend), CCR4 
(L291H4, Biolegend), CCR6 (G034E3, Biolegend), and CD25 (B1.49.9, Beckman 
Coulter). For intracellular transcription factor staining, cells were fixated and 
permeabilized with Fixation/Permeabilization Concentrate and Diluent (both 
eBioscience) and stained in Permeabilization Buffer (eBioscience) with antibodies for 
T-bet (4B10, eBioscience), GATA3 (16E10A23, Biolegend), RORγT (AFKJS-9, 
eBioscience) and FOXP3 (3G3, eBioscience). Intracellular staining of CD4+ T cell 
cytokines was performed upon fixation and permeabilization with Fixation/Permeabi-
lization Concentrate and Diluent after overnight restimulation in presence of Brefeldin 
A (Golgiplug, BD Biosciences) to analyze IFNγ (B27, BD Biosciences), IL4 (8D4-8, BD 
Biosciences) and IL17 (BL168, Biolegend), or Monensin (Golgistop, BD Biosciences) 
to analyze IL10 (JES3-9D7, BD Biosciences). CD8+ T cell polyfunctionality was 
analyzed after overnight stimulation in presence of Brefeldin A and CD107a (H4A3, 
Biolegend) after which cells were fixated with 4% paraformaldehyde (BOOM) for 10 
minutes at RT in the dark, followed by permeabilization with 0.1% saponin buffer 
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(Sigma) containing 10% fetal calf serum (FCS, Integro B.V.) for 10 minutes at RT. 
Staining of IFNγ, IL2 (5344.111, BD Biosciences) and TNFα (MAb11, BD Biosciences) 
was performed in 0.1% saponin buffer for 30 minutes at 4°C in the dark. 
 After staining, cell data acquisition was performed on the Gallios flow cytometer 
(Beckman Coulter). Flow cytometry data was analyzed with Kaluza software 
(Beckman Coulter, version 1.5a and 2.1). Delta median fluorescence intensity (ΔMFI) 
was calculated by subtracting the MFI of the marker of interest with the MFI of the 
background fluorescence of CD45RO+CD3+CD4+ or CD45RO+CD3+CD8+ T cells. 
Polyfunctionality of CD8+ T cells was visualized using SPICE version 5.3 (NIH/NIAID, 
MD, USA).
Statistical analysis
Statistical analysis was performed with Prism software (Graphpad Software Inc., 
version 5.03) using a Student’s T-test or One-way ANOVA, followed by a Bonferroni 
post-hoc test as indicated in the figure legends.
Results
AKT-inhibition preserves CD4+ memory differentiation but promotes 
CD4+ Th2 skewing at the expense of Th1 cells.
We previously showed that TSCM-like CD8+ T cells can be generated by AKT-inhibition 
during ex vivo T cell activation and expansion by allo-antigen or minor histocompati-
biliy antigen-presenting DCs.7, 11 To study the effect of AKT-inhibition on effector 
memory differentiation of CD4+ T cells, we stimulated CD4 TN cells with allogeneic 
mDCs in combination with increasing dosages of AKT-inhibitor. First, DMSO drug 
solvent effects were excluded, as viability, activation, expansion and differentiation of 
CD4+ T cells was not affected (Supplementary Figure 1). Notably, increasing dosages 
of AKT-inhibitor did not affect viability (Figure 1A) nor activation (Figure 1B), though a 
dose dependent effect on expansion was observed (Figure 1C). CD4+ T cell 
expansion reduced from 40-fold in control conditions to 20-fold at the highest dose 
of AktiVIIII (18µM) and GDC (10µM) during the 10-day culture period. Importantly, the 
naïve-associated marker CD62L was dose-dependently retained on CD4+ T cells 
cultured with AKT-inhibitors (Figure 1D&E). In addition, CCR7 and CXCR4 were 
preserved on AktiVIII-treated CD4+ T cells, while these effects were less prominent 
for GDC-treated CD4+ T cells. Especially, CCR7 could not be preserved by this ATP- 
competitive AKT-inhibitor. Overall, ex vivo AKT-inhibition preserved memory  differentiation 
of CD4+ TN cells upon stimulation in a dose dependent manner, with the strongest 
effects shown for the allosteric inhibitor AktiVIII.
 Besides effector memory differentiation, CD4+ T cell subsets with distinct effector 
functions are generated upon activation of naive T cells. Therefore, the effect of 
AKT-inhibition on subset skewing towards Th1, Th2, Th17 and Tregs was evaluated 
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Figure 1 | AKT-inhibition preserves CD4+ T cell differentiation. CD4+ TN cells were 
stimulated with allogeneic mature dendritic cells (mDCS) in presence of DMSO (Ctrl), AktiVIII 
(18µM, 12µM, 6µM) or GDC (10µM, 5µM, 2.5µM) for 10 days. (A) Percentage viable and (B) 
activated (CD45RO+) CD4+ T cells. Mean+SEM for 5 independent donors is shown. (C) Fold 
expansion of CD4+ T cells between day 0-10. Individual donors are depicted with unique 
symbols. (D-E) Surface expression of CD62L, CCR7 and CXCR4 on CD3+CD4+CD45RO+ T 
cells of (D) 1 representative donor (filled) with corresponding background staining (open), 
where numbers represent delta median fluorescent intensity (ΔMFI), and (E) expression 
overview for 4-5 independent donors. Statistical analysis was performed using Repeated 
Measures ANOVA followed by Bonferroni’s Multiple Comparison Test, comparing AKT-inhibited 
with Ctrl T cells. ***p<0.001, **p<0.01, *p<0.05.
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Figure 2 | AKT-inhibition modulates CD4+ T cell skewing of Th1 and Th2. CD4+ TN cells 
were stimulated with mDCS in presence of DMSO (Ctrl), AktiVIII (18µM) or GDC (10µM) for 10 
days. (A) Surface expression (filled) or (B) intracellular transcription factor expression (filled) and 
corresponding background staining (open) on/in CD3+CD4+CD45RO+ T cells. Data shown for 1 
representative donor. Numbers represent delta median fluorescent intensity (ΔMFI). (C) Cytokine 
production of CD3+CD4+CD45RO+ T cells of 1 representative donor after overnight restimulation 
with mDCs in absence of AKT-inhibitors. Numbers show percentages cytokine producing cells. 
(D) Heatmap showing fold change compared to Ctrl condition of different T-helper cell associated 
parameters for 4-5 independent donors. Grey = no data. Darkest colors represent fold change 
≥2. (E) Total cytokine production and composition of CD3+CD4+CD45RO+ T cells for 4-5 
independent donors. IL10 production was analyzed in separate tube and is therefore not corrected 
for co-production. Statistical analysis performed on total percentage cytokine producing cells. 
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based on extracellular phenotype, intracellular expression of transcription factors and 
cytokine secretion profiles. The Th17-associated markers (CCR6, RORγT and IL17) 
were not found upon activation of CD4+ TN cells and therefore not further evaluated 
in this assay. Remarkably, while the Th1 population was most dominant in control 
cultures, extracellular expression of the Th1-associated marker CXCR3 was lower on 
AKT-inhibited CD4+ T cells (Figure 2A&D; Supplementary Figure 2A). On the contrary, 
Th2-associated CCR4 was significantly higher expressed on AktiVIII cultured cells. 
(Figure 2A&D and Supplementary Figure 2A). Effects on transcription factor 
expression were less pronounced, with only significant higher levels of Th2-associated 
GATA3 in AktiVIII cultured cells (Figure 2B&D and Supplementary Figure 2B). 
Additionally, cytokine secretion profiles were analyzed after overnight restimulation 
with allogeneic mDCs. AKT-inhibited cultures showed significantly lower percentages 
of IFNγ-producing T cells, confirming the inhibitory effect of AKT-inhibition on Th1 
differentiation (Figure 2C&D and Supplementary Figure 2C). Again, skewing towards 
the Th2 subset was observed as reflected by the increased percentage of 
AKT-inhibited T cells producing IL4. Although the percentage of IL10-producing cells 
was low (≤3%), a small increase in Treg-associated IL10 production was observed for 
GDC-cultured conditions. Together, these data indicate that both AKT-inhibitors 
AktiVIII and GDC markedly skew the acquisition of CD4+ effector functions towards 
Th2 traits and less towards Th1 cell differentiation (Figure 2D and Supplementary 
Figure 2D). Moreover, the total proportion of cytokine producing CD4+ T cells was 
significantly lower in AKT-inhibited cultures (Figure 2E). Notably, when cells were 
cultured for an additional week in absence of AKT-inhibitor, the negative effect on Th1 
skewing was sustained, as IFNγ-production remained significantly lower in cultures 
previously treated with AktiVIII (Figure 2F). Together, these data show that in vitro 
AKT-inhibition promotes CD4+ T-helper subset skewing towards Th2 cells while 
diminishing Th1 skewing.
AKT-inhibition changes CD4+ T cell skewing in total CD3+ T cell 
cultures resulting in reduced CD8+ T cell polyfunctionality
As manufacturing of most adoptive T cell products starts with total CD3+ T cells, 
containing total CD4+ instead of CD4+ TN cells, we investigated the effect of 
AKT-inhibition on CD4+ T cell differentiation when starting with either total CD3+ or 
CD4+ T cell bulk cultures. Similar to starting from CD4+ TN cells, preserved memory 
differentiation of AKT-inhibited CD4+ T cells was observed (Figure 3A and 
Supplementary Figure 3). Interestingly, though AKT-inhibition impeded the proportion 
(F) Percentage IFNγ, IL4 or IL10 producing cells on day 18 upon overnight restimulation with 
mDCs after 1 week of rechallenge in absence of AKT-inhibitors. Data shown for 4-5 independent 
donors. Individual donors are depicted with unique symbols. Statistical analysis was performed 
using Repeated Measures ANOVA followed by Bonferroni’s Multiple Comparison Test, comparing 
AKT-inhibited with Ctrl T cells. ***p<0.001, **p<0.01, *p<0.05.
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Figure 3 | AKT-inhibition does not impede Th1 skewing of CD4+ T cells in cultures with 
total CD3+ T cells.  Total CD3+ T cells  or CD4+ T cells were stimulated with allo-mDCS in 
presence of DMSO (Ctrl), AktiVIII (18µM) or GDC (10µM) for 10 days. (A) CD62L expression 
(delta median fluorescent intensity, ΔMFI) of CD3+CD4+CD45RO+ T cells in CD3+ or CD4+ T 
cell cultures. Mean+SD (n=2) shown for 1 representative out of 3 donors. (B-D) On day 11 
intracellular cytokine staining was performed after O/N restimulation with mDCs in absence of 
AKT-inhibitors. (B) Dotplots of 1 representative donor, numbers represent percentage cytokine 
producing cells. (C) Percentages IFNγ-, IL4-, IL17- and IL10-producing cells for 3 independent 
donors. Individual donors are depicted with unique symbols. (D) Total cytokine production and 
composition of CD3+CD4+CD45RO+ T cells. Mean+SEM of 3 independent donors. IL10 
production was analyzed in separate tube and therefore not corrected for co-production. 
Percentages are corrected for non-stimulated background staining. Statistical analysis was 
performed using (A) One-Way ANOVA and (C-D) Repeated Measures ANOVA followed by 
Bonferroni’s Multiple Comparison Test, comparing AKT-inhibited with Ctrl T cells. ***p<0.001, 
**p<0.01, *p<0.05.
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of CD4+ T cells producing IFNγ when cultures were started with CD4+ T cells, this 
was not observed when total CD3+ T cells were used as starting material. (Figure 
3B&C). Moreover, also negative effects on CXCR3 and T-bet expression were less 
pronounced and more variable in total CD3+ T cell cultures compared to cultures 
started with solely CD4+ T cells (Supplementary Figure 4). The observed differences 
could be mainly attributed to differences in IFNγ production capacity of control 
(non-AKT-inhibited) CD4+ T cells. Here, non-AKT-inhibited CD4+ T cells in CD4+ T 
cell cultures produced more IFNγ compared to CD4+ T cells in CD3+ T cell culture 
(33% vs 10% respectively), while AKT-inhibited CD4+ T cells showed similar levels in 
both cultures (17% vs 16%). Nevertheless, for both CD3+ and CD4+ T cell cultures 
skewing towards Th2 cells was still observed upon AKT-inhibition (Figure 3B&C and 
Supplementary Figure 4). Moreover, IL17-producing CD4+ T cells could be detected 
when starting cultures with either total CD3+ or CD4+ T cells, with a trend towards 
increased percentages of IL17-producing cells upon AKT-inhibition, when starting 
with total CD3+ T cells. Lastly, IL10-production was again low (≤3%) in these cultures, 
no significant effect on IL10 producing cells upon AKT-inhibition. Together, a tendency 
towards increased total percentages cytokine producing AKT-inhibited CD4+ T cells 
was observed in CD3+ T cell cultures (Figure 3D). The total proportion of cytokine 
Figure 4 | AKT-inhibition preserves early memory CD8+ T cell differentiation and 
improves rechallenge capacity of CD8+ T cells. Total CD3+ T cells or CD8+ T cells were 
stimulated with mDCS in presence of DMSO (Ctrl), AktiVIII (18µM) or GDC (10µM) for 10 days. 
(A) CD62L expression on CD3+CD8+CD45RO+ T cells for 2 independent donors. Delta median 
fluorescent intensity (ΔMFI), Mean+SD, n=2. (B) Fold expansion between day 10 and 17 upon 
rechallenge with mDCs in absence of AKT-inhibitors, 2 independent donors, mean+SD, n=2. 
Statistical analysis was performed using One-Way ANOVA followed by Bonferroni’s Multiple 
Comparison Test, comparing AKT-inhibited with Ctrl T cells within each starting population. Ctrl 
conditions were compared with a two-tailed unpaired T test. ***p<0.001, **p<0.01, *p<0.05.
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producing CD4+ T cells was not increased in AKT-inhibited CD4+ T cell cultures 
because of the higher percentages IFNγ- and IL17-producing cells in the control 
(non-AKT-inhibited) condition. Collectively, these data show that AKT-inhibition does 
not impede Th1 skewing in CD3+ T cell cultures, though skewing towards IL4-producing 
Th2 subsets by AKT-inhibition remains dominant. 
 As changes in the CD4+ T-helper skewing could affect CD8+ T cell functionality, 
which is pivotal for effective anti-tumor efficacy, we analyzed the effect of AKT-inhibition 
on CD8+ T cell functionality in presence and absence of CD4+ T cells. First, we 
confirmed the preserved early memory phenotype of CD8+ T cells in AktiVIII and 
GDC cultured conditions when starting with total CD3+ or CD8+ T cells based on 
CD62L expression (Figure 4A). Notably, in (non-AKT-inhibited) control conditions the 
presence of CD4+ T cells reduced CD8+ T cell differentiation, shown by higher CD62L 
expression compared to cultures with only CD8+ T cells. Furthermore, in control conditions 
the presence of CD4+ T cells also improved the rechallenge expansion capacity of 
CD8+ T cells upon antigen recall as was expected (Figure 4B). Importantly, 10-day 
AktiVIII or GDC treatment provided significantly enhanced CD8+ T cell expansion 
capacity upon rechallenge, though effects were less pronounced when CD4+ T cells 
were present in the starting material. As most T cell therapies are generated using 
polyclonal stimulation, AKT-inhibition was also investigated in combination with 
anti-CD3/CD28 beads stimulation instead of allo-mDCs. Here, effects on CD62L 
expression were less prominent, however also in this setting AKT-inhibition could 
preserve expression of CCR7 and CXCR4 indicating an early memory phenotype of 
both CD4+ and CD8+ T cells (Figure 5A). Similarly, also in this setting a change in 
T helper cytokine production was observed with less IFNγ-producing and more 
IL4-producing CD4+ T cells (Figure 5B). In contrast to allo-mDC stimulation the reduction 
of IFNγ-producing T cells was also observed in CD3+ T cell cultures. Importantly, 
rechallenge experiments showed clearly enhanced CD8+ T cell expansion capacity 
in AKT-inhibited CD8+ T cells cultures (Figure 5C). However, this could not be 
observed in CD3+ T cell cultures, were T cell expansion levels of non- AKT-inhibited 
CD8+ T cells were already higher, most likely due to the presence of CD4+ T cells 
(Figure 5C). Combined, also in CD3/CD28 polyclonal stimulated T cell cultures, 
AKT-inhibition preserved the early memory phenotype of CD4+ and CD8+ T cells. 
Though the effect on phenotype was independent of the presence of CD4+ T cells, 
the rechallenge expansion capacity of CD8+ T cells upon polyclonal stimulation 
could not be enhanced with AKT-inhibition. 
 As killing capacity and cytokine production of CD8+ T cells is pivotal for their 
function in anti-tumor immunity, we further analyzed the CD8+ T cell functionality on 
degranulation and polyfunctional effector cytokine production after one week of 
rechallenge in absence of AKT-inhibitors. Here, some effect of AKT-inhibition was 
found in CD3/CD28 polyclonal stimulated cells. A trend toward somewhat higher 
degranulation capacity was seen for AKT-inhibited CD8+ T cells in the absence of 
CD4+ T cells (Figure 6A). Furthermore, while IL2 and TNFα production was not affected, 
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production of IFNγ was lower in CD8+ T cells expanded from AKT-inhibited cultures 
(Figure 6B and Supplementary Figure 5A). More striking effects were seen on CD8+ 
T cells expanded by AKT-inhibited allo-mDCs stimulated cultures showing improvement 
of degranulation, but only in the absence of CD4+ T cells (Figure 6C). Accordingly, 
an enhancement of cytokine production was observed for IFNγ, IL2 and TNFα as well 
as polyfunctionality. However, the (polyfunctional) cytokine production of CD8+ T cells 
was only enhanced in AKT-inhibited cultures when starting with CD8+ T cells alone 
(Figure 6D-F; Supplementary Figure 5B&C). Altogether, these data demonstrate that 
the beneficial effect of AKT-inhibition on polyfunctionality of CD8+ T cells is dependent 
on the composition of the cell starting material and stimulation strategy, where 
AKT-inhibited CD4+ T cells impede the favorable effect of AKT-inhibition on CD8+ T cells. 
Figure 5 | AKT-inhibition in polyclonal stimulated T cells induces early memory T cells 
and affects Th1 and Th2 skewing. Total CD3+ T cells or CD8+ T cells were stimulated with 
CD3/CD28 Dynabeads in presence of DMSO (Ctrl), AktiVIII (18µM) or GDC (20µM) for 10 days. 
(A) CD62L, CCR7 and CXCR4 expression on CD3+CD8+CD45RO+ T cells. (B) IFNγ- and 
IL4-producing cells. (C) Fold expansion of CD8+ T cells between day 10 and 17 upon 
rechallenge with CD3/CD28 Dynabeads in absence of AKT-inhibitors. Data is depicted as (A & 
C) delta median fluorescent intensity (ΔMFI) with Mean+SEM. or as (B) individual donors 
depicted with unique symbols, of 4 independent donors. Statistical analysis was performed 
using Repeated Measures ANOVA followed by Bonferroni’s Multiple Comparison Test, 
comparing AKT-inhibited with Ctrl T cells within each starting population. Ctrl conditions were 
compared with a two-tailed paired T test. ***p<0.001, **p<0.01, *p<0.05.
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Figure 6 | AKT-inhibition of allo-mDC stimulated CD8+ T cells enhances polyfunctionality 
in absence of CD4+ T cells. Total CD3+ T cells or CD8+ T cells were stimulated with CD3/
CD28 Dynabeads (A&B) or allo-mDCs (C-E) in presence of DMSO (Ctrl), AktiVIII (18µM) or 
GDC (20µM in A&B and 10uM in  C-E) for 10 days. Cells were restimulated in absence of 
AKT-inhibition for 7 days. Degranulation and cytokine production were analyzed after O/N 
PMA/Ionomycin (A&B) or allo-mDC stimulation (C-E). (A) Percentages CD107a+ within 
polyclonal stimulated CD3+CD8+ T cells. Mean+SEM of 3 independent donors. (B) Percentages 
IFNγ-, IL2-, and TNFα-producing CD3+CD8+ T cells, analyzed using SPICE software. The pie 
arcs depict the proportion of cells that produces a specific cytokine and pie slices the proportion 
of cells co-producing 0 to 3 different cytokines (C) Percentages CD107a+ T cells within 
allo-mDC stimulated CD3+CD8+ T cells. Mean+SEM of 3 independent donors. (D) IFNγ-, IL2-, 
and TNFα-producing CD3+CD8+ T cells, analyzed using SPICE software. (E) Total IFNγ-, IL2-, 
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Discussion
Adoptive T cell therapy is a promising treatment for hematological malignancies as 
shown by impressive responses of anti-CD19 CAR T cells in patients with acute 
lympho blastic leukemia and B cell lymphoma.38-40 However, in other malignancies 
like chronic lymphocytic leukemia complete response rates with CAR-T cells are 
lower, because of early loss of tumor-reactive T cell persistence.5, 40, 41 Importantly, 
complete responses have been associated with robust T cell expansion and persistence, 
and an early memory phenotype of the infused T cells.5, 38, 42-45 Therefore, efficacy of 
adoptive T cell therapy could be improved by infusion of tumor-reactive T cells with 
early memory traits. Previously, we and others showed that inhibition of the 
AKT-pathway is a powerful means to generate these stem cell memory-like CD8+ 
T cells ex vivo.7-9, 11 Furthermore, AKT-inhibition did not harm the expansion of minor 
histocompatibility antigen-specific CD8+ T cells from the naïve repertoire for post- 
allogeneic stem cell transplantation immunotherapy.11 Hereto, it would be interesting 
to apply pharmacological AKT-inhibition also to manufacturing protocols of other 
adoptive T cell therapeutics. However, when generating or expanding tumor-reactive 
T cells for CAR T cell, TCR-transduced T cell or TIL therapy, PBMCs or total CD3+ 
T cells are mostly used instead of purified CD8+ T cells.2, 38-41, 46 This can be an 
advantage because of the supportive role of CD4+ T helper cells for CD8+ T cells.16-18 
As the effect of ex vivo AKT-inhibition on CD4+ T cells is not well studied, we here aimed 
to investigate the effect of pharmacologic AKT-inhibition on CD4+ T cell differentiation, 
functionality and their support to CD8+ T cell function. 
 In agreement to our previous finding for (naïve) CD8+ T cells, both AktiVIII and 
GDC preserved the CD4+ early memory T cell phenotype, showing higher expression 
of CCR7, CD62L and CXCR4 while allowing T cell proliferation. Interestingly, mouse 
studies also revealed the superior anti-tumor effect of early memory CD4+ T cells.44 
Anti-CD19 CAR T cells generated from CD4+ TN and TCM cells exhibited a higher 
expression of CD62L and had favorable effects on survival of tumor-bearing mice 
compared to treatment with CAR T cells generated from CD4+ TEM. This was also 
observed in combination with anti-CD19 CAR T cell treatment generated from CD8+ 
TCM. Together this indicates that the preserved CD4+ early memory T cell phenotype, 
could by itself be beneficial for adoptive T cell therapy efficacy.    
 However, besides the favorable effect on the CD4+ T cell early memory state, we 
observed that ex vivo AKT-inhibition also modulated the CD4+ T-helper subset 
skewing. We demonstrated that AKT-inhibition reduced Th1-characterisitics, while 
promoting Th2 differentiation. As cytokine production generally reflects the functional 
TNFα- and (F) triple-producing CD3+CD8+ T cells. Statistical analysis was performed using 
Repeated Measures ANOVA followed by Bonferroni’s Multiple Comparison Test, comparing 
AKT-inhibited with Ctrl T cells within each starting population. Ctrl conditions were compared 
with a two-tailed paired T test. ***p<0.001, **p<0.01, *p<0.05.
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characteristics of T cells, this is the most important parameter to evaluate positive 
and negative effects of AKT-inhibition. The stimulating effect of AKT-signaling on Th1 
skewing has been described before, and fits with our observation that ex vivo inhibition 
of AKT-signaling results in less Th1/IFNγ-producing cells.15, 47, 48 While the increased 
Th2 differentiation by AKT-inhibition has not been described previously, it is known 
that Th1 and Th2 cells can inhibit each other via production of IFNγ and IL4, 
respectively.49 Therefore, less Th1-produced IFNγ in AKT-inhibited compared to 
control cultures might result in reduced inhibition of Th2 differentiation, resulting in 
higher numbers of Th2 cells. Together, this demonstrates that while AKT-inhibition 
might be beneficial by preserving early memory CD4+ T cells, it has undesirable 
effects on skewing towards anti-tumor immunity promoting T-helper subsets. 
 Since therapeutic T cell products are most often generated from PBMCs or 
CD3+ T cell fractions, which contain besides CD4+ TN cells also effector and memory 
CD4+ T cells, as well as CD8+ T cells, we evaluated the effect of AKT-inhibition on 
CD4+ T cells starting with either total CD4+ T or CD3+ T cell cultures. When starting 
the cultures with total CD4+ T cells instead of CD4+ TN alone, we still observed 
preserved early memory differentiation though the effects on CD4+ T-helper subset 
skewing were less pronounced. This is probably due to the difference in skewing-po-
tential of naïve versus effector and memory subsets, as well as the presence of cyto-
kine-producing CD4+ effector T cells in the starting population could play a role.29 
Similarly, when cultures were started with CD3+ T cells, the cytokines produced by 
CD8+ T cells most likely affected (AKT-inhibition of) CD4+ T cells. The presence of 
CD8+ T cells reduces the IFNγ-production of (non-AKT-inhibited) control CD4+ T 
cells. As a consequence, addition of an AKT-inhibitor does no longer reduce the 
percentage IFNγ-producing CD4+ T cells. Additionally, less memory differentiation 
was observed, but the preservation of CD62L expression of AKT-inhibited CD4+ T 
cells was diminished in presence of CD8+ T cells. The effect of AKT-inhibition is most 
likely dependent on the balance between AKT-inhibition and the magnitude of T cell 
stimulation, meaning that smaller effects of AKT-inhibition in total CD3+ T cells 
cultures might be a result of stronger T cell stimulation. We observed previously that 
more CD8+ T cell expansion is indeed associated with lower CD62L expression.11 
Furthermore, it has been described that CD8+ effector T cells can boost both 
phenotypic and functional differentiation of naïve T cells.50 The cytokines produced 
by CD8+ T cells in total CD3+ T cell cultures might therefore result in stronger T cell 
stimulation and as a consequence smaller effects of AKT-inhibition on CD4+ effector 
memory and T-helper differentiation. Taken together, several factors produced by 
CD4+ and CD8+ T cells influence the balance of stimulation and thereby the effect of 
AKT-inhibition on their counterparts.
 Finally, in our study allogeneic mDCs were used as potent stimulators as they 
form the most physiological activation stimulus for T cells. However, current 
approaches employ polyclonal stimulation for the generation of therapeutic T cell 
products. Stimulation with anti-CD3/CD28 beads instead of allo-mDCs also resulted 
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in preserved early memory differentiation as well as a change in CD4+ T-helper 
cytokine production. However, CD62L expression was less preserved and also 
reduced percentages of CD4+ and CD8+ IFNγ-producing T cells in total CD3+ T cell 
cultures indicate differences in the final T cell products. Additionally, no clear effect 
on degranulation was observed. Strikingly, stimulation by DCs which induce more 
co-stimulation signals, as well as a variety of cytokines did favor the functionality of 
CD8+ T cells. Moreover, the duration of stimulation may differ between CD3/CD28 
beads and DCs. These differences in stimulation has shown to be critical in 
AKT-inhibition during ex vivo T cell stimulation, as AKT-inhibition could not improve 
polyfunctionality of CD3/CD28 bead-stimulated T cells, while expansion, degranulation 
and (polyfunctional) cytokine production of IFNγ, IL2 and TNFα was impressively 
enhanced in DC-stimulated CD8+ T cells.
 As described for CD4+ T helper cells, we observed a supportive role of CD4+ T 
cells to CD8+ T cell functionality in control cultures.16-18 In DC stimulated cultures, the 
presence of CD4+ T cells in Ctrl conditions resulted in a better expansion capacity, 
degranulation and more polyfunctionality of non-AKT-inhibited CD8+ T cells. This 
supportive role, based on cytokine support and a positive balance in co-stimulatory 
and co-inhibitory molecule expression provides rational for adoptive T cell therapies 
containing both CD4+ and CD8+ T cells.16 Importantly, AKT-inhibition in these allo-DC 
cultures preserved the early memory CD8+ T cell phenotype and resulted in a further 
increased CD8+ T cell expansion upon antigen recall both in the absence and 
presence of CD4+ T cells. However, AKT-inhibition did no longer increase the poly-
functionality of CD8+ T cells when CD4+ T cells were present in the culture. Previously, 
we demonstrated that when AKT-inhibition was applied in CD8+ T cell cultures a 
significant increase in polyfunctionality was observed.11 These polyfunctional T cells 
mediate multiple anti-tumor functions and this is therefore an important advantage of 
AKT-inhibited CD8+ T cells. 
 Other studies have shown that AKT and PI3K-inhibition is feasible during CAR 
transduction, and preserves CD62L expression on CAR T cells.9, 12, 15 With this 
strategy, pharmaceutical inhibitors are solely applied to the ex vivo culture protocol, 
but not present in vivo as it is washed away in the therapeutic product before infusion. 
Most studies where AKT- or PI3K-inhibition was applied during the generation of 
CAR T cells, focused on effects on CD8+ T cells. Only minor attention was given to 
modulation of CD4+ T cells following PI3K/AKT-pathway inhibition.9, 15 In Petersen 
et al. anti-CD5 CAR T cells were generated in the presence of a PI3K-inhibitor.15 
They analyzed the cytokine production profiles for CD4+ and CD8+ T cells separately 
and showed a trend towards lower percentages of IFNγ-producing cells for both cell 
types, similar to our observations. Moreover, Urak et al. applied AKT-inhibition for 
the generation of anti-CD19 CAR T cells and showed retained CD62L expression on 
AKT-inhibited T cells.12 In mouse models, a combination of AKT-inhibited CD4+ and 
CD8+ CAR T cells showed better anti-tumor effects compared to control CAR T cells. 
However, this study did not include a control condition to state whether AKT-inhibited 
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CD8+ CAR T cells with untreated CD4+ CAR T cells would have been better, 
considering our data. Here, PI3K/AKT-pathway inhibition of CD4+ T cells also might 
have had non-optimal effects. 
 Since ex vivo AKT-inhibition during T cell stimulation by DCs or CD3/CD28 beads, 
facilitates the generation of CD8+ T cells with TSCM phenotype and superior rechallenge 
capacity, it is a promising strategy to apply in the generation of CAR T cells, 
TCR-transduced T cells, and TIL therapeutic products. However, despite favorable 
effects on CD8+ T cells, our data show unfavorable consequences of AKT-inhibition 
on CD4+ helper-T cell differentiation and their subsequent negative influence on 
CD8+ T cell polyfunctionality in both allo-mDC and CD3/CD28 bead-stimulation 
assays. Moreover, the stimulation of choice largely affected the proportion of 
cytokine- producing CD8+ T cells in both Ctrl and AKT-inhibited conditions. Since, 
TSCM-like differentiation status and polyfunctional characteristics of CD8+ T cells 
are postulated to be pivotal for therapeutic efficacy, we recommend to generate 
AKT-inhibited CD8+ T cells in the absence of CD4+ T cells, where CD4+ T cells could 
be CAR/TCR transduced and expanded separately followed by co-infusion for 
therapy of cancer patients. 
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Supplementary Figure 1 | DMSO has no effect on viability, activation, expansion and 
differentiation of CD4+ T cells. CD4+ TN cells were stimulated with mDCs in absence or 
presence of 0.1% DMSO and analyzed on day 10 for viability, activation, expansion, memory 
(CD62L, CCR7, CXCR4) and T cell subset (CXCR3, CCR4, CD25) phenotype. Mean + SEM of 
2 independent donors. Statistical analysis was performed using a two-tailed unpaired T test, no 
significant changes were found.
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Supplementary Figure 2 | AKT-inhibition modulates CD4+ T cell skewing towards Th1, 
Th2 and Tregs. CD4+ TN cells were stimulated with mDCS in presence of DMSO (Ctrl), AktiVIII 
or GDC for 10 days. (A-C) Relative (A) surface expression or (B) intracellular transcription factor 
expression and (C) cytokine production after O/N restimulation with mDCs in absence of AKT-
inhibitors, of CD3+CD4+CD45RO+ T cells, corresponding to data shown in heat-map (Figure 
2D, AktiVIII (18µM) and GDC (10µM)). Mean+SEM shown for 4-5 independent donors. (D) 
Heatmap showing fold change compared to Ctrl condition of different T-helper cell associated 
parameters for 4-5 independent donors using 12 or 6µM Akt-inhibitor VIII and 5 or 2.5µM 
GDC-0068. Grey = no data. Darkest colors represent fold change ≥2. Statistical analysis was 
performed using Repeated Measures ANOVA followed by Bonferroni’s Multiple Comparison 
Test of AKT-inhibited versus Ctrl T cells. ***p<0.001, **p<0.01, *p<0.05.
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Supplementary Figure 3 | Preserved memory differentiation of CD4+ T cells by 
AKT-inhibition in CD3+ T cell and CD4+ T cell cultures. CD3+ T cells  or CD4+ T cells were 
stimulated with mDCS in presence of DMSO (Ctrl), AktiVIII (18µM) or GDC (10µM). CD4+ T cell 
differentiation was analyzed on day 10. (A) Dotplots of CD62L and CCR7 expression gated on 
CD3+CD4+CD45RO+ T cells of 1 representative donor on day 10. Gates were placed based on 
background staining, numbers represent percentage gated cells. (B) CCR7 and CXCR4 
expression of 1 representative donor out of 3 donors, Mean+SD, n=2. Statistical analysis was 
performed using One-way ANOVA followed by Bonferroni’s Multiple Comparison Test of 
AKT-inhibited versus Ctrl T cells within each starting population. ***p<0.001, **p<0.01, 
*p<0.05.
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Supplementary Figure 4 | AKT-inhibition does not impede Th1 skewing of CD4+ T cells 
in cultures with total CD3+ T cells. Total CD3+ T cells or CD4+ T cells were stimulated with 
mDCS in presence of DMSO (Ctrl), AktiVIII (18µM) or GDC (10µM) for 10 days. (A) Heatmap and 
(B) statistical analysis showing fold change of expression of extracellular markers and 
transcription on  AKT-inhibited compared to Ctrl conditions, gated on CD3+CD4+CD45RO+ T 
cells within each starting material on day 10. Mean+SEM of 3 independent donors. Statistical 
analysis was performed using Repeated Measures ANOVA followed by Bonferroni’s Multiple 
Comparison Test of AKT-inhibited versus Ctrl T cells. ***p<0.001, **p<0.01, *p<0.05.
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Supplemental Figure 5 | AKT-inhibition of allo-mDC stimulated CD8+ T cells enhances 
polyfunctionality also at lower dosages. Total CD3+ T cells or CD8+ T cells were stimulated 
with CD3/CD28 Dynabeads (A) or allo-mDCs (B&C) in presence of DMSO (Ctrl), AktiVIII (18µM 
in A and 12 µM in B&C) or GDC (20µM in A and 5uM in  B&C) for 10 days. Cells were restimulated 
in absence of AKT-inhibition for 7 days. Degranulation and cytokine production were analyzed 
after O/N PMA/Ionomycin (A) or allo-mDC stimulation (B&C). (A) Percentages IFNγ-, IL2-, and 
TNFα-producing cells within polyfunctional stimulated CD3+CD8+ T cells. Mean+SEM of 4 
independent donors. (B) Percentages IFNγ-, IL2-, and TNFα-producing CD3+CD8+ T cells, 
analyzed using SPICE software. The pie arcs depict the proportion of cells that produces a 
specific cytokine and pie slices the proportion of cells co-producing 0 to 3 different cytokines. 
(C) Percentages IFNγ-, IL2-, TNFα-triple-producing CD3+CD8+ T cells. Statistical analysis was 
performed using Repeated Measures ANOVA followed by Bonferroni’s Multiple Comparison 
Test of AKT-inhibited versus Ctrl T cells within each starting population. ***p<0.001, **p<0.01, 
*p<0.05.
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Abstract
Early memory T cells are known for their proliferative capacity, polyfunctionality and 
longevity and are associated with clinical efficacy of immunotherapy. Previously, we 
and others showed that AKT-inhibition during in vitro T cell expansion maintains 
CD8+ T cells in an early memory state which is beneficial for adoptive T cell therapy. 
In this study, we investigated whether in vivo T cell expansion and functionality via 
tumor-specific vaccination could be improved by temporary in vivo AKT-inhibition in 
the OT-1 mouse model. First, the direct effects of AKT-inhibition on in vitro memory T 
cell differentiation of CD8+ OT-1 T cells was assessed. We found that in vitro 
AKT-inhibition preserved early memory differentiation of OT-1 T cells, based on higher 
expression of CD62L and CD27, while minor effects on T cell proliferation were 
observed. Furthermore, we observed increased maximal respiration and spare 
respiratory capacity in AKT-inhibited cells as well as improved degranulation of T 
cells upon in vitro re-stimulation. Thereafter, C57BL/6 wild type mice received 
adoptive T cell transfer of naïve OT-1 T cells in combination with OVA long-peptide 
vaccination and administration of AKT-inhibitor. This resulted in a temporary 
preservative effect on early memory differentiation of antigen stimulated OT-1 T cells 
in the blood on day 7. Together, this study shows the possibility to preserve early 
memory CD8+ OT-1 T cells via in vivo AKT-inhibition. 
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Introduction 
Early memory T cells are associated with better anti-tumor responses and long-lasting 
memory.1,2 Moreover, adoptive transfer of tumor-reactive T cells with an early memory 
phenotype has been associated with sustained clinical remission in patients.2 In order 
to generate early memory T cell therapy products, we and others showed that inhibition 
of the AKT-pathway during ex vivo expansion of CD8+ T cells facilitates the generation 
of stem cell memory like T cells with polyfunctional traits.3-7 Furthermore, adoptive 
transfer of ex vivo AKT-inhibited T cells was associated with better anti-tumor responses 
in mice.4,6 However, ex vivo expansion of tumor-specific T cells from the naïve repertoire 
for clinical application is laborious and expensive. Alternatively, vaccine-based T cell 
expansion with temporary AKT-inhibition in vivo could be an attractive strategy for 
boosting stem cell memory like T cells directly in cancer patients. Additionally, as the 
PI3K/AKT/mTOR signaling pathway is involved in many different cellular functions 
including cell proliferation, survival, metabolism and apoptosis, it is often more active in 
malignant cells.8,9 As a consequence, increased AKT-signaling in tumor cells promotes 
cell growth and tumor progression by promoting local invasion and metastasis.10-12 
For this reason, AKT-inhibitors for in vivo application are under development to directly 
target tumor progression. In addition, therapeutic cancer vaccines have the potential to 
strengthen especially CD8+ T cell mediated anti-tumor immune responses, but need to 
be further potentiated to improve clinical benefit.13 One strategy could be combining 
tumor-specific vaccination with temporary in vivo AKT-inhibition, to improve in vivo 
tumor-specific T cell memory formation and functionality.
 Inhibition of phospoinositide 3-kinase (PI3K)-AKT-mechanistic (m)TOR signaling 
has previously been studied in vivo. mTOR-inhibitor rapamycin treatment during T cell 
expansion in acute viral or bacterial infections increased the number of memory 
(CD62L+) T cells and improved long-term memory maintenance and T cell expansion 
upon antigen recall.14 Furthermore, mTOR-inhibition has shown to improve anti-tumor 
effects in combination with cancer vaccines.15,16 Additionally, a combination of 
CTLA-4 blockade and rapamycin during immunization of mice with bacteria improved 
memory T cell formation and recall responses as well as anti-tumor responses.17 Also 
tumor-antigen vaccination in combination with daily administration of PI3Kα-inhibitor, 
followed by a second vaccination in absence of PI3K inhibition enhanced 
tumor-specific T cell expansion.18 Additionally, CD8+ T cell infiltration in tumor tissue 
increased, resulting in diminished tumor growth and survival benefits. These studies 
demonstrate the feasibility to inhibit the PI3/AKT/mTOR pathway in vivo in combination 
with tumor-vaccination strategies. This gives a rationale to use our results on 
AKT-inhibition and explore the possibility to improve anti-tumor immunity by in vivo 
AKT-inhibition.
 In this study, we investigated the effect of AKT-inhibition on CD8+ T cell differen-
tiation and expansion. First, in vitro effects of AKT-inhibition on the activation, 
expansion, metabolism and functionality of CD8+ OT-1 T cells were investigated. 
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Furthermore, C57BL/6 mice received OT-1 adoptive transfer in combination with OVA 
long-peptide vaccination and AKT-inhibitor treatment for 10 subsequent days. CD8+ 
OT-1 T cell effector memory differentiation was effectively inhibited in ex vivo assays 
and also in vivo AKT-inhibition lead to a larger proportion of CD62L+ early memory T 
cells after 7 days of treatment. Together, this shows that AKT-inhibition has potential 
to inhibit effector memory differentiation in vivo. However, further optimization is 
needed to investigate whether in vivo AKT-inhibition will improve T cell functionality in 
combination with vaccination therapies.
Methods
Mice
C57BL/6JRccHsd (WT, Harlan Laboratories) and C57BL/6 OT-1xCD90.1 (Thy-1.1) 
(OT-1) mice were bred and housed in the local Central Animal Laboratory in Nijmegen 
under specific pathogen-free conditions and ad libitum access to food and water and 
used for experiments at  8-10 weeks of age.
 C57BL/6JxCD45.2 (WT) and OT-1xCD45.2xCD45.1 (OT-1) mice were bred and 
housed in the local Central Animal and Transgenic Facility Leiden under specific 
pathogen-free conditions and ad libitum access to food and water. WT and OT-1 
mice were used for in vivo experiments at 6-12 and 6-20 weeks of age respectively. All 
mouse experiments were controlled by the animal welfare committee (IvD) of the 
Leiden University Medical Center and approved by the national central committee of 
animal experiments (CCD), in accordance with the Dutch Act on Animal Experimen-
tation and EU Directive 2010/63/EU
Bone-marrow-derived dendritic cells 
Bone-marrow-derived dendritic cells (BMDCs) were generated from bone marrow 
isolated from C57BL/6 WT mice. Single-cell suspensions were cultured in DC 
medium, consisting of Roswell Park Memorial Institute medium (RPMI-1640 + 
L-Glutamine, Gibco) supplemented with 10% fetal bovine serum (FBS, Integro), 1% 
Penicillin-Streptomycin (P/S,MP Biomedicals), 5.96 mg/ml Hepes (Sigma), and 
28.6µM β-mercapto-ethanol (Sigma). This DC medium was supplemented with 20ng/
ml IL4 and GM-CSF (both PeproTech) and cells were seeded in 10cm petri-dishes 
(non-tissue culture treated, Falcon), On day 3 and day 6, DC medium supplemented 
with IL4 and GM-CSF was added to reach an end concentration of minimal 8.75ng/
ml. Additionally, Lipopolysacharides (LPS, Sigma, final concentration 1µg/ml) was 
added on day 6 to induce BMDC maturation. On day 7, non-adherent cells were 
harvested and phenotype was analyzed by flow cytometry, resulting in an average of 
60% (ranging between 45-80%) CD11b+CD11c+I-A/I-E+CD80+CD86+ BMDCs. For 
further ex vivo CD8+ T cell activation studies, BMDCs were loaded with 5µM OVA257-
264-peptide (Peptide facility LUMC) in serum-free medium for 30min at 37°C.
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Ex vivo CD8+ OT-1 assays
Single-cell suspensions were prepared from spleens and lymph nodes of OT-1 mice. 
Additionally, CD8+ OT-1 cells were isolated via magnetic bead isolation resulting in a 
purity of 90% (ranging between 75-95%) CD8+CD90.1+ T cells, using the EasySepTM 
Mouse CD8+ T Cell Isolation Kit (Stemcell Technologies). CD8+ T cells were labeled 
with 10µM Cell Proliferation Dye eFluor450 (ThermoFisher) according to the manufactures 
protocol. CD8+ T cells were cultured for 6 days together with OVA257-264 peptide-loaded 
BMDCs at a 2:1 T cell:BMDC ratio in Isove’s Modified Dulbecco’s Medium (IMDM, 
Gibco), supplemented with 10% FBS, 1%P/S, 15ng/ml IL2, 20ng/ml IL7 and 20ng/ml 
IL15 (all PeproTech). When indicated, Akt-inhibitor VIII (AktiVIII, Cat#A6730, Sigma) or 
GDC-0068 (GDC, Cat#HY-15186, MedChemExpress), dissolved in dimethylsulfoxide 
(DMSO, Merck Millipore), was added. Control conditions were supplemented with 
corresponding concentrations of DMSO (≤0.1% in all experiments). Half of the culture 
volume was refreshed with medium supplemented with cytokines and AKT-inhibitor 
of DMSO on day 3. 
 To determine functionality, T cells were restimulated with 1µM OVA257-264-peptide 
in absence of AKT-inhibitors. After 1 hour, Brefeldin A (Golgiplug, BD Biosciences) 
and CD107a was added, and degranulation was analyzed using flow cytometry 14h 
post-activation. 
Flow cytometry
Cells were washed with PBS (Braun) containing 1% FBS followed by extracellular 
staining for 30 minutes at 4°C in the dark. BMDCs were analyzed with the following 
antibodies: CD11c (clone N418), CD11b (M1/70), CD80 (16-10A1), CD86 (GL-1) and 
I-A/I-E (M5/114.152, all Biolegend). In the ex vivo model T cells were analyzed with 
CD8 (53-6.7), CD27 (LG.3A10), CD44 (IM7), CD62L (MEL-14), CD90.1 (OX-7), CD122 
(TM-β1), KLRG1 (2F1/KLRG1) and Sca1 (D7, all Biolegend). Additionally, Fixable 
Viability Dye eFluor780 (ThermoFisher) was added during the extracellular staining. 
In vivo AKT-inhibited T cells were analyzed with CD3 (145-2C11, BD Horizon), CD4 
(RM4-5, Biolegend), CD8 (53-6.7 eBioscience), CD44 (IM-7, Biolegend), CD45.1 
(A20, Biolegend), CD45.2 (104, eBioscience), CD62L (MEL-14, Biolegend), CD69 
(H1.2F3, Biolegend), CD127 (A7R34, Biolegend), KLRG1 (2F1, Biolegend) and 
viability dyes 7AAD (Invitrogen) and Fixable Viability Dye BV510 (Aqua, Biolegend). 
Intracellular staining of cytokines was performed upon fixation and permeabilization 
with Fixation/Permeabilization Concentrate and Diluent (both eBioscience). Data 
acquisition was performed with the Gallios (Beckman Coulter) or Fortessa (BD 
Biociences) flow cytometer and flow cytometry data was analyzed with Kaluza 
software (Beckman Coulter, version 2.1). The delta median fluorescence intensity 
(ΔMFI) was calculated by subtracting the MFI of the marker of interest with the MFI of 
the background fluorescence of the cell population of interest.
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Metabolic assays
Ex vivo expanded eFluor780-CD90.1+ T cells were FACS-sorted and rested overnight 
in IMDM+10%FBS+1%P/S supplemented with 15ng/ml IL2, 20ng/ml IL7, 20 ng/ml 
IL15 and the corresponding AKT-inhibitor or DMSO control. In vivo expanded CD45.1+ 
T cells were obtained from spleens with the Magnisort mouse CD45.1 positive 
selection kit (Thermofisher scientific) and used directly in metabolic assays.
 Oxygen consumption rate (OCR) were measured with the XF96 Extracellular 
Flux Analyzer (Seahorse, Agilent). Cells were plated in DMEM (Sigma) supplemented 
with 143mM NaCl (Baker), 3 ml/L Phenol Red (Sigma), 2mM L-glutamine (Life 
Technologies), 1mM sodium pyruvate (Life Technologies) and 25mM d-glucose 
(VWR) for mitochondrial stress tests (MST). OCR was analyzed In response to 5µM 
oligomycin, 9µM fluoro-carbonyl cyanide phenylhydrazone (FCCP, Sigma), 10µM 
rotenone (Sigma) and 10µM antimycin A (Sigma). Maximal respiration (increase in 
OCR upon FCCP injection) and spare respiratory capacity (difference in OCR 
between baseline t=0 and maximal respiration) were determined.
In vivo procedures
For adoptive transfer, lymph nodes and spleen were isolated from OT-1*CD45.1 
transgenic mice and B cells were depleted via nylon wool columns (MKN-50, Kisker 
Biotech GmbH &Co). 5x106 cells (containing 50% CD3+ T cells of which 85% CD8+ 
T cells) were injected intravenously in C57BL/6 recipient mice. On day 1, half of the 
mice were  subcutaneously vaccinated with 50µg OVA30 long peptide (Peptide 
facility LUMC) and 20µg CpG (ODN1826, Invivogen). GDC-0068 was formulated in 
methylcellulose (0.5%, Sigma)/Tween-80 (0.2%, Sigma) containing 5% DMSO, and 
75mg/kg GDC-0068 or vehicle was administered via oral gavage on day 1-10. Blood 
was taken on day 7 and 11 for flow cytometry analysis. 
Statistical analysis
Statistical analysis was performed using Prism software (Graphpad Software Inc., 
version 5.03) using Two-way or One-way ANOVA followed by a Bonferroni’s Multiple 
Comparison Tests, Student’s T tests or paired T tests, as indicated in the figure legends. 
P values < 0.05 were considered to be significant, and were used as predefined 
response definition.
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Results 
AKT-inhibition preserves effector memory differentiation of  
OT-1 T cells ex vivo
Before studying the effects of AKT-inhibition on T cells in vivo, we first examined the 
effect of AKT-inhibition on CD8+ OT-1 T cell differentiation in an ex vivo model. For 
this, CD8+ OT-1 T cells were stimulated with OVA short-peptide loaded bone marrow 
derived dendritic cells (BMDCs) in combination with different dosing of AKT-inhibitors 
AktiVIII or GDC. The presence of AktiVIII or GDC did not harm the viability of BMDCs 
(Supplemental Figure 1A-C), though upregulation of co-stimulatory molecule CD80 
was slightly hampered after 48 hours, in the presence of high levels of GDC 
(Supplemental Figure 1D). In T cell cultures at day 6, viability was higher in 
AKT-inhibited T cells than non-inhibited T cells (Figure 1A) and there was a tendency 
toward higher cell numbers in AKT-inhibited cultures (Figure 1B). All OT-1 T cells were 
activated and had proliferated, however, addition of  high dose AktiVIII did reduce the 
extent of proliferation (Figure 1C-E). To analyze the effects of AKT-inhibition on 
memory differentiation of OT-1 T cells, expression of early memory markers CD62L 
and CD27 were analyzed. We observed a dose dependent effect of AKT-inhibition on 
effector memory differentiation, with a higher percentage CD62LhighCD27high early 
memory T cells in AKT-inhibited cultures (Figure 1F&G). Approximately one third of 
the T cells showed reduced expression of CD62L and CD27 in control conditions, this 
was less than 5% in high dose AKT-inhibited cultures. Also the delta median 
fluorescent intensity (ΔMFI) of CD62L and CD27 was significantly higher on 
AKT-inhibited cells (Supplemental Figure 2A). No differences in expression of KLRG1 
(overall low) and Sca-1 (overall high) but a trend towards lower percentages of 
CD122+ cells between AKT-inhibited and control T cells were observed (Supplemental 
Figure 2 A&B). To explore the in vivo situation where T cell might be first activated 
before inhibition of the AKT-pathway, AKT-inhibitors were added at varying timepoints 
in the in vitro model. The observed effects on proliferation and CD62L expression 
were also observed upon delayed administration of AKT-inhibitors (Supplemental 
Figure 3). AKT-inhibited T cells showed higher expression of CD62L, even when 
AKT-inhibitors were added 24 hours after start of the co-culture. Together, this shows 
that AKT-inhibition is a powerful approach to preserve early memory CD8+ OT-1 T 
cell differentiation.
 Because effector memory differentiation is associated with a change in T cell 
metabolism from oxidative phosphorylation towards glycolysis, we subjected the 
AKT-inhibited CD8+ OT-1 T cells in glycolytic and mitochondrial stress tests. The 
change in ECAR was analyzed upon glucose injection, and did not result in significant 
differences in glycolysis between AKT-inhibited and Ctrl conditions (data not shown). 
However, the mitochondrial stress test showed increased oxidative phosphorylation 
upon AKT-inhibition (Figure 2A&B). Both the maximal respiration and spare respiratory 
capacity were increased in AKT-inhibited compared to Ctrl OT-1 T cells. This indicates 
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Figure 1 | AKT-inhibition preserves early memory CD8+ OT-1 T cells. CD8+ OT-1 T cells 
were labeled with cell proliferation dye and stimulated with bone marrow derived dendritic cells 
(BMDCs) for 6 days in presence of DMSO (Ctrl), AktiVIII (5, 2.5, 1.25µM) or GDC (20, 10, 5µM). 
(A) Viability and (B)  number of CD8+CD90.1+ OT-T cells. (C) Activation based on percentage 
CD44+ within CD8+CD90.1+ cells. (D-E) Proliferation of CD8+CD90.1+ cells of Ctrl, 5µM AktiVIII 
and 20µM GDC based on cell proliferation dye of (D) 1 representative experiment with numbers 
for median fluorescent intensity (MFI), and (E) MFI of all experiments combined. (F-G) CD62L 
and CD27 expression on CD8+CD90.1+CD44+ cells. (F) Plots of one representative experiment 
of Ctrl, 5µM AktiVIII and 20µM GDC conditions, numbers show percentage gated, and (G) total 
subset distribution based on gating strategy shown in (F). Mean±SEM is shown of N=9 
independent experiments. Statistical analysis is shown compared to the Ctrl condition, and 
was performed with Repeated measures ANOVA in Figure A, B and E, and Two-way ANOVA 
in Figure G, followed by a Bonferroni’s Multiple Comparison Test, of AKT-inhibited versus Ctrl 
T cells. *p<0.05, **p <0.01 and ***p <0.001.
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that AKT-inhibited OT-1 T cells rely more on oxidative phosphorylation, which is a 
known characteristic of naïve and early memory T cells. 
 To evaluate the functional characteristics of AKT-inhibited OT-1 T cells, cells were 
re-stimulated with OVA short peptide in the absence of inhibitor and degranulation 
capacity and cytokine production was analyzed. The percentage degranulating cells 
was significantly increased in AKT-inhibited cultures (Figure 3A-B). Together, these 
data show that AKT-inhibition during T cell stimulation preserves early memory differ-
entiation of CD8+ OT-1 T cells ex vivo. 
In vivo AKT-inhibition retained effector memory differentiation  
of CD8+ OT-1 T cells
Next, we explored the possibility to maintain early memory OT-1 T cells upon 
vaccination, in combination with temporary AKT-inhibition in vivo. For this, adoptively 
transferred OT-1 T cells were activated with OVA long-peptide vaccination while mice 
were treated for 10 subsequent days with GDC (Figure 4A). Analysis of blood on day 
7 showed strong inhibition of CD45.1+ OT-1 T cell expansion in mice vaccinated in the 
presence of GDC (Figure 4B). Additionally, OVA long-peptide vaccination induced 
Figure 2 | AKT-inhibition increases maximal mitochondrial respiration and spare respiratory 
capacity. CD8+ OT-1 T cells were stimulated for 6 days with BMDCs in presence of DMSO 
(Ctrl), AktiVIII (5µM) or GDC (20µM) and challenged in different metabolic assays. (A) 
Mitochondrial stress test of one representative experiment. (B) Maximal respiration and spare 
respiratory capacity, Mean+SEM of 4 independent experiments. Statistical analysis is shown 
compared to the Ctrl condition, was performed with Repeated measures ANOVA followed by a 
Bonferroni’s Multiple Comparison Test. *p< 0.05.
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activation and differentiation of CD8+CD45.1+ OT-1 T cells as the percentage CD44+ 
T cells increased and CD62L+ T cells reduced (Figure 4C&D) Activation and differentiation 
of endogenous CD45.1-CD45.2+CD8+ T cells did not differ between vaccination and 
non-vaccinated mice (Supplementary Figure 4). Importantly, in vivo AKT-inhibition 
resulted in a significant larger proportion of CD44+CD62L+ central memory CD8+ 
T cells and less CD44+CD62L- effector memory CD8+ T cells (Figure 4D). effector 
OT-1 T cells (Figure 4E). Furthermore, CD8+ OT-1 T cells of AKT-inhibitor treated mice 
showed in total more CD62L+ OT-1 CD8+ T cells and a tendency towards higher 
percentage positive OT-1 T cells for CD127 and activation marker CD69, while a 
slightly lower percentage for co-inhibitory receptor KLRG1 was observed (Figure 4E). 
On day 11, PBL analysis showed still the presence of CD62L+CD8+ OT-1 T cells, 
however, the percentage CD62L+ CD8+ OT-1 T cells did no longer differ between 
GDC- and vehicle-treated mice (Figure 4F). Together, this shows that in vivo 
AKT-inhibition in combination with OVA long-peptide vaccination preserved early 
memory CD8+ T cells temporarily. Further optimization of the model is required to 
find out whether in vivo AKT-inhibition improves the potential of anti-tumor vaccination 
strategies.
Figure 3 | AKT-inhibition improves degranulation of OT-1 T cells. CD8+ OT-1 T cells were 
stimulated with BMDCs in presence of DMSO (Ctrl), AktiVIII (5µM) or GDC (20µM) for 6 days, 
and re-stimulated O/N with OVA short-peptide in the absence of inhibitor. (A-B) CD107a 
expression of (A) 1 representative experiment, number show percentage positive cells and (B) 
combined data showing of 3 independent experiments Mean+SEM. Statistical analysis is 
shown compared to the Ctrl condition, was performed with One-way ANOVA followed by a 
Bonferroni’s Multiple Comparison Test of AKT-inhibited versus Ctrl T cells. **p < 0.01.
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Discussion
Therapeutic cancer vaccines have potential to strengthen especially CD8+ T cell 
mediated anti-tumor immune responses, resulting in elimination of cancer cells.19 
Different kinds of cancer vaccines have been developed, including dendritic cell, 
peptide/protein and tumor cell vaccines.20-24 These vaccination strategies all aim at 
tumor-antigen specific presentation by infused or natural occurring antigen presenting 
cells, followed by induction or expansion of tumor-antigen specific T cell immunity. 
Figure 4 | In vivo AKT-inhibition delays OT-1 T cell differentiation. (A) Experimental setup: 
WT mice (CD45.2+) were adoptively transferred with splenocytes of OT-1 mice (CD45.1+CD45.2+) 
in combination with OVA long-peptide vaccination and/or daily treatment with GDC. (B) 
Percentage CD45.1+CD45.2+ OT-1 cells within total CD8+CD45.2+ population in blood on day 
7. Dots represent independent mice. (C) one representative mouse per group, number 
represent percentage gated and (D) subset distribution based on gating strategy shown in D 
for 8-10 independent mice per group. Significance counts for CD44+CD62L+ and CD44+CD62L- 
populations. (E) Percentage CD62L+, CD127+, CD69+ and KLRG1+ cells within CD45.1+CD8+ 
T cell population on day 7 in blood. (F) Percentage CD62L+ cells within CD45.1+CD8+ T cell 
population on day 11 in blood. Statistical analysis was performed with One-way ANOVA 
followed by a Bonferroni’s Multiple Comparison Test in B, a Two-way ANOVA followed by a 
Bonferroni’s Multiple Comparison Test in D, and a student T test in E&F. *p< 0.05.
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While most cancer vaccines succeeded in induction of these tumor-specific immune 
responses, overall clinical outcomes need to be improved, for example by enhanced 
memory T cell formation and persistence.13 In this regard, adoptive T cell strategies 
have demonstrated that clinical efficacy of tumor-specific T cells is associated with 
high and persistent T cell numbers in vivo, as well as infusion of a T cell product with 
early memory characteristics.2,25,26 Interestingly, we and others previously found that 
temporary inhibition of the AKT-pathway preserved early memory CD8+T cells ex 
vivo, resulting in superior T cell expansion and polyfunctionality upon antigen re-
encounter.3,4,6 Therefore, the possibility to apply AKT-inhibition in vivo, to tumor-antigen 
specific T cells upon vaccination was investigated in an OT-1 T cell model.
 To investigate whether proliferating CD8+ OT-1 T cells can be inhibited in differ-
entiation by AKT-inhibition, we stimulated in vitro OT-1 T cells with OVA short-peptide 
pulsed BMDCs in the presence of AKT-inhibitors. While the tested AKT-inhibitors 
have a different mode of action, either an allosteric (AktiVIII) or adenosine triphosphate 
(ATP)-competitive mode of action, overall similar effects were observed. Both 
inhibitors preserved early memory OT-1 T cells based on higher expression of CD62L 
and CD27. Fraietta et al. showed that CD27 expression is a clinically relevant 
early-memory associated T cell marker, as infusion of T cell therapy containing high 
levels of CD8+CD27+ tumor-specific CAR T cells was associated with a good clinical 
response.2 Additionally, it is described that while naïve and memory T cells rely more 
on fatty acid oxidation, effector T cells depend more on glycolyis and that AKT 
signaling is involved in the switch from fatty acid oxidation to aerobic glycolysis.27,28 
Interestingly, we observed that AKT-inhibited T cells indeed showed enhanced fatty 
acid oxidation and spare respiratory capacity. This matches previously described 
data where reduced AKT-phosphorylation and enhanced spare respiratory capacity 
and fatty acid oxidation favored CD8+ memory T cells in response to Listeria 
infection.29 Together, this shows that ex vivo AKT-inhibition preserves early memory 
CD8+ OT-1 T cells based on both phenotypical and metabolic characteristics. 
 Additionally, the effect of AKT-inhibition on OT-1 T cells was studied in vivo using 
AKT-inhibitor GDC. Here, in vivo AKT-inhibition showed preserved early memory T 
cells in peripheral blood based on CD62L expression, but this effect could only be 
detected temporarily. To improve the preservation of early memory cells, the dosing 
of GDC could be improved. Pre-clinical research in xenograft models showed that 
the used dosage should result in levels of 5-8µM in plasma and 12-20µM in 
subcutaneously transplanted tumors, both 4 hours post-treatment.30 However, 
though this matches our ex vivo used concentrations, concentration levels in the 
lymphoid organs, were most T cells reside, were unknown. Therefore, levels of GDC 
might have been too low for robust effects on inhibition of T cell differentiation. 
However, increasing the dosage of GDC in this mouse model might not be desirable 
as the current dosage already caused discomfort in all mice and even resulted in 
lethality of 3 out of 20 mice. A possibility to increase in vivo concentrations might be 
a different route of administration (e.g. intraperitoneal or intravenous injections), which 
121
Combining vaccination and in vivo AKT-inhibition to improve T cell immunity
5
could potentially result in higher concentrations in the lymphoid tissues and might be 
better tolerated in the mice. Another improvement might be a change in treatment 
schedule. So far, AKT-inhibitor treatment was started the day of vaccination. Possibly 
starting treatment 1 or 2 days prior to activation of the T cells would favor AKT-inhibitor 
levels in the lymphoid tissues at time of peptide vaccination. It has been shown that 
short-term high dose treatment with rapamycin favors CD8+ T cell persistence and 
recall responses, while low dose treatment was not effective, and even a prolonged 
treatment suppressed CD8+ T cell memory responses.31 This indicates that an 
effective treatment schedule is essential, and therefore could further improve the 
robustness of the effect of in vivo AKT-inhibition.
 Another factor which could explain the differences observed between the effect 
ex vivo and in vivo would be the difference in OT-1 T cell composition as well as the 
presence of other leukocytes. While our ex vivo studies were performed with as 
isolated product of >90% CD8+ OT-1 T cells, in the in vivo studies PBMCs from OT-1 
mice depleted for B cells were infused in WT mice. Here, non-CD8+ and non-OT-1 T 
cells most likely have also interacted in the effect. In a parallel study, we observed that 
the presence of CD4+ T cells affects the outcome of AKT-inhibition on human CD8+ 
T cells. Here, human CD4+ T cells also preserved CD62Lhigh early-memory T cells, 
but their T helper phenotype skewed from  1 (TH1) to TH2 resulting in less IFNγ 
support for CD8+ T cells (Mousset et al. JITC, in revision). Moreover, effects of 
AKT-inhibition might affect other immune cells like B cells and for example myeloid 
derived suppressor cells, which could interfere the outcome of AKT-inhibition of 
CD8+ T cells.15,32 
 Although, the observed effects on in vivo T cell differentiation were small and 
temporary, in vivo application of AKT-inhibition shows potential to a synergistic 
approach where next to directly targeting of tumor cells, the immune response can 
be boosted. AKT-inhibition has also shown to prevent upregulaton of one of the 
important co-inhibitory ligands on tumor cells, namely programmed death ligand 1 
(PD-L1).33,34. PD-L1 binds to its co-inhibitory receptor programmed cell death protein 
1 (PD1) on T cells and hereby suppresses anti-tumor immunity. As a consequence, 
inhibition of the PI3K-AKT signaling pathway can enhance the immunogenicity of 
tumors.35,36 Importantly, in vivo administration of PI3K-inhibitors worked synergisti-
cally in combination with checkpoint inhibitors aPD1 and aCTLA4 17,18.Besides PD-L1, 
also anti-apoptotic molecules are up regulated in tumor cells by AKT-signaling, 
resulting in improved CD8+ T cell mediated apoptosis by AKT-inhibition.36 Together, 
this shows that in vivo AKT-inhibition is not only interesting for its direct effects on T 
cells, but has also potential to improve CD8+ T cell anti-tumor immunity by affecting 
intratumoral signaling pathways.
 GDC-0068 is currently tested in clinical studies for its direct effects on tumor 
growth.10-12 Importantly, in vivo administration of GDC has been well tolerated by 
patients and showed anti-tumor effects in part of the patients.37 Here, clinically 
feasible levels of GDC resulted in robust AKT-pathway inhibition.38 Additionally, 
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downstream mTORC1-inhibitors like Rapamycin are tested in a larger number of 
clinical trials and lead most often to disease stabilization, as it inhibits cell proliferation 
rather than inducing cell death 39,40 It is important to notify here that mTORC1 
signaling forms a feedback loop with receptor tyrosine kinase (RTK)-PI3K signaling, 
whereby mTOR kinase inhibitors stimulates AKT phosphorylation.41,42 This promotes 
cell survival and might therefore explain the sometimes modest efficacy in tumors 
where important benefits were expected.8,43 Together, this indicates that in vivo 
AKT-mTOR pathway inhibition may be well tolerated in patients and has advantages 
as compared to downstream mTORC1 inhibition. 
 This current study shows that AKT-inhibition has potential to inhibit CD8+ effector 
memory T cell differentiation in vivo. However, further optimization is needed to 
investigate whether in vivo AKT-inhibition during vaccination will improve T cell 
functionality, and to analyze possible negative effects on the rest of the immune 
system including CD4+ helper T cell skewing. Although this requires complex and 
extensive studies, in vivo AKT-inhibition could have great potential via targeting of 
malignant cells via various mechanisms. Inhibition of AKT-signaling in tumor cells 
can inhibit tumor growth, boost the immunogenicity of the tumor, and preserve early 
memory T cells to potentiate their anti-tumor reactivity. Future studies should reveal 
whether the combination of these different therapeutic mechanisms will result in 
effective immunotherapy. 
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Supplementary Figure 1 | AKT-inhibition has no effects on BMDCs. BMDCs were plated in 
IMDM+10% FBS in absence or presence of DMSO (Ctrl), AktiVIII (5, 2.5, 1.25µM) or GDC (20, 
10, 5µM). BMDCs were analyzed after 4, 24 and 48 hours. (A) Absolute number of BMDCs 
harvested at indicated time points. (B) Percentage CD11b+CD11c+ BMDCs within total cells (C) 
Percentage I-A/I-E+ and CD80+CD86+ BMDCs within CD11b+CD11c+ cells. (D) Expression 
(deltaMFI) of CD80 and CD86 on CD11b+CD11C+BMDCs. Mean+SD of N=2 in 1 representative 
experiment is shown. Statistical analysis was performed with One-way ANOVA followed by a 
Bonferroni’s Multiple Comparison Test of AKT-inhibited versus Ctrl T cells within a specific time 
point. *p<0.05.
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Supplementary Figure 2 | Phenotypic analysis of AKT-inhibited OT-1 T cells. OT-1 T cells 
were stimulated with BMDCs in presence of DMSO (Ctrl), 5µM AktiVIII or 20µM GDC. Delta 
median fluorescence intensity (ΔMFI) of CD62L, CD27, KLRG1, Sca-1 and (B) percentage 
CD122+ CD8+CD90.1+CD44+ cells. Mean+SEM of (A) 9 and (B) 3 individual experiments is 
shown. Statistical analysis was performed with One-way ANOVA followed by a  Bonferroni’s 
Multiple Comparison Test of AKT-inhibited versus Ctrl T cells within a specific time point. **p 
<0.01 and ***p <0.001.
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Supplementary Figure 3 | Delayed administration of AKT-inhibitor can still preserve early 
memory differentiation. CD8+ OT-1 T cells were labeled with cell proliferation dye and 
stimulated with BMDCs for 6 days. DMSO (Ctrl), AktiVIII (5, 2.5, 1.25µM) or GDC (20, 10, 5µM) 
was added at T=0h, T=4h or T=24h. (A) Percentage activated CD44+ T cells and (B) MFI of cell 
proliferation dye. (C) Expression (deltaMFI) of CD62L on CD8+CD90.1+CD44+ T cells. 
Mean+SD of N=2 in 1 representative experiment is shown. **p <0.01 and ***p <0.001.
Supplementary Figure 4 | Tendency towards inhibition of differentiation of endogenous 
T cells. Subset distribution based on CD44 and CD62L expression of CD45.1-CD45.2+CD8+ 
OT-1 T cells in blood on day 7.
A Activation
T=0h T=4h T=24h
0
20
40
60
80
100
C
D
44
+ 
(%
)
0% DMSO
Ctrl
5µM AktiVIII
2.5µM AktiVIII
1.25µM AktiVIII
20µM GDC
10µM GDC
5µM GDC 
B
C
Proliferation
T=0u T=4u T=24u
0
5
10
15
***
***
***
**
***
***
**
***
***
***
**
C
el
l p
ro
lif
er
at
io
n 
dy
e 
(M
FI
)
CD62L
T=0u T=4u T=24u
0
100
200
300
400
***
***
***
***
***
***
***
***
*** ***
***
***
***
C
D
62
L 
(∆
M
FI
)
T cell differentiation
0
50
100 CD44-CD62L-
CD44+CD62L-
CD44-CD62L+
CD44+CD62L+
%
Vaccination
GDC
+ +
+ +
- -
- -

PD-L1 siRNA-mediated silencing 
in acute myeloid leukemia enhances 
anti-leukemic T cell reactivity  
Charlotte M. Mousset*, Diede van Ens*, Tim J.A. Hutten*, 
Anniek B. van der Waart, Sanne van der Heijden, Hanny Fredrix, Rob Woestenenk, 
Joop H. Jansen, Nicolaas P.M. Schaap, Eva Lion, Harry Dolstra, Willemijn Hobo
* These authors contributed equally
Chapter 6
130
Chapter 6
Abstract
Immunotherapeutic approaches have demonstrated responses in high-risk myeloid 
malignancies like acute myeloid leukemia (AML). However, despite induction of 
tumor-reactive immune responses, many patients eventually develop relapsed 
disease. Leukemia cells can escape by creating a suppressive micro-environment 
via upregulation of co-inhibitory molecules like PD-L1 which upon ligation with their 
counter receptor PD-1 expressed on the tumor-reactive T cells result in T cell inhibition. 
Importantly, systemic immune checkpoint blocking antibodies, targeting e.g. the 
PD-1/PD-L1 signaling pathway, have demonstrated impressive clinical results in 
cancer patients. Yet, the negative consequence of systemically releasing the immune 
brake is the induction of (severe) toxicity in healthy tissues, especially after allogeneic 
stem cell transplantation. This emphasizes the need for alternative treatment 
modalities to modulate the immune brake in the local tumor micro-environment.
 The aim of this proof-of-concept study was to locally interfere with inhibitory 
PD-1/PD-L1 signaling in AML cells through PD-L1 siRNA delivery. Notably, using 
siRNA/SAINT-RED transfection technology, we demonstrated efficient silencing of 
PD-L1 in AML cell lines as well as in patient’ AML cells. Most importantly, we observed 
increased activation of WT1-T cell receptor mRNA transfected PD-1+ Jurkat cells 
upon co-culture with PD-L1 silenced WT1+ AML. Moreover, we showed significantly 
enhanced activation, degranulation and IFN-γ production of minor histocompatibility 
antigen (MiHA)-specific CD8+ T cells in response to PD-L1 silenced MiHA+ AML 
cells. Importantly, PD-L1 silencing was equally effective as PD-1 antibody blockade 
in boosting tumor-reactive T cell function.
 Together, these results demonstrate that PD-L1 silencing is an effective strategy 
to augment the immune-susceptibility of AML cells, facilitating improved recognition 
and attack by tumor-reactive CD8+ T cells. This provides rationale for further development 
of targeted approaches to selectively interfere with immune escape mechanisms in 
the local myeloid tumor micro-environment, without inducing severe systemic 
toxicities. In combination with adoptive T cell transfer, this strategy could be very 
appealing to improve outcome in patients with high-risk myeloid malignancies.
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Introduction
Acute myeloid leukemia (AML) is characterized by clonal expansion and accumulation 
of immature myeloid progenitor cells in the bone marrow. The incidence increases 
with age and long-term clinical remissions can only be induced in a minority of the 
patients.1 Depending on patient characteristics, treatment includes chemotherapy 
and/or hypomethylating agents to reduce tumor burden and achieve complete 
remission, followed by allogeneic stem cell transplantation (allo-SCT). The therapeutic 
efficacy of allo-SCT is for a major part attributed to donor-derived T cells recognizing 
disparate minor histocompatibility antigens (MiHA) and tumor-associated antigens 
(TAA) on residual leukemia cells.2  This beneficial graft-versus-leukemia (GVL) effect 
can result in complete cure. Nevertheless, still 30-40% of the patients develops 
relapse and/or progressive disease3-6
 Immune evasion mechanisms play an important role in dampening GVL immunity 
towards leukemia, thereby contributing to disease relapse after allo-SCT.7-9 Effective 
T cell activation requires T cell receptor (TCR) signaling, initiated upon interaction with 
the cognate peptide/human leukocyte antigen complex, together with co-stimulatory 
signaling via CD28:CD80/CD86. Additionally, cytokine receptor signaling further boosts 
T cell activation. Tumor cells can attenuate T cell responses by reducing co-stimulatory 
and increasing co-inhibitory ligand expression levels, including PD-L1, which results 
in suppressed T cell activation upon interaction with their counter receptors on 
tumor-reactive T cells.10,11 We and others have previously shown that tumor-reactive 
CD8+ T cells exhibit high expression of multiple co-inhibitory receptors, including 
PD-1, BTLA, TIGIT and TIM-3.8,9,12-14 Furthermore, patients with relapsed disease 
showed increased expression of PD-1 on T cells and PD-L1 on tumor cells, and 
reinvigorated T cell reactivity upon PD-1 blockade in vitro. Importantly, we demonstrated 
that initially unresponsive tumor-reactive CD8+ T cells could be effectively reinvigorated by 
ex vivo PD-1/PD-L1 blockade, especially in patients who relapsed after allo-SCT.8,15,16 
 Recently, impressive clinical responses have been obtained with blocking antibodies 
targeting the PD-1/PD-L1 signaling pathway in various solid and hematological 
malignancies.17-19 Especially immunogenic tumors, with high mutational load and 
pre-existing anti-tumor immunity show high responsiveness to checkpoint blockade.20 
Although the mutational load in AML is low, a MiHA mismatch after allo-SCT or donor 
lymphocyte infusion makes AML an immunoresponsive malignancy where immuno-
suppressive mechanisms, including PD-L1 upregulation, limit anti-tumor responses.21,22 
Systemic blocking of PD-1/PD-L1 signaling induces not only activation of tumor- 
specific T cells, but activates all T cells which became tolerant as a consequence of 
PD-1/PD-L1 signaling. Especially after allo-SCT, allogeneic T cells can induce life- 
threatening immune responses against healthy tissues of the graft, resulting in graft 
versus host disease (GVHD).22,23 Several clinical studies reported the application of 
PD-1/PD-L1 blocking antibodies post allo-SCT.22 Here, complete responses were 
reported, however in the majority of patients accompanied by GVHD.24-27 Notably, 
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also usage of PD-1/PD-L1 blocking antibodies prior to allo-SCT might enhance acute 
GVHD.23,28-30 The incidence of grade 4 acute GVHD appeared and early deaths 
resulted in a recommendation from the US Food and Drug Administration to avoid 
allo-SCT in patients who were previously treated with PD-1 blockade.28 The increased 
risk to develop severe GVHD when using systemic PD-1/PD-L1 blocking antibodies 
before or after allo-SCT, emphasizes the need to develop strategies for local PD1/
PDL1 interference in the leukemia micro-environment.
 In this study, we performed proof-of-concept studies exploiting silencing RNA 
(siRNA) technology to locally interfere with PD-L1 signaling in AML cells. We showed 
efficient siRNA-mediated knockdown of PD-L1 in AML cell lines and patient’ AML 
cells. Importantly, this resulted in enhanced activation WT1-TCR mRNA transfected 
PD-1+ Jurkat cells upon co-culture with PD-L1 silenced WT1+ AML. Moreover, we 
showed significantly enhanced activation, degranulation and IFN-γ production of 
MiHA-specific CD8+ T cells in response to PD-L1 silenced MiHA+ AML cells. Importantly, 
PD-L1 silencing was equally effective as PD-1 antibody blockade in boosting tumor- 
reactive T cell function. Together, these results demonstrate that PD-L1 expression on 
AML dampens T cell functionality, which can be effectively abolished by siRNA 
mediated PD-L1 silencing on AML cells. This provides rationale for the development 
of targeted strategies to interfere with PD-L1 in the local leukemic environment in 
combination with adoptive T cell therapy in order to enhance anti-leukemic T cell 
reactivity in patients with high-risk myeloid malignancies.
Material and Methods
Cell material
Mononuclear cells were isolated from bone marrow using Ficoll-paqueTM PLUS 
gradient (Sigma-Aldrich) density centrifugation and subsequently cryopreserved. Bone 
marrow samples or peripheral blood samples of AML patients were obtained at time of 
diagnosis and varied in disease-FAB classification from M1-M5. LRH-1 and HA-1 
specific cytotoxic T cell (CTL) were isolated from 2 different allo-SCT patients and 
cultured as described previously 31 Patient material and data were obtained in 
accordance with the Declaration of Helsinki and institutional guidelines and regulations 
(CMO 2013/064). 2D3 cells were generated as described previously from TCRαβ- 
deficient PD1-overexpressing Jurkat 76 cells by transduction with a CD8 alpha-E2A-CD8 
beta construct, and plasmid vector containing enhanced green fluorescent protein 
(EGFP) gene under control of a nuclear factor of activated T-cell (NFAT) promoter.32,33 
2D3 cells were cultured in Roswell Park Memorial Institute 1640 (RPMI) culture medium 
(Gibco Invitrogen) supplemented with 10% fetal calf serum (FCS; Integro). AML cell line 
HL-60 was cultured in RPMI + 10% FCS and the HLA-A*02:01-positive T2 cell line was 
cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) + 10% FCS.34 Cell lines were 
maintained in logarithmic growth phase at 37°C, 5% CO2.
133
PD-L1 silencing in AML enhances anti-tumor reactivity
6
siRNAs targeting PD-L1 
The sequences of PD-L1 siRNA (Alnylam Therapeutics/Nitto-Denko Avecia) were as 
follows: 5’AGAccuuGAuAcuuucAAAdTsdT-3’ (sense), 5’-UUUGAAAGuAUcAAGGU-
CUdTsdT-3’(anti-sense). 35,36 As a negative control (Ctrl) Luciferase siRNA was used: 
5’-cuuAcGcuGAGuAcuucGAdTsdT-3’ (sense) and 5’-UCGAAGuACUcAGCUcAGC-
GuAAGdTsdT-3’ (anti-sense). Small cases represent 2’-O-methyl modified residues. 
Silencing PD-L1 in AML cells
AML cell line HL-60 or primary AML cells were plated in serum-free phenol red-free 
X-VIVO-15 (Lonza, Verviers, Belgium), 0.25x106 cells per well in 24-well plates (Corning 
Costar). Negative control (Ctrl) siRNA or PD-L1 siRNA was pre-complexed for 15 
minutes with 0.75 mM SAINT-RED at a 1:10 w/v ratio (Synvolux Therapeutics) in 
serum-free and phenol red-free X-VIVO-15. Subsequently, siRNA/SAINT-RED 
lipoplexes were added to AML cells resulting in a final dose of 0.33 or 1µg 
siRNA/0.25x106 AML cells. After 1 hour incubation at 37˚C, phenol red-free X-VIVO-15 
medium supplemented with human serum (HS, Sanquin Blood Supply Foundation, 
final concentration:10%), with or without IFN-γ (final concentration: 250 IU/ml in 
experiments with HL-60 and 100 IU/ml with primary AML cells) and TNF-α (final 
concentration: 1.25 ng/ml; both Immunotools) was added. Primary AML cultures 
were additionally supported with the AML cytokine mix (final concentration: 15.9 ng/
ml GM-CSF, 12.5 ng/ml G-CSF, 6.25 ng/ml IL-3, 3 ng/ml SCF and 2.5 ng/ml FLT3L; all 
from Immunotools). Subsequently, AML cells were harvested and PD-L1 knockdown 
efficiency was determined via flow cytometry at indicated time-points. 
WT1126-134 electroporation
TAA WT1126-134-specific TCR mRNA was generated from CTL clones as described by 
Campillo-Davo et al. (2018).32 For electroporation, 2D3 cells were washed twice in 
cold serum-free Opti-MEM medium (Gibco Invitrogen), resuspended in the same 
medium and transferred in 4.0 mm electroporation cuvettes. Then, 1 µg WT1126-134 
mRNA per 106 2D3 cells was added and cells were pulsed in a Gene Pulser XcellTM 
device (Bio-Rad Laboratories) using the Square Wave protocol (500 V, 5 ms, 0 gap, 
1 pulse). As a control, 2D3 cells were electroporated in absence of any mRNA 
(“Mock”). After electroporation, cells were resuspended in pre-warmed RPMI 
supplemented with 10% FCS and incubated for 30 minutes at 37°C, 5%CO2. 2D3 
cells were counted and resuspended in IMDM supplemented with 10%FCS at 1x106/
ml and incubated at 37°C, 5%CO2 for a minimum of 4 hours before start of AML 
co-culture. WT1 TCR expression was analyzed before start co-culture by flow 
cytometry.
2D3 stimulation assays
PD-L1 silenced and control AML cells were loaded with/without 5 µM WT1126-134-pep-
tide (RMFPNAPYL) for 30 minutes at 37°C. Then, AML cells were washed, resuspended 
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at 0.5x106 cells/ml and 50µl/well was seeded in 96-well round bottom plates. WT1 
TCR expressing 2D3 cells were resuspended at 1x106/ml and 50 µl/well was seeded 
resulting in a AML:Jurkat ratio of 1:2. As controls PD-1 blocking antibody (Nivolumab; 
BMS-936558; MDS-1106; ONO-4538) and hIgG4 control (kindly provided by 
Dr. A. Korman; Bristol-Myers Squibb, Biologics Discovery) were taken along at final 
concentrations of 10 µg/ml. Additionally, mock electroporated 2D3 cells were included 
as control. Co-cultures were performed in a total volume of 200 µl IMDM + 10% HS. 
The following day, EGFP expression was analyzed via flow cytometry as a measure 
of T cell activation.
CTL stimulation assays
PD-L1 silenced and Ctrl siRNA treated AML cells were loaded with 10 µM MiHA-peptide 
(LRH-1: TPNQRQNVC; HA-1: VLHDDLLEA) for 30 minutes at 37°C. Then, AML cells 
were washed, resuspended at 2x104 cells/ml and 100µl/well was seeded in a 96-well 
round bottom plate (Corning Costar). Subsequently, corresponding MiHA-specific 
CTL were added at a 1:1 ratio. As control conditions, PD-1 blocking antibody or hIgG4 
control were taken along at final concentrations of 10 µg/ml. Co-cultures were 
performed in a total volume of 200 µl IMDM + 10% HS in the presence of CD107a 
antibody (clone H4A4, Biolegend). The following day, supernatant was harvested for 
IFNγ analysis and cells were analyzed via flow cytometry for their activation (CD69 
and CD137) and degranulation (CD107a) potential.
Flow cytometry
PD-L1 knockdown efficiency was determined by flow cytometry. HL60 and primary 
AML cells were harvested and incubated for 15 minutes at room temperature in 
PBS/0.5% BSA supplemented with 1 mg/ml total hIgG (Sanquin). Thereafter, cells 
were labeled for 30 minutes with anti-PD-L1 (clone MIH1, BD Biosciences), anti-ICAM-1 
(clone HCD54) or IgG1 isotype controls (clone MOPC-21; all Biolegend) and CD45 
(clone J.33, Beckman Coulter) to gate on CD45dimSSlow AML blasts. Finally, cells 
were labeled with 1:4000 diluted Viability dye eFluor780 or 1:5000 diluted Sytox blue 
(both Thermo Fisher Scientific) to discriminate viable cells. 
 The percentage WT1 TCR expression 2D3 cells was analyzed with WT1/
HLA-A*02:01 PE-labeled tetramers (RMFPNAPY, Medical & Biological Laboratories 
Co) for 15 minutes at room temperature in the dark. Jurkat activation was analyzed 
based on EGFP expression, following co-culture with WT1 expressing AML cells. 
Alternatively, activation of MiHA-specific T cells following CTL:AML co-culture was 
analyzed. CD107a (H4A3, Biolegend) was present throughout co-culture, and 
additional staining was performed with CD69 (clone FN50), CD8 (clone RPA-T8; both 
Biolegend) and CD137 (clone 4B4-1, BD Biosciences) for 30 minutes at 4 °C. After 
wash, cells were resuspended in 1:5000 diluted Sytox blue (Thermo Fisher Scientific) 
for live/dead staining.
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Data acquisition was performed on the Gallios or CytoFLEX (both Beckman Coulter) 
flowcytometer. Flow cytometry data was analyzed with Kaluza software (Beckman 
Coulter, version 2.1). The ΔMFI was calculated by subtracting the median fluorescence 
intensity (MFI) of PD-L1 with MFI of the isotype control. PD-L1 knockdown efficiency 
was calculated as follows: 100%-((ΔMFI PD-L1 siRNA treated AML/ΔMFI Ctrl siRNA 
treated AML) x 100%). Isotype-matched controls were used to evaluate the positivity 
for PD-1 and PD-L1 (i.e. each isotype gate was set at ≤1% positive).
IFN-γ ELISA
Production of IFN-γ by MiHA-specific CTL was determined by enzyme-linked immuno - 
sorbent assay (ELISA; Pierce Endogen, Rockford, IL, USA;) according to manufacturer’s 
protocol. 
Data and statistical analyses
Data quantifications were made in Graphpad Prism (V5.03, GraphPad Software, 
La Jolla, CA, USA). The p-values were obtained using a two-tailed t-test, One-way or 
Two-way ANOVA followed by a Bonferroni post-hoc test, as indicated, with * p<0.05; 
** p<0.01, *** p<0.001.
Results
PD-L1 siRNA/SAINT-RED lipoplexes efficiently silence PD-L1 
expression on HL-60 and patient primary AML
To investigate the involvement of PD-L1 in AML immune escape and to establish the 
siRNA silencing technology, we studied siRNA-mediated silencing of PD-L1 in AML 
cells. The siRNA/SAINT-RED transfection technology was first studied in AML cell line 
HL-60. Under homeostatic conditions, HL-60 cells did not express PD-L1 (Figure 1A, 
upper panel). However, upon activation with IFNγ and TNFα, mimicking the 
inflammatory tumor micro-environment, PD-L1 and ICAM-1 were strongly up-regulated 
(Figure 1 A&B; Supplementary Figure 1A). Subsequently, we pre-treated the HL-60 
cells for 1h with 0.33 or 1µg of Ctrl or PD-L1 siRNA followed by overnight activation by 
IFNγ and TNFα. Importantly, we observed a dose-dependent reduction in PD-L1 
expression upon PD-L1 siRNA treatment compared to the corresponding controls, 
resulting in knockdown efficiencies of 36% and 51% for 0.33µg and 1µg PD-L1 siRNA, 
respectively (Figure 1C&D). Notably, ICAM expression was not affected by siRNA 
transfection (Supplementary Figure 1B&C). Analysis over time showed stable PD-L1 
silencing for at least 4 days (Figure 1E). 
 In addition, we investigated PD-L1 siRNA silencing efficacy in patient’ AML cells. 
In accordance with our HL-60 model, primary patient AML cells highly expressed 
PD-L1 upon IFNγ and TNFα stimulation (Figure 2A&B). In primary AML cells both 
0.33µg and 1µg PD-L1 siRNA efficiently silenced PD-L1 expression (Figure 2C). More 
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importantly, up to 80% PD-L1 silencing could be achieved, which lasted for at least 4 
days following treatment (Figure 2D&E). Together, these data demonstrate that 
treatment with PD-L1 siRNA/SAINT-RED lipoplexes induces efficient and durable 
silencing of PD-L1 in AML cells.
PD-L1 silencing enhances tumor-specific CD8+ T cell responses 
Next, the functional effect of the PD-L1 silencing on AML immune-susceptibility was 
investigated in ex vivo models using various tumor-reactive T cells. First, siRNA treated 
patient’ AML cells were tested in co-cultures with WT-1 TCR or mock transduced 2D3 
Figure 1 | siRNA-mediated silencing of PD-L1 on HL-60 cells. HL-60 cells were transfected 
with control (Ctrl) or PD-L1 siRNA/SAINT-RED lipoplexes and consecutively activated with IFNγ 
and TNFα. Samples were analyzed for surface expression of PD-L1 by flow cytometry. (A) 
Histograms of PD-L1 (filled) and corresponding isotype (open) staining after O/N culture with 
or without activation stimuli. Numbers represent delta median fluorescent intensity (ΔMFI) of 
PD-L1. Line is set at isotype control =1% for each condition. Data of 1 representative experiment 
out of 7 is shown. (B) ΔMFI of PD-L1 surface expression and (C) relative PD-L1 expression after 
O/N incubation with/without activating cytokines. (D) PD-L1 knockdown efficiency after O/N 
activation in presence of 0.33 or 1µg PD-L1 siRNA. Knockdown efficiency is calculated as 
follows: 100%-((ΔMFI PD-L1 siRNA treated AML/ΔMFI control siRNA treated AML) x 100%). (E) 
PD-L1 expression over time shown as relative ΔMFI. Non-silenced condition is set to 1. 
Mean±SEM is shown of N=7 independent experiments in B-D and N=3 experiments in E. 
Statistical analysis was performed using a paired two-tailed T test in B, Repeated Measures 
ANOVA with Bonferroni’s Multiple Comparison Test in C, and Two-way ANOVA with Bonferroni’s 
posttest in E. *p<0.05, **p<0.01, ***p<0.001.
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cells, a PD1-overexpressing Jurkat T cell line. WT1 is a TAA that has been implicated 
with important anti-leukemic T cell responses and is being investigated as a peptide 
vaccination strategy or TCR-transduced T cell therapy for AML.37,38 The percentage 
WT-1 TCR expressing 2D3 cells at start was >75%. Importantly, both PD-L1 silencing 
by PD-L1 siRNA/Saint-RED lipoplexes or PD-1 blocking by systemic blocking 
antibody αPD-1 enhanced WT-1 specific Jurkat T cell activation. This resulted in 
increased percentages GFP-positive T cells in both cultures (Figure 3).
Figure 2 | Effective siRNA-mediated silencing of PD-L1 in patient AML cells. Primary AML 
cells isolated from patient bone marrow or peripheral blood were transfected with control (Ctrl) 
or PD-L1 siRNA/SAINT-RED lipoplexes and consecutively activated with IFNγ and TNFα. (A) 
Surface expression of PD-L1 (filled) and corresponding isotype (open) on AML cells (CD45DIM) 
after O/N activation. Numbers represent delta median fluorescent intensity (ΔMFI) of PD-L1. 
Line is set at isotype control =1%. Data of 1 representative AML sample out of 6 is shown. (B) 
ΔMFI of PD-L1 on AML cells, after O/N incubation with/without activating cytokines. (C) Relative 
PD-L1 expression after O/N activation. (D) PD-L1 knockdown efficiency after O/N activation in 
presence of 0.33 or 1µg PD-L1 siRNA. Knockdown efficiency is calculated as follows: 
100%-((ΔMFI PD-L1 siRNA treated AML/ΔMFI control siRNA treated AML) x 100%). (E) PD-L1 
expression over time shown as relative ΔMFI. Non-silenced condition is set to 1. Mean±SEM is 
shown of N=6 AML samples in B, N=6 (non-silenced, 0.33µg Ctrl/PD-L1) or N=4 (1µg hIgG4/
PD-L1) AML samples in Figure C&D, and N=3 patients in Figure E. Statistical analysis was 
performed using a paired two-tailed T test in B, One way ANOVA with Bonferroni’s Multiple 
Comparison Test in C, and Two-way ANOVA with Bonferroni’s posttest in E. *p<0.05, 
***p<0.001.
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Additionally, the impact of siRNA-mediated PD-L1 silencing on leukemia-reactive 
T cell activation was evaluated in antigen recall experiments. Hereto, patient derived 
cytotoxic T lymphocytes (CTLs) specific for hematopoietic-restricted MiHA HA-1 and 
LRH-1 (>90% MiHA+) were cultured with MiHA+ primary AML cells. The percentage 
PD-1 expressing MiHA-specific CTLs was in all assays >20% at start of the co-culture 
(Supplementary Figure 2). Both PD-L1 silencing and PD-1 blocking antibody 
treatment resulted in significantly increased activation of MiHA-specific CTLs in 
response to AML cells, as reflected by augmented expression of activation markers 
CD137 and CD69 (Figure 4A-C). Furthermore, CTL degranulation (CD107a) and IFNγ 
production was significantly improved in case of PD-L1 knockdown and PD-1 
blockade as compared to the corresponding controls (Figure 4D&E). Together, these 
data demonstrate that siRNA-mediated silencing of PD-L1 in AML cells results in 
improved CTL cell recognition and activation. 
Figure 3 | Enhanced activation of WT1 TCR expressing 2D3 cells by PD-L1 silenced AML 
cells. AML patient bone marrow cells were treated with/without 1µg Ctrl or PD-L1 siRNA/
SAINT-RED lipoplexes and activating cytokines IFNγ and TNFα for 24 hours. Then, WT-1 TCR 
or mock transduced 2D3 cells were co-cultured with WT1 peptide-loaded AML cells at a 1:2 
AML:T cell ratio for 24 hours. α-PD-1 and hIgG4 were taken along as controls. Percentage 
GFP+CD8+ 2D3 cells was analyzed as measure of T cell activation. Graphs show percentage 
GFP+ 2D3 cells for 2 representative AML samples.  Statistical analysis was performed using a 
One way ANOVA with Bonferroni’s Multiple Comparison Test. *p<0.05, **p<0.01.
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Figure 4 | siRNA-mediated silencing of PD-L1 on AML cells improves cytotoxic T 
lymphocyte responses. AML patient bone marrow cells were treated with/without 1µg Ctrl or 
PD-L1 siRNA/SAINT-RED lipoplexes and activating cytokines IFNγ and TNFα for 24 hours. 
Then, CTLs were co-cultured with MiHA peptide-loaded or non-peptide-loaded AML samples 
from different patients at a 1:1 AML:T cell ratio for 24 hours. α-PD-1 and hIgG4 isotype control 
were taken along as additional controls. Thereafter, CTLs were analyzed for activation and 
degranulation by flow cytometry. (A) Dotplots showing CD137 and CD107 expression of CD8+ 
T cells. Numbers represent percentage positive CTLs for the indicated gate. (B) Percentage 
CD137+ T cells for 3 independent CTL:AML combinations. (C) Percentage CD69+ and (D) 
percentage CD107a+ CD8+ T cells as Mean+SD. (E) IFNγ production analyzed using ELISA. 
(A and C-E) are shown for 1 representative patient (patient 2), n=3. Statistical analysis was 
performed using a (B) Repeated Measures ANOVA with Bonferroni’s Multiple Comparison Test 
or (C-E) One way ANOVA with Bonferroni’s Multiple Comparison Test. *p < 0.05, **p<0.01, 
***p<0.001.
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Discussion
The potential of immunotherapy as treatment for cancer is significantly increasing. 
One of the oldest and potentially curative forms of immunotherapy for the treatment 
of AML is allo-SCT. Here, tumor-reactive CD8+ T cell responses from donor derived 
T cells can target malignant hematopoietic cells. Nevertheless, many patients still 
suffer from refractory or recurring disease after allo-SCT. The last decade, we and 
others demonstrated that tumor-reactive T cells can lose functionality via inhibitory 
mechanisms. In this regard, it has been shown that PD-1 is one of the important 
co-inhibitory receptors which contributes to the functional suppression of 
tumor-reactive T cells after interaction with co-inhibitory ligand PD-L1 on tumor 
cells.39 Blocking antibodies targeting the PD-1/PD-L1 signaling pathway functionally 
reinvigorated tumor-specific T cell responses and resulted in impressive clinical 
responses in various solid and hematological malignancies.17-19,39,40 
 However, systemic checkpoint blockade can cause toxicity in healthy tissues. 
Immune related adverse events (irAEs) were reported in up to 70% of cancer patients 
treated with PD-1/PD-L1 blockade.17,39 Especially patients suffering from auto-immune 
disease and patients who received allo-SCT are at risk of developing severe irAEs 
and GVHD, respectively.41,42 In the study of Haverkos et al. rapid onset of severe 
GVHD was reported in 55% of the lymphoma patients after 1 or 2 infusions of PD-1 
blocking antibody, of whom only 2/17 patients responded to GVHD therapy.24 
Although, improvement of GVL immune responses is required to enhance disease-free 
and overall survival, the risk of inciting detrimental GVHD with systemic checkpoint 
blockade is considerable. Therefore, development of strategies to locally interfere 
with checkpoint pathways is highly attractive to improve anti-tumor immunity with 
minimal risk of toxicity in healthy tissues.
 To investigate whether tumor-reactive T cell immunity could be improved by 
targeted interference of co-inhibitory molecules, we explored siRNA-mediated 
silencing of PD-L1 in myeloid tumor cells. PD-L1 siRNA was transfected into AML 
cells using SAINT-RED lipoplexes, which was previously demonstrated to be an 
effective and non-toxic approach in monocyte-derived dendritic cells.43 Efficient and 
durable PD-L1 silencing of up to 80% was observed in activated AML cells. Importantly, 
PD-L1 silencing on AML cell resulted in augmented T cell recognition and activation. 
Notably, these results were confirmed using the PD-1 blocking antibody Nivolumab, 
as was previously shown by Norde et al.8 Our data illustrate that targeted interference 
with the PD-1/PD-L1 pathway in the tumor micro-environment would be an attractive 
approach to strengthen anti-tumor T cell responses in AML patients locally. This 
would provide a safer treatment option for allo-SCT patients, or patients that might 
need allo-SCT in the future.25,44 
 In order to deliver the targeted therapy into the myeloid blasts, a clinically 
applicable nanocarrier should be used to protect the siRNAs from RNAses in the 
serum. Currently, different carriers, including lipid nanoparticles, poly-lactic-co-gly-
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colic acid (PLGA) particles, layered double hydroxide (LDH) particles and lipid-coated 
calcium phosphate (LCP) particles are being developed and explored for in vivo drug 
delivery, including siRNAs.45-49 siRNA delivery by LCP particles resulted in effective 
PD-1 and PD-L1 silencing in T cells and a breast cancer cell line respectively, and 
enhanced T cell functionality.50 However, to achieve specific delivery into AML cells a 
selective targeting moiety is required. We and others demonstrated previously that 
protein C-type lectin domain family 12 member A (CLEC12A) is selectively expressed 
by AML stem cells and blasts, while expression on healthy hematopoietic stem cells 
is lacking. Additionally, CLEC12A is also expressed on mature myeloid cells including 
monocytes, DCs, macrophages, myeloid derived suppressor cells (MDSCs) and 
granulocytes, but not on lymphoid cells or healthy tissue cells.51 This finding resulted 
in the development of CLEC12A-directed bispecific antibodies and CAR T cells.52,53 
Importantly, CLEC12A can effectively internalize cargo, which makes it an interesting 
target for siRNAs delivery.54-56 CLEC12A specific particles could be loaded with 
PD-L1 siRNA and potentially other siRNAs to target immunosuppressive mechanisms 
from multiple angles.
 Altogether, we have shown that PD-L1 can be efficiently silenced in AML cell lines 
as well as in patient’ AML cells using siRNA technology. This augments the 
 immune-susceptibility of AML cells and as a consequence, T cell activation, 
degranulation and IFN-γ production was enhanced. These data provide rationale for 
the development of targeted approaches to selectively interfere with immune escape 
mechanisms in the local myeloid tumor micro-environment, without evoking severe 
systemic toxicity in AML patients. In combination with allo-SCT and/or adoptive T cell 
transfer, this strategy could be very appealing to improve outcome in patients with 
high-risk myeloid malignancies. 
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6Supplementary Figure 1 | PD-L1 siRNA/SAINT-RED lipoplexes do not affect ICAM expression. 
HL-60 cells were transfected with control (Ctrl) or PD-L1 siRNA/SAINT-RED lipoplexes and 
consecutively activated with IFNγ and TNFα. Samples were analyzed for surface expression of 
ICAM by flow cytometry. (A) ΔMFI of ICAM surface expression after O/N incubation with/without 
activating cytokines. (B) Relative ICAM expression after O/N activation and (C) relative ICAM 
expression over time in activated conditions. Non-silenced condition is set to 1. Mean±SEM is 
shown of N=5 independent experiments in A and B and N=3 experiments in C. Statistical 
analysis was performed using a paired two-tailed T test in A, Repeated Measures ANOVA with 
Bonferroni’s Multiple Comparison Test in B, and Two-way ANOVA with Bonferroni’s posttest in 
C. ***p < 0.001.
A
No
n-s
ile
nc
ed
g C
trl
µ
0.3
3 g 
PD
-L1
µ
0.3
3
g C
trl
µ1 g P
D-
L1
µ1
0.0
0.5
1.0
1.5
NS
NS
IC
A
M
 (r
el
at
iv
e 
∆
M
FI
)
NS
B
C
NS
siRNA
- +
0
100
200
300
400 ***
IC
AM
 (∆
M
FI
)
Day 1 Day 2 Day 3 Day 4
0.0
0.5
1.0
1.5
Non-silenced
1µg Ctrl
1µg PD-L1
IC
A
M
 (r
el
at
iv
e 
∆
M
FI
)
146
Chapter 6
Supplementary Figure 2 | CTLs express PD-1 on at least 20% of the cells prior to co-culture 
with AML. PD-1 expression of MiHA-specific CD8+ CTL was determined by flow cytometry 
prior to co-culture with patient AML cells. CTL was characterized as life, CD3+, CD8+ and 
MiHA-tetramer positive. (A) PD-1 expression (filled) compared to isotype staining (open) on 
MiHA-specific CD8+ T cells of patient 2. (B) Percentage PD-1+ MiHA-specific CD8+ T cells for 
patient 1, 2 and 3.
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English Summary
Tumor-reactive effector and memory T cells have the potential to eliminate malignant 
cells and provide life-long protection against tumor cell recurrence. However, the 
immune system of cancer patients is not able to eliminate malignant cells. Therefore, 
cancer immunotherapy aims to revive or enhance existing, and/or provoke new anti- 
tumor immune to boost patient’s anti-tumor immunity. In this thesis, we investigated 
different strategies to improve anti-tumor T cell immunity. By temporary inhibition of 
the AKT-pathway we aim to improve the efficacy of adoptive T cell-based immuno -
therapy and tumor-specific vaccination strategies. Additionally, by targeting a major 
immune-escape mechanism of tumor cells we aim to enhance tumor antigen-specific 
T cell responses in the local tumor microenvironment. 
In chapter 2 we describe how the different T cell subsets with a wide variety of 
 functionalities can be discriminated by flow cytometry. We report an overview for 
the identification of CD4+ T-αβ cells (T-helper (Th)1, Th2, Th9, Th17, Th22 and CD4+ 
regulatory T cells), CD8+ T-αβ cells (cytotoxic T lymphocyte (Tc)1, Tc2, Tc9, Tc17, 
CD8+ regulatory T cells) and their additional effector memory status (naïve (TN), stem 
cell memory (TSCM), central memory (TCM), effector memory (TEM), effector (TEFF)) 
using flow cytometry. These different subsets can be discriminated based on selective 
extracellular markers, in combination with intracellular transcription factor and/or cytokine 
staining. Together, they form a balanced immune system with controlled defense 
mechanism against for example pathogens and malignant cells, while keeping the 
immune system in check to prevent autoimmunity. 
 In chapter 3 and 4 we investigate the ex vivo application of AKT-inhibition to 
improve adoptive T cell therapies. Adoptive T cell therapy has shown clinical potential 
for patients with cancer, though effective treatment is dependent on longevity and 
potency of the exploited tumor-reactive T cells. As previous studies showed that ex 
vivo inhibition of AKT using the research compound Akt-inhibitor VIII preserved CD8+ 
T cells differentiation and improved functionality of tumor-specific CD8+ T cells, we 
aimed to further translate this treatment strategy to the clinic. We compared a panel 
of clinically applicable AKT-inhibitors with an allosteric or adenosine triphosphate- 
competitive mode of action. We analyzed phenotype, functionality, metabolism and 
transcriptome of AKT-inhibited CD8+ T cells using different T cell activation models. 
Most inhibitors facilitated T cell expansion while preserving an early memory 
phenotype, reflected by maintenance of CD62L, CCR7 and CXCR4 expression. 
Moreover, transcriptome profiling revealed that AKT-inhibited CD8+ T cells clustered 
closely to naturally occurring stem cell-memory CD8+ T cells, while control T cells 
resembled effector-memory T cells. Interestingly, AKT-inhibited CD8+ T cells showed 
enrichment of hypoxia-associated genes, which was consistent with enhanced glycolytic 
function. Notably, AKT-inhibition during minor histocompatibility antigen (MiHA)-
specific CD8+ T cell priming uncoupled preservation of early memory differentiation 
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from ex vivo expansion. Furthermore, AKT-inhibited MiHA-specific CD8+ T cells 
showed increased polyfunctionality with co-secretion of IFNγ and IL2 upon antigen 
recall. Together, these data demonstrate that AKT-inhibitors with different modality of 
action promote the ex vivo generation of stem cell memory-like CD8+ T cells with a 
unique metabolic profile and retained polyfunctionality. Akt-inhibitor VIII and 
GDC-0068 outperformed other inhibitors, and are therefore promising candidates for 
ex vivo generation of superior tumor-reactive T cells for adoptive immunotherapy in 
cancer patients. 
 Additionally, we investigated in chapter 4 the possibility to apply ex vivo AKT- 
inhibition to other adoptive T cell therapies, including chimeric antigen receptor or 
T cell receptor engineered T cells. However, these products are mostly generated 
from total lymphocytes or CD3+ T cells, containing also CD4+ T cells that can affect 
CD8+ T cells dependent on the helper subset. Therefore, we investigated the effect 
of AKT-inhibition during CD4+ T cell expansion, focusing on memory and T-helper 
subset differentiation. Akt-inhibitor VIII and GDC-0068 were added during activation 
and expansion of (naïve or total) CD4+, CD8+ or CD3+ T cells, whereupon phenotype, 
transcription factor profile, cytokine production, and expansion capacity were 
analyzed. Interestingly, ex vivo AKT-inhibition preserved the early memory phenotype 
of stimulated CD4+ T cells based on higher CD62L, CXCR4 and CCR7 expression. 
However, in the presence of AKT-inhibition T-helper subset differentiation was skewed 
towards more T-helper 2 at the expense of T-helper 1 cells. Additionally, the total 
percentage cytokine producing CD4+ T helper cells was lower in AKT-inhibited 
cultures. The enhanced induction of T-helper 2 cells was still observed in total CD3+ 
T cell cultures and with both dendritic cell and polyclonal stimulation. Nevertheless, 
enhanced rechallenge capacity, degranulation and polyfunctionality upon antigen 
recall of AKT-inhibited CD8+ T cells was only observed in dendritic cell stimulated 
cultures. Importantly, the favorable effect of AKT-inhibition on CD8+ T cell polyfunc-
tionality upon dendritic cell stimulation diminished in presence of AKT-inhibited CD4+ 
T cells. These findings indicate that for ex vivo generation of superior polyfunctional 
CD8+ T cells with stem cell memory-like characteristics, it is recommended to apply 
AKT-inhibition in absence of CD4+ T cells. 
 AKT-inhibitors are currently under development for in vivo application because of 
their direct tumor-targeting potential. This would make the in vivo administration of 
AKT-inhibition in combination with tumor-specific T cells stimulation an interesting 
approach to target cancer cells via multiple ways. In chapter 5 we investigated the 
combination of AKT-inhibition and OVA-specific peptide vaccination in an OT-1 
model. First, direct effects of AKT-inhibition on effector memory T cell differentiation 
of CD8+ OT-1 T cells were investigated. Here, AKT-inhibition preserved early memory 
differentiation of OT-1 T cells in vitro, based on higher expression of CD62L and CD27, 
while minor effects on proliferation were observed. Furthermore, we observed 
increased maximal respiration and spare respiratory capacity in AKT-inhibited cells 
as well as improved degranulation of T cells upon in vitro re-stimulation in absence of 
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AKT-inhibition. Thereafter, C57BL/6 wild type mice received adoptive T cell transfer of 
OT-1 T cells in combination with OVA long-peptide vaccination and in vivo AKT-inhibitor 
administration. This showed preserved early memory differentiation of T cells in 
blood on day 7. Together, this study shows the possibility to preserve early memory 
CD8+ OT-1 T cells via AKT-inhibition. Future studies and optimization should reveal 
the potential of in vivo AKT-inhibition to improve adoptive T cell and vaccination 
therapies.
 Besides, the generation of potent tumor-specific T cells, it is also important to 
eliminate immunosuppressive mechanism of tumor cells. By exploiting suppressive 
mechanisms, including inhibitory signaling via checkpoint molecules, tumor cells 
can suppress tumor-reactive T cell responses. Importantly, systemic immune 
checkpoint blocking antibodies, targeting e.g. the PD-1/PD-L1 signaling pathway, 
have demonstrated impressive clinical results in cancer patients. Yet, the negative 
consequence of systemically releasing the immune brake is the induction of (severe) 
toxicity in healthy tissues. In chapter 6 we aimed to locally interfere with inhibitory 
PD-1/PD-L1 signaling in the acute myeloid leukemia (AML) micro-environment by 
PD-L1 siRNA delivery. Notably, using siRNA/SAINT-RED transfection technology, 
we demonstrated efficient silencing of PD-L1 in AML cell lines as well as in patient’ 
AML cells. Next, the functional effect of the PD-L1 silencing in AML on leukemia- 
reactive T cell activity was investigated in co-culture assays. We observed increased 
activation of WT1 TCR mRNA transfected PD-1+ Jurkat cells upon co-culture with 
PD-L1 silenced WT1+ AML. Moreover, we showed significantly enhanced activation, 
degranulation and IFNγ production of MiHA-specific CD8+ cytotoxic T cells in 
response to PD-L1 silenced MiHA+ AML cells. Importantly, PD-L1 silencing was 
equally effective as PD-1 antibody blockade in boosting tumor-reactive T cell function. 
Together, these results demonstrate that PD-L1 silencing using RNAi technology 
enhances the immunosusceptibility of AML cells, facilitating improved recognition by 
tumor-reactive CD8+ T cells. This provides rationale for development of targeted 
siRNA delivery technology to selectively interfere with immune escape mechanisms 
in the local myeloid tumor micro-environment. Hereby, the risk of eliciting severe 
toxicity can be limited as compared to systemic checkpoint interference. In combination 
with adoptive T cell transfer, this strategy could be very appealing to improve outcome 
in patients with high-risk myeloid malignancies.
In conclusion, this thesis describes the pre-clinical development of various immuno-
therapeutic strategies that could potentially be applied to improve anti-tumor immune 
responses. Ex vivo AKT-inhibition has shown to be a powerful tool to preserve stem 
cell memory CD8+ T cell with polyfunctional anti-tumor characteristics. Also CD4+ 
early memory T cells are preserved upon AKT-inhibition. However, a shift in skewing 
of T helper population and reduced CD8+ T cell functionality in presence of 
AKT-inhibited CD4+ T cells, shows that ex vivo AKT-inhibition should be applied in 
absence of CD4+ T cells. Nevertheless, in vivo AKT-inhibition is worth further 
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investigation because it may enhance tumor-reduction via multiple mechanisms. We 
found that early memory CD8+ T cells can be preserved when combining in vivo 
AKT-inhibition and antigen-specific T cell vaccination. Additionally,  local silencing of 
PD-L1 showed enhanced tumor-specific T cells responses. Together, both temporarily 
AKT-inhibition to improve CD8+ T cell functionality and longevity, and PD-L1 silencing 
provide two different and possibly complementary strategies to enhance anti-tumor 
immunity.
155
English summary
7

Discussion and future perspectives
Chapter 8
158
Chapter 8
159
Discussion and future perspectives
8
Discussion and future perspectives 
Adoptive T cell therapy can be a promising strategy for the treatment of advanced 
cancer, as shown by impressive anti-tumor responses in patients treated with donor 
T cell infusions after allogeneic stem cell transplantation, chimeric antigen receptor 
(CAR)-expressing T cells or expanded tumor infiltrating lymphocytes (TILs). These 
immunotherapies show the potential of adoptively transferred tumor-reactive T cells 
as cancer therapy. However, while impressive responses are obtained in part of the 
patients, other patients do not respond or relapse. As an early memory phenotype of 
adoptively transferred T cells has been associated with improved treatment outcome, 
we improved the ex vivo expansion of tumor-reactive CD8+ T cells with an early 
memory phenotype by temporary pharmacological inhibition of the AKT-pathway, as 
described in chapter 3.
Role of AKT-signaling in CD4+ and CD8+ T cell differentiation
Generally, a linear T cell differentiation model has been proposed were naïve CD8+ T 
cells (TN) differentiate into stem cell memory (TSCM), central memory (TCM), effector 
memory (TEM) and effector T cells (TEFF) accordingly. However, it is described that 
dedifferentiation of TEFF into memory CD8+ T cells as a consequence of demethylation 
of effector genes, and re-expression of naïve-associated genes is possible.1-3 In our 
studies, we did however not observe re-expression of memory-associated molecules 
on non-AKT-inhibited T cells, possibly because cells were cultured in vitro and for a 
short time of maximum 18 days.4,5 
 In the transcriptome analysis in chapter 3, we compared AKT-inhibited with 
non-AKT-inhibited T cells and showed that AKT-inhibited T cells clustered more 
closely to the gene expression profiles of naturally occurring TSCM cells, while 
non-AKT-inhibited T cells clustered closer to TEFF T cells. However, the gene 
expression profile did not overlap completely with naturally occurring TSCM or TCM T 
cells. This indicates the generation of a unique T cell subset, which may follow a 
unique model of differentiation compared to naturally occurring TSCM cells as a 
consequence of AKT-inhibition in vitro. T cell receptor (TCR) and cytokine stimulation 
induce AKT-phosphorylation at Ser473 and T308, and this leads to inactivation of 
forkhead box O1 (FOXO1) and activation of T-bet, respectively.6,7 FOXO1 is a crucial 
transcription factor for the survival and trafficking of naïve T cells, and regulates the 
expression of CD62L, CCR7, IL7Rα and the transcription factor KLF2.8,9 Although we 
did not observe significant differences in FOXO1 expression, downstream SELL 
(CD62L) and IL7R were higher expressed in AKT-inhibited T cells. Also memory T 
cell-associated BCL6, a crucial factor for the formation of self-renewing TCM cells, 
was higher expressed in AKT-inhibited T cells.10 A recently identified transcription 
factor for maintenance of CD8+ TSCM/CM cells is c-Myb which activates TCF7 
(encoding TCF1).11 This TCF1 enforces memory formation by inducing EOMES 
expression and suppression of T-bet expression.7,12 It has been shown that the 
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balance of effector T cell associated T-bet and eomesodermin (EOMES) is key, where 
EOMES suppresses T-bet expression and increasing amounts of T-bet induce TEFF 
differentiation.7,12-15 However, In our in vitro T cell culturing methods we observed lower 
expression of TN-associated TCF7 and no difference in T-bet expression, though a 
lower expression of EOMES was observed in AKT-inhibited T cells. Additionally, 
TEFF-associated genes like B lymphocyte-induced maturation protein 1 (BLIMP1, also 
known as PRDM1) were even higher expressed in AKT-inhibited T cells.16 On the other 
hand ID2, known to be important for the formation of terminal effector T cells, was lower 
expressed in AKT-inhibited T cells.17 Also a previous study of van der Waart et al. (2014) 
showed that AKT-inhibition during minor histo compatibility antigen (MiHA)-specific 
T cell expansion induces a unique gene expression profile were besides upregulation 
of TN- also several TEFF-associated genes were upregulated.4 Together, this shows 
that in vitro AKT-inhibition during human CD8+ T cell expansion induces a TSCM-like 
transcriptome, though with a unique gene expression profile.
 This unique profile indicates that AKT-signaling was not completely blocked during 
the generation of AKT-inhibited T cells. This is in concordance with the observation 
that AKT-inhibition had minimal effects on proliferation, while this is an important 
downstream effect of the PI3K/AKT-pathway.18 The incomplete or temporary inhibition 
of AKT phosphorylation is possibly an important characteristic for the applicability of 
this strategy, as this also facilitates the ex vivo expansion during the generation of 
tumor-reactive T cells for adoptive T cell therapy. 
Next to differentiation, PI3K/AKT/mTOR signaling also induces a switch in T cell 
metabolism. Where effector T cells perform high rates of aerobic glycolysis, gluta-
minolysis and anabolic metabolism, early memory T cells rely more on fatty acid 
oxidation (FAO) and mitochondrial oxidative phosphorylation (OXPHOS).19-21 
Unexpectedly, in chapter 3, we did not observe increased oxidative phosphorylation, 
but instead enhanced glycolysis in AKT-inhibited human CD8+ T cells, especially 
when cells were treated with Akt inhibitor VIII. This observation matched the higher 
expression of glycolysis-associated PFKM and decreased expression of OXPHOS- 
associated Carnitine palmitoyl-transfersase 1a (CPT1A) in our transcriptome analysis. 
(CPT1a) is an enzyme required for fatty acid transport, and knockdown is associated 
with suppressed memory CD8+ T cell survival after infection.22 This observation 
shows that besides discrepancies in gene expression profile, also metabolic data 
showed that the AKT-inhibited CD8+ T cells expanded in our protocol share not all 
characteristics with TSCM and TCM cells. The consequence for T cell functionality 
should be investigated in in vivo studies. While early memory CD8+ T cells are 
normally characterized by increased OXPHOS metabolism, AKT-inhibited early 
memory T cells might allow better tumor-targeting in low-oxygen environments like in 
tumor mass or bone marrow. Additionally, limited OXPHOS might facilitate effector 
T cell responses in limiting glucose tumor-microenvironments.23 On the other hand, 
TCM cells with enhanced OXPHOS are associated with enhanced survival and 
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anti-tumor activity in vivo.24 Interestingly, in chapter 5, we also studied AKT-inhibited 
murine OT-1 CD8+ T cells in metabolic assays. Here, AKT-inhibited OT-1 cells showed 
increased maximal respiration and spare respiratory capacity, indicating enhanced 
mitochondrial OXPHOS. Like in chapter 3, cells were stimulated with IL2, IL7 and IL15 
and DCs, however in this case DCs were cultured from total bone marrow of mice, 
whereas in stimulation of human CD8+ T cells we exploited monocyte-derived DCs. 
These observations indicate that AKT-inhibition can change the metabolic characteristics 
of CD8+ T cells, however others factors in the culture can modulate the outcome this 
effect. In line with this, a recent study of Pilipow et al. (2018) describes that factors in 
the culture media, like the presence of antioxidant and as a consequence limited 
reactive oxygen species metabolism, induces early memory T cells with enhanced 
OXPHOS.25 Additionally, cytokines like for example IL15 have shown to affect CD8+ 
T cell metabolism in vitro, by stimulating CPT1a expression and OXPHOS.22 
While IL15 was added to both cultures, differences in median composition, cytokine 
consumption and secretion by human and mouse T cells and DCs might affect the 
metabolic state at the end of the culture period. By further optimization of different 
in vitro culture conditions during expansion of tumor-reactive AKT-inhibited T cells, 
resulting in different metabolic characteristics followed by investigation of in vivo 
functionality and persistence should reveal the optimal protocol for clinical translation. 
In chapter 3-5, different AKT-inhibitors with different modes of action were investigated 
in various T cell models. In general, similar effects were observed in the inhibition of 
effector memory differentiation of CD4+ and CD8+ T cells. Furthermore, skewing of 
CD4+ T helper subsets by both the ATP-competitive GDC-0068 as well as the 
allosteric AKT-inhibitor Akt-inhibitor VIII was revealed. This was partly unexpected as 
it is suggested that ATP-competitive AKT inhibitors may preferentially target active 
phosphorylated AKT, while allosteric AKT-inhibitors bind the pleckstrin homology 
(PH)-domain and are less effective against pre-activated AKT.26,27 Also when starting 
with total CD3+, CD4+ or CD8+ T cells, which most likely contain phosphorylated 
AKT, no big differences between inhibition by GDC or AktiVIII were observed. This 
indicates that either ATP-competitive or allosteric inhibitors can be used for the 
expansion of tumor-reactive T cells with a preserved early memory T cell phenotype. 
However, it would be interesting to see if a combination of both inhibitors would 
further improve the potency of AKT-inhibited T cells. Preliminary experiments with 
OT-1 CD8+ T cells (data not shown) did not show enhanced expression of CD62L 
when a combination of both AKT-inhibitors was used in vitro. In addition, polyfunc-
tionality by co-production of IFNγ, IL2 and TNFα upon restimulation was not enhanced 
in cells cultured with a combination of both AktiVIII and GDC compared to cells 
cultured with only one of these AKT-inhibitors. This suggests again that inhibition 
of the AKT-pathway is important for the generation of early memory T cells with 
polyfunctional characteristics, and that this effect can be obtained via either ATP- 
competitive and allosteric AKT-inhibitors. 
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Effect of stimulation on T cell differentiation
As mentioned before, different factors during T cell expansion affect T cell differentiation 
and functional characteristics, including the strength of T cell stimulation. This was 
for example observed in chapter 4, were similar assays were performed with either 
DC-mediated or CD3/CD28 bead-based stimulation. While AKT-inhibition preserved 
early memory CD4+ and CD8+ T cells in both models, CD62L expression was less 
preserved in CD3/CD28 bead-stimulated assays. Also differences in functional 
 characteristics were observed, with in general more cytokine producing T cells in 
CD3/CD28 bead stimulated T cells. These observations may be explained by a 
 signal-strength model.28 According to this model, T cell differentiation is dependent 
on TCR avidity, co-stimulation, duration of DC/bead-T cell interaction and the 
subsequent overall strength of TCR signaling.29-31 Additionally, also factors in the 
microenvironment including antigen abundance and cytokines might affect T cell 
fate.28,32 In our in vitro models, allo-mDCs most likely induce more co-stimulation and 
cytokine support than CD3/CD28 beads. On the other hand, CD3/CD28 beads might 
stimulate T cells throughout the whole culture period, while DCs are expected to die 
within a few days of culture, and were generally not observed in flowcytometric 
analysis at day 7 or 10. 
In our models, ex vivo T cell expansion was performed in presence of cytokine support 
by low dose IL2, IL7 and IL15. IL2 is important for T cell activation and expansion of 
T cells. The longevity of memory T cells is dependent on IL7 and IL15 which promote 
survival and self-renewal.33,34 IL7Rα signaling is critical for memory CD8+ T cell 
survival and it has been described that a small fraction of CD8+ T cells with increased 
expression of IL-7R become memory T cells that could persist.34-37 Also IL15 is 
described as being critical for memory T cell homeostasis and self-renewal.33,35,37
 Besides IL7 and IL15, also the usage of a combination of IL7 with IL21 and IL12 
during ex vivo expansion has been associated with an early memory phenotype and 
improved persistence in vivo.38
 One of the advantages of DC instead of CD3/CD28 bead-stimulation might be 
their IL12 production, which is mostly likely absent in CD3/CD28 bead stimulated 
cultures. Additionally, we investigated the addition of IL21 during ex vivo T cell priming 
experiments in combination with AKT-inhibition (Figure 1). The addition of IL21 to our 
culture protocol reduced the total fold expansion of MiHA-specific T cells upon 
stimulation with DCs. However, with a concentration of 3ng/ml IL21, MiHA-specific 
CD8+ T cell expansion was still observed, but this concentration did not result in 
higher expression of CCR7. Therefore, it was decided not to include IL21 in our ex vivo 
AKT-inhibition culture procedure. While IL21 is known to induce AKT-phosphorylation 
and therefore reduced effects on inhibition of proliferation would be expected, IL21 
also activates multiple other signaling pathways involved in proliferation, including 
the JAK-STAT and MAPK pathways.39 It is therefore unexpected that IL21 would 
diminish T cell proliferation. One explanation for the observed effects might be that 
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IL21 negatively affects the DCs and its capacity to induce T cell proliferation, which 
has been described for the expansion of CD4+ T cells.40 Therefore, it would be 
interesting to re-investigate the addition of IL21 in non-DC assays, for example upon 
CD3/CD28 bead stimulation.
CD4+ T cell help
In chapter 4 we studied the effect of AKT-inhibition on effector memory and helper 
subset differentiation of CD4+ T cells and showed that inhibition of the AKT-pathway 
preserves early memory differentiation but affects Th1 and Th2 development. This 
could be explained as T-bet is known to play a role in T helper 1 (Th1) differentiation.41 
Moreover, differentiation towards Th1 is regulated via mTORC1, and Th2 development 
required mTORC2.31 Inhibition of the AKT-pathway has also been associated with 
enhanced proliferation of CD4+ Tregs.42-45 However, we could not demonstrate 
enhanced induction of Tregs in ex vivo expanded and AKT-inhibited CD4+ T cultures, 
and the overall percentage IL-10 producing cells was low (1-3%) though slightly 
increased in AKT-inhibited cultures. Most likely, the culture conditions did not favor 
Treg expansion. However, this should be investigated in each specific T cell expansion 
protocol where AKT-inhibition is applied, as this might enhance Treg induction when 
more Treg-stimulating factors (e.g TGFβ and higher concentration of IL2) are present.46 
 As in vitro AKT-inhibition skews CD4+ T cells towards Th2 at the expense of Th1, 
we studied how these AKT-inhibited CD4+ T cells affect CD8+ T cells in the culture. 
Here we observed unfavorable effects, where the increase in polyfunctional CD8+ 
T cells was diminished. Therefore we recommend in chapter 4 that CD4+ T cells 
should be expanded separately and added to the AKT-inhibited CD8+ T cells just 
Figure 1 | IL21 in combination with AKT-inhibition preserves CCR7 expression but also 
inhibits MiHA-specific CD8+ T cell expansion. CD8+ T cells were stimulated with MiHA-pep-
tide-loaded mDCs for 14 days in the presence of 12µM AktiVIIIDose toevoegen, 50IU/ml IL2, 
5ng/ml IL7, 5ng/ml IL15 and varying concentration of IL21. Half of the medium was refreshed 
with AKT-inhibitor and cytokines every 2-3 days and T cells were restimulated with MiHA- 
peptide-loaded mDCs at day 7. (A) Expansion of MiHA-specific CD8+ T cells. Expansion was 
calculated from an estimated precursor frequency of 1:107 (B) Median fluorescent intensity of 
CCR7, expression on MiHA-specific CD8+ T cells. Data shown of 1 representative experiment.
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before infusion of the cell therapy product. Alternatively, leaving out CD4+ T cells in 
the therapeutic product is not desirable, as the value of CD4+ T cell help in improving 
CD8+ T cell functions has been extensively described. CD4+ T cells help CD8+ 
T cells during initial T cell activation, their effector phase and in execution of cytolytic 
activity.47-49 CD4+ T cells may help via improvement of APC function mediated by 
interaction via CD40/CD40L50 and production of IL2.49 Additionally, they have also 
shown importance in CD8+ memory T cell maintenance and their expansion upon 
antigen recall.51-54 On the other hand, it is also described that memory programming 
of CD8+ T cells is cell intrinsic and not determined by CD4+ T cell help. Here, mainly 
the timing of antigen clearance was associated with the degree of memory expansion, 
and antigen persistence induced CD8+ T cell exhaustion.55-57 We observed effective 
T cell activation during in vitro expansion of CD8+ T cells in absence of CD4+ T cells 
in both DC and CD3/CD28 bead activation assays, where optimal conditions can be 
obtained by for example addition of IL2 to the culture media. However, for in vivo 
functionality of CD8+ T cells we would prefer co-transfusion with CD4+ T cells.
 The importance of CD4+ T cell help has also been described directly in relation 
to adoptive cell therapy, as they showed to be important to maintain effector and 
memory CD8+ T cells.58,59 Adoptive transfer of both CD4+ and CD8+ T cells has 
been associated with increased CD8+ T cell numbers in vivo.58,60 Additionally, 
in case of hematological malignancies it may be a possibility to give patients not only 
antigen-specific CD8+ but also CD4+ T cells, whereas CD4+ T cell therapy may 
be repeated in case of disease stabilization or relapse. A similar strategy has shown 
success in a patient with epithelial cancer.61 Furthermore, specifically in mice bearing 
MHC class II positive tumors, antigen-specific CD4+ T cells have shown to be able to 
rescue CD8+ T cell functionality in anti-PD-L1 resistant tumors.62 Here, CD8+ T cells 
with an exhausted (PD1+Tim3+) phenotype were residing in the tumor, and gained 
functionality after adoptive transfer of antigen-specific CD4+ T cells. IFNγ and TNFα 
production by CD8+ T cells increased, PD-1 expression reduced and the amount of 
circulating antigen-specific CD8+ T cells improved.62 This implicates that co-infusion 
of CD4+ T cells is important to obtain optimal CD8+ T cell anti-tumor functionality, 
and additionally as tumor-targeting therapy in some cases. Because we observed in 
chapter 4 negative effects of CD4+ T cells on CD8+ T cells in AKT-inhibited cultures, 
it is important to develop an alternative strategy to generate optimal supporting CD4+ 
T cells in a separate culture. 
 For clinical application, it has shown to be feasible to select CD4+ and CD8+ TCM 
cells and transduce CARs separately, followed by CAR T cell infusion in a fixed 1:1 
CD4+:CD8+ T cell ratio.63 Importantly, the absolute CD8+ TCM counts were sufficient 
for selection and manufacturing of CAR-T cell products. According to our findings 
in chapter 4, it would be interesting to besides enrichment of early memory CD8+ 
T cells (and subsequent expansion under AKT-inhibition), also isolate naïve or early 
memory CD4+ T cells. Additionally, CD4+ T cells could be transduced and expanded 
separately in the absence of AKT-inhibition. Because it has been shown that 
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anti-CD19 CAR T cells generated from naïve and central memory CD4+ (and CD8+) 
T cells were more effective compared to CAR T cells generated from effector T cells, 
it is important to limit effector T cells differentiation during ex vivo culture procedures.64 
As CD4+ T cells form in general 2/3 of the total CD3+ T cell population, these cells 
need less expansion to end up with appropriate numbers of CD4+ T cells. Therefore, 
it would be interesting to investigate the possibility to change the cytokine cocktail 
during ex vivo expansion by for example leaving out IL2 and adding IL21. Possibly, 
this might result in the beneficial early memory CD4+ T cell population, without 
changing the Th1 and Th2 skewing as a consequence of AKT-inhibition. Another 
strategy might be reduction of CD4+ T cell expansion and differentiation by using a 
different stimulation strategy (e.g. TransAct), lowering the amount of CD3/CD28 
beads or DCs per T cells or removing magnetic beads after a few days of stimulation. 
Hereby, some proliferation can take place which is required for TCR or CAR 
transduction, but cells might still have an early memory phenotype at time of infusion. 
Finally, infusion of AKT-inhibited stem cell-like CD8+ CAR T cells plus CART CD4+ 
Th1 cells could lead to increased expansion and persistence associated with better 
anti-tumor effects.
T cell tolerance
While the immune system should reject cancer cells as ‘aberrant’, often tolerance of 
T cells towards cancer cells is observed. One of the mechanisms that induces this 
tolerance is the upregulation of co-inhibitory receptors, including PD-1, on CD8+ 
T cells and the interacting ligand PD-L1 on tumor cells.65,66 To interfere with this 
immune escape mechanisms, anti-PD-1 and anti-PD-L1 blocking antibodies have 
been developed for immunotherapy, which resulted in durable objective responses 
and improved survival in 20-40% of patients with advanced melanoma, non-small- 
cell-lung cancer and renal carcinoma.65 This led to regulatory approval by the FDA 
for these and other cancers including several hematological malignancies. 
Additionally combination treatment with blocking of the immune checkpoint cytotoxic 
T lymphocyte associated antigen (CTLA4) resulted in survival advantages in for 
example advanced melanoma.67 CTLA4 blocking has shown to improve priming and 
activation of CD8+ T cells, and can additionally block the suppressive activity of 
Tregs.65 Because of the high risks to induce graft-versus-host disease or severe 
immune-related adverse events when treating patients systemically with checkpoint 
inhibitors after allogeneic stem cell transplantation or in the autologous setting, 
respectively, we investigated siRNA-mediated PD-L1 silencing in chapter 6. Via local 
delivery of PD-L1 siRNA at the tumor-site, this strategy has the potential to block the 
inhibitory PD1-PD-L1 signaling locally. Importantly, siRNA-mediated PD-L1 silencing 
improved T cell functionality to a similar extent as anti-PD1 blocking antibodies in 
in vitro assays. The local PD-L1 silencing strategy would also be interesting after 
adoptive T cell therapy with AKT-inhibited CD8+ T cells. It has been found that PD-1 
blockade acts on TCF1+CD28+CXCR5+stem-like CD8+ T cells, and that especially 
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these cells provide the proliferative burst.68,69 This CD8+ T cell population expressed 
furthermore CD62L and CD127 and showed self-renewal as well as differentiation 
into effector subsets.68 Also exhausted CD8+ TILs were defined as ‘progenitor 
exhausted’ cells which showed more coproduction of IFNγ, IL2 and TNFα, increased 
proliferative capacity and persistence, and especially this population responded to 
PD-1 blockade.36,70 Possibly, adoptive transfer of AKT-inhibited CD8+ T would 
respond better to PD-1/PD-L1 blockade therapy, once they start to express PD-1, 
compared to adoptive transfer of effector T cells.
 The next challenge for further translation of this strategy is local delivery of siRNA 
in the tumor cells. As discussed in chapter 6, different particles are developed to use 
as siRNA carrier, and additionally C-type lectin domain family 12 member A 
(CLEC12A) has been identified as potential target since this is expressed by AML 
stem cells and blasts. In future studies it is important to identify the most optimal 
siRNA delivery strategy. Additionally, in vivo studies are needed to investigate if this 
will result in sufficient siRNA delivery resulting in PD-L1 silencing, the duration of this 
effect and  possibly confounding factors in the microenvironment. When this 
optimized, it opens a very interesting new treatment strategy which can be used for 
PD-L1 silencing but also to deliver other immune stimulating component like siRNA 
targeting other co-inhibitory receptors are high dose tumor-targeting drugs like 
AKT-inhibitor.
  
Temporary in vivo application of AKT-inhibition in conjunction with adoptive T cell 
tranfer or tumor-antigen based vaccination might be another interesting treatment 
option as described in chapter 5. Besides it’s potential to preserve early memory 
T cells, it might also reduce the PD-L1 expression on cancer cells. In some tumors, 
PTEN mutations result in PI3K/AKT pathway activation, thereby constitutively driving 
PD-L1 expression (Figure 2).65,71 Also the IFNγ-mediated induction of PD-L1 is 
regulated via the AKT-mTOR signaling pathway.72 In a pilot experiment we investigated 
the effect of AKT-inhibition on upregulation of PD-L1 on AML cells (Figure 3). While 
AKT-inhibition did not have direct effects on the survival of AML cells (Figure 3A), 
especially the addition of AKT-inhibitor GDC-0068 resulted in reduced PD-L1 
expression (Figure 3B). Systemic administration of AKT-inhibitor during tumor-antigen 
peptide vaccination might therefore improve the anti-tumor effect via the enhanced 
formation of memory CD8+ T cells (chapter 5) as well as diminished expression of 
PD-L1 on tumor cells, resulting in less T cell tolerance. Future studies should focus on 
both the optimization of AKT-inhibition of CD8+ T cells upon vaccination, as well as 
direct effects on tumor cells. Additionally, a combination of tumor-antigen vaccination 
and OT-1 adoptive transfer in tumor-bearing mice should reveal whether in vivo 
AKT-inhibition can preserve both early memory CD8+ T cells as well as reduce PD-L1 
expression on tumor cells.   
 A pre-clinical study testing a PI3Kγ-inhibitor in combination with anti-PD-1 and 
anti-CTLA4 showed improved tumor regression and long-term survival compared to 
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Figure 2 | Enhanced AKT-pathway signaling negatively affects anti-tumor T cell immunity. 
Enhanced AKT-pathway signaling is common in tumorigenesis, often as a consequence of 
mutations and loss of tumor-suppressor gene PTEN. This induces increased PD-L1 expression, 
which inhibits T cell activation upon interaction with receptor PD-1. Additionally, enhanced 
AKT-pathway signaling increases proliferation and glucose uptake of tumor cells. As a 
consequence, reduced glucose availability for T cells also hampers T cell functionality.
Figure 3 | AKT-inhibition reduces PD-L1 upregulation in AML cells. Primary AML patient 
bone marrow cells were activated O/N with IFNγ (100IU/ml) and TNFα (1.25ng/ml) in presence 
of DMSO (Ctrl), AktiVIII or GDC (both 10-5-2.5-1.25µM). (A) Relative number AML cells 
harvested at the end of the O/N culture. Mean+SD is shown of N=2 of 1 experiment. (B) 
Percentage PD-L1+ AML cells (isotype control was set at 1% positive) and delta median 
fluorescence intensity (ΔMFI; MFI PD-L1 staining corrected for MFI isotype control) of PD-L1 on 
total AML cells. Statistical analysis was performed using a One way ANOVA with Bonferroni’s 
Multiple Comparison Test. *p<0.05, **p<0.01, ***p<0.001.
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treatment with checkpoint blocking antibodies only.73 This therapeutic effect was 
explained via targeting of suppressive myeloid cells which highly express PI3Kγ. 
This finding raises the question whether AKT-inhibition might have more beneficial 
effects within the tumor micro-environment besides PD-L1 downregulation. T cells 
can become rapidly dysfunctional in the tumor-microenvironment of especially 
solid tumors, which is characterized by oxidative stress, nutritional depletion, acidic 
pH and hypoxia.74 Tumors and T cells compete for glucose, and this competition 
can affect the glycolysis-dependent function of tumor-reactive T cells.75 In vivo 
AKT-inhibition in tumor cells, results in reduced proliferation and glucose consumption 
(Figure 2).76 This more glucose-rich environment will then possibly improve T cell 
function. Another major cause for escape from CD8+ T cell-mediated control can be 
the loss or reduced expression of MHC class I molecules.77,78 A recently published 
study describes that oxygen- and glucose-deprivation of tumor cells reduced MHC 
Class I antigen presentation, which was interestingly prevented by inhibition of the 
PI3K-signalling patway.79 This shows that in vivo AKT-inhibition might improve 
anti-tumor T cell functionality even further by reducing the glucose consumption and 
MHC class I downregulation of tumor cells. Additionally this would be interesting to 
investigate in our in vivo experiments. Additionally, before clinical translation it is also 
important to investigate toxicity and possible negative effects on other (immune) 
cells. Chapter 4 revealed for example changes in CD4+ T cells skewing which should 
be investigated in vivo. Conclusively, these findings show that in vivo AKT-inhibition 
has potential to improve anti-tumor immunity via several mechanisms, however 
because the PI3K/AKT/mTOR-pathway plays a role in many different cells, extensive 
preclinical studies are required.   
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Future perspectives in AKT-inhibited adoptive  
T cell therapy 
The main goal of this thesis is the development of AKT-inhibited T cells for adoptive 
T cell therapy. With the development of TCR- and CAR-transduced T cells, the 
applicability of adoptive T cell therapies has largely increased.80 Anti-CD19 CAR 
T cells for the treatment of B cell acute lymphoblastic leukemia (B-ALL) has resulted 
in high rates of complete remission.63,81,82 Also encouraging results have been seen 
in treatment of non-Hodgkin’s Lymphoma (NHL)  and chronic lymphocytic leukemia 
(CLL).83,84 Also CAR T cells generated from allogeneic T cells after allogeneic stem 
cell transplantation showed high rates of complete remission, similar to non-trans-
planted patients.63 Because clinical efficacy has been associated with the infusion of 
early memory T cells, we optimized the ex vivo expansion of stem cell like T cells 
exploiting pharmacological AKT-inhibition.85,86 This should be combined with other 
strategies which are also associated with better persistence.  For example, the 
combination of Cy/Flu lymphodepletion prior to adoptive T cell therapy results in 
better expansion and persistence of both CD8+ and CD4+ CAR T cells because of 
increased levels of homeostatic cytokines.63 Additionally, CAR T cell persistence 
could be improved by replacing the murine scFV in the CAR transgene product, as 
CD8+ T cells of the patient can develop immunity to this.63. Also genetic modification 
of CAR T cells by for example FAS signaling disruption has shown to improve T cell 
persistence.87 Together with the infusion of early memory T cells, this can potentially 
improve CAR T cell therapy.
 With the addition of AKT-inhibition during ex vivo tumor-reactive T cell generation, 
we aim to improve the CD8+ memory T cell characteristics. Ex vivo AKT-inhibition 
results in a transient effect, and does not prevent reactivation of AKT in vivo upon 
antigen rechallenge. This is important, since effective cancer immunotherapy requires 
collective efforts of effector and memory T cells.80 Memory T cells are required to 
maintain effector T cells for weeks or months for complete tumor eradiation.88,89 
Additionally, local PD-L1 silencing might be an effective strategy to improve 
tumor-reactive T cell immunity by correcting adaptive resistance, and might especially 
enhance the functionality of T cell with early-memory characteristics. This makes a 
combination of adoptive T cell transfer with local PD-L1 silencing an interesting 
strategy. Additionally, also in vivo AKT-inhibition forms an interesting treatment 
strategy to induce more memory T cells upon tumor-specific peptide vaccinations, 
and future studies should clarify whether this will improve anti-tumor immunity, 
possibly also via reduced PD-L1 expression, reduced glucose consumption by tumor 
cells, or reduction of other suppressive immune cells. However, for the application of 
in vivo AKT-inhibition, also possible changes in CD4+ T cell skewing and impact on 
other immune cells, should be studied extensively. Collectively, this thesis provides 
important insight in different strategies to improve anti-tumor immunity, which can 
potentially improve the effectivity of adoptive T cell therapies.
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Tumor-reactieve effector en geheugen T-cellen hebben het potentieel om kwaadaardige 
cellen te elimineren en kunnen een levenslange bescherming bieden. Het immuun -
systeem van kankerpatiënten is echter niet in staat kwaadaardige cellen te elimineren. 
Daarom is immunotherapie voor de behandeling van kanker gericht op het doen 
herleven of versterken van bestaande en/of provoceren van nieuwe anti-tumor- 
immuun responsen om de anti-tumor immuniteit van de patiënt te versterken. In dit 
proefschrift hebben we verschillende strategieën onderzocht om de anti-tumor 
immuniteit van T-cellen te verbeteren. Door tijdelijke remming van de AKT-signalerings-
route proberen we de werkzaamheid van op T-cellen gebaseerde adoptieve immuno-
therapie en tumor-specifieke vaccinatiestrategieën te verbeteren. Bovendien willen we, 
door ons te richten op een belangrijk immuun-ontsnappingsmechanisme van tumor - 
cellen, tumor-antigeen-specifieke T-celreacties in de lokale tumor-omgeving verbeteren.
In hoofdstuk 2 beschrijven we hoe de verschillende T-cel populaties met een grote 
verscheidenheid aan functionaliteiten kunnen worden onderscheiden door flow-
cytometrie. We rapporteren een overzicht voor de identificatie van CD4+ T-αβ-cellen 
(T-helper (Th) 1, Th2, Th9, Th17, Th22 en CD4+ regulerende T-cellen), CD8+ 
T-αβ-cellen (cytotoxische T-lymfocyt (Tc) 1, Tc2, Tc9, Tc17, CD8+ regulerende T-cellen) 
en hun effectorgeheugenstatus (naïef, stamcelgeheugen, centraal geheugen, effect-
orgeheugen, effector) met behulp van flowcytometrie. Deze verschillende populaties 
kunnen worden onderscheiden op basis van selectieve extracellulaire markers, in 
combinatie met intracellulaire transcriptiefactor en/of cytokinekleuringen. Samen 
vormen deze T cellen een gebalanceerd immuunsysteem met een gecontroleerd 
afweermechanisme tegen bijvoorbeeld pathogenen en kwaadaardige cellen, maar 
met behoud van controle om auto-immuniteit te voorkomen.
 In hoofdstuk 3 en 4 onderzoeken we de ex vivo toepassing van AKT-remming 
om de adoptieve T-cel therapieën te verbeteren. Adoptieve T-cel therapie heeft 
klinisch potentieel aangetoond voor patiënten met kanker, waarbij een effectieve 
behandeling afhankelijk is van de levensduur en  functionaliteit van de geïnfundeerde 
tumor-reactieve T-cellen. Omdat eerdere onderzoeken hebben aangetoond dat ex 
vivo remming van AKT met behulp van de AKT-remmer VIII de CD8+ T-celdifferentiatie 
remt en zorgt voor verbeterde functionaliteit van tumor-specifieke CD8+ T-cellen, was 
het doel van deze studie om deze behandelstrategie verder richting de kliniek te 
brengen. We vergeleken een groep van klinisch toepasbare AKT-remmers met een 
allosterische of adenosine trifosfaat-competitieve werkingswijze. We analyseerden 
fenotype, functionaliteit, metabolisme en het transcriptoom van AKT-geremde CD8+ 
T-cellen met behulp van verschillende T-cel activeringsmodellen. De meeste remmers 
vertoonden geen of gering effect op de expansie van T-cellen terwijl een fenotype 
met vroege geheugencellen werd behouden, wat wordt gekenmerkt door behoud 
van expressie van CD62L, CCR7 en CXCR4. Bovendien lieten transcriptoom profielen 
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zien dat AKT-geremde CD8+ T-cellen veel overeenkomsten hadden met natuurlijk 
voorkomende stamcelgeheugen-CD8+ T-cellen, terwijl controle-T-cellen meer op ef-
fector-geheugen-T-cellen leken. Interessant is dat AKT-geremde CD8+ T-cellen 
verrijking van met hypoxie geassocieerde genen vertoonden, wat paste bij de 
verbeterde glycolytische functie. AKT-remming tijdens minor histocompatibility 
antigen (MiHA)-specifieke CD8+ T-cel priming zorgde ook voor T-cellen met 
kenmerken van vroege geheugendifferentiatie, terwijl ex vivo expansie niet werd 
geremd. Verder vertoonden AKT-geremde MiHA-specifieke CD8+ T-cellen verhoogde 
polyfunctionaliteit met co-secretie van zowel IFNy als IL2 wanneer de cellen opnieuw 
werden gestimuleerd. Samen laten deze gegevens zien dat AKT-remmers met 
verschillende werkingsmechanismen de ex vivo generatie van stamcelgeheugen- 
achtige CD8+ T-cellen bevorderen. Deze cellen hebben een uniek metabolisch 
profiel en behouden polyfunctionaliteit. Akt-remmer VIII en GDC-0068 presteerden 
beter dan andere remmers en zijn daarom veelbelovende kandidaten voor de ex vivo 
generatie van superieure tumor-reactieve T-cellen voor de behandeling van kanker-
patiënten met adoptieve immunotherapie.
 Daarnaast hebben we in hoofdstuk 4 de mogelijkheid onderzocht om ex vivo 
AKT-remming toe te passen op andere adoptieve T-cel therapieën, waaronder 
chimere antigeen receptor of T-cel-receptor geconstrueerde T-cellen. Deze producten 
worden echter meestal gegenereerd vanuit totale CD3+ T lymfocyten, en bevatten 
dus ook CD4+ T-cellen die, afhankelijk van de helper populatie, verschillende effecten 
kunnen hebben op de CD8+ T-cellen. Daarom onderzochten we het effect van 
AKT-remming tijdens CD4+ T-cel expansie, met de nadruk op differentiatie van 
geheugen en T-helper populaties. Akt-remmer VIII en GDC-0068 werden toegevoegd 
tijdens activering en expansie van (naïeve of totale) CD4+, CD8+ of CD3+ T-cellen, en 
vervolgens werden het fenotype, transcriptiefactor profiel, cytokineproductie en 
 expansiecapaciteit geanalyseerd. Interessant was dat ex vivo AKT-remming ook het 
vroege geheugenfenotype van gestimuleerde CD4+ T-cellen behoudt op basis van 
hogere CD62L-, CXCR4- en CCR7-expressie. In de aanwezigheid van AKT-remming 
werd de differentiatie van T-helper populaties echter ook verschoven naar meer 
T-helper 2 ten koste van T-helper 1-cellen. Bovendien was het totale percentage 
cytokine producerende CD4+ T-helpercellen lager in AKT-geremde kweken. De 
verhoogde inductie van T-helper 2-cellen werd ook waargenomen in totale CD3+ 
T-celkweken en met zowel dendritische cel als polyklonale stimulatie. Desalniettemin 
werd een verhoogde expansiecapaciteit, degranulatie en polyfunctionaliteit na 
antigeen restimulatie van AKT-geremde CD8+ T-cellen alleen waargenomen in door 
dendritische cellen gestimuleerde kweken. Belangrijk is dat het gunstige effect van 
AKT-remming op CD8+ T-cel polyfunctionaliteit na dendritische cel-stimulatie 
verminderde in aanwezigheid van AKT-geremde CD4+ T-cellen. Deze bevindingen 
laten zien dat voor ex vivo generatie van superieure polyfunctionele CD8+ T-cellen 
met stamcelgeheugenachtige kenmerken, het wordt aanbevolen om AKT-remming 
toe te passen in afwezigheid van CD4+ T-cellen. 
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AKT-remmers zijn momenteel in ontwikkeling voor in vivo toepassing vanwege hun 
direct remmende effecten op tumorcellen. Dit zou de in vivo toediening van 
AKT-remming in combinatie met tumor-specifieke T-cel stimulatie een interessante 
toepassing maken waarbij kankercellen via meerdere wegen worden aangevallen. In 
hoofdstuk 5 hebben we de combinatie van AKT-remming en OVA-specifieke pepti-
de-vaccinatie in een OT-1-model onderzocht. Eerst werden in vitro de directe effecten 
van AKT-remming op effector en geheugen T-cel differentiatie van CD8+ OT-1 
T-cellen onderzocht. Hier zorgde AKT-remming voor behoud van vroege geheugen-
differentiatie van OT-1 T-cellen, op basis van hogere expressie van CD62L en CD27, 
terwijl minimale effecten op proliferatie werden waargenomen. Verder observeerden 
we verhoogde capaciteit voor oxidatieve fosforylering in AKT-geremde cellen evenals 
verbeterde degranulatie van T-cellen na in vitro restimulatie in afwezigheid van 
AKT-remming. Daarna ontvingen C57BL/6-wildtype muizen adoptieve T-cel therapie 
bestaande uit OT-1 T-cellen in combinatie met OVA-lang-peptidevaccinatie en in vivo 
toediening van de AKT-remmer. Deze studie laat de mogelijkheid zien om vroege 
geheugen CD8+ OT-1-T-cellen te behouden via AKT-remming. Toekomstige studies 
en optimalisatie zijn echter nodig om het potentieel van in vivo AKT-remming voor het 
verbeteren adoptieve T-cel en vaccinatietherapieën verder te onderzoeken. 
 Naast het genereren van krachtige tumor-specifieke T-cellen, is het ook belangrijk 
om het immunosuppressieve mechanisme van tumorcellen te elimineren. Door gebruik 
te maken van onderdrukkende mechanismen, waaronder remmende signalering via 
controlemoleculen, kunnen tumorcellen tumor specifieke T-celreacties onderdrukken. 
Belangrijk is dat systemisch toegediende blokkeringsantilichamen, gericht tegen 
bijvoorbeeld de PD-1/PD-L1-signaleringsroute indrukwekkende klinische resultaten 
bij kankerpatiënten hebben aangetoond. Toch is de negatieve consequentie van het 
systemisch toedienen het risico op inductie van (ernstige) toxiciteit in gezonde 
weefsels. In hoofdstuk 6 hebben we geprobeerd om de PD-1/PD-L1-signalering 
lokaal te remmen in de acute myeloïde leukemie (AML) omgeving door lokale effecten 
van PD-L1 siRNA. Door middel van siRNA/SAINT-RED-transfectietechnologie 
demonstreerden we efficiënte vermindering van PD-L1 in AML-cellijnen evenals in 
AML-cellen van patiënten. Vervolgens werd het functionele effect van de PD-L1 
vermindering in AML op leukemie-reactieve T-celactiviteit onderzocht in co-kweek 
experimenten. We observeerden verhoogde activering van met WT1 TCR mRNA ge-
transfecteerde PD-1+ Jurkat-cellen bij kweken met  WT1+ AML cellen met verminderde 
PD-L1 expressie. Bovendien toonden we significant verbeterde activering, 
degranulatie en IFNy-productie van MiHA-specifieke CD8+ cytotoxische T-cellen aan 
in kweken met MiHA+ AML-cellen met verminderde PD-L1 expressie. Belangrijk is dat 
de vermindering van PD-L1 door middel van siRNA even effectief was als gebruik van 
PD-1-antilichaamblokkering bij het stimuleren van tumor-reactieve T-cel functies. 
Samen tonen deze resultaten aan dat PD-L1 vermindering met behulp van siR-
NA-technologie de immuunreacties tegen AML-cellen verhoogt, waardoor herkenning 
door tumor-reactieve CD8+ T-cellen wordt verbeterd. Dit biedt reden voor de 
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ontwikkeling van gerichte siRNA-toedieningstechnologie om specifiek de lokale 
myeloïde tumormicro-omgeving te beïnvloeden waarbij het risico op het teweeg -
brengen van ernstige toxiciteit wordt beperkt in vergelijking met systemische 
antilichaam toediening. In combinatie met adoptieve T-cel therapie kan deze strategie 
zeer aantrekkelijk zijn om de behandeling van patiënten met myeloïde maligniteiten te 
verbeteren.
Concluderend beschrijft dit proefschrift de preklinische ontwikkeling van verschillende 
immuno-therapeutische strategieën die mogelijk kunnen worden toegepast om de 
anti-tumor immuunrespons te verbeteren. Ex vivo AKT-remming is een krachtig 
hulpmiddel gebleken om stamcelgeheugen CD8+ T-cellen te behouden met poly-
functionele anti-tumor kenmerken. Ook CD4+ vroege geheugen-T-cellen worden 
geconserveerd na AKT-remming. Een verschuiving in de T-helper populatie en 
verminderde CD8+ T-celfunctionaliteit in aanwezigheid van AKT-geremde CD4+ 
T-cellen, toont echter aan dat ex vivo AKT-remming zou moeten worden toegepast in 
afwezigheid van CD4+ T-cellen. Niettemin is in vivo AKT-remming de moeite waard 
om verder te worden onderzocht, omdat het de tumorreductie via meerdere 
mechanismen kan verbeteren. We ontdekten dat CD8+ T-cellen uit het vroege 
geheugen kunnen worden behouden wanneer in vivo AKT-remming en antigeen- 
specifieke T-celvaccinatie worden gecombineerd. Bovendien toonde lokale verlaging 
van PD-L1 expressie verbeterde tumor-specifieke T-cellen responsen. Samen bieden 
zowel tijdelijke AKT-remming om CD8+ T-celfunctionaliteit en levensduur te verbeteren, 
en PD-L1 vermindering twee verschillende en mogelijk complementaire strategieën 
om anti-tumor immuniteit te verbeteren.
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logie van het Anthonie van Leeuwenhoek onder begeleiding van dr. Seth Coffelt en 
prof. dr. Karin de Visser, waarmee ze haar bachelor opleiding in 2012 afrondde. Deze 
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Nu de resultaten van de afgelopen 4 jaar zijn gebundeld in dit proefschrift, wil ik graag 
even stil staan bij alle mensen die hier op hun manier aan hebben bijgedragen. 
Harry, ik wil jou bedanken voor je betrokkenheid en steun tijdens de afgelopen 4 jaar. 
Het PhD traject was voor mij een enerverende tijd waar succesvolle momenten 
werden afgewisseld met moeilijke momenten die horen bij onderzoek doen. Jouw 
betrokkenheid bij het hele traject zorgde ervoor dat ik er altijd in ben blijven vertrouwen 
dat het uiteindelijk goed zou komen. Even een praatje op de gang over hoe alles 
ervoor staat en oprecht blij zijn bij een succes. Dat was voor mij zo belangrijk! 
Ik waardeer het dat je altijd open staat voor nieuwe ideeën en mogelijkheden ziet in 
plaats van problemen. Dit betekent natuurlijk niet dat alles kan worden uitgevoerd, 
maar het leidde wel tot goede discussies waar ik met plezier op terug kijk. We vonden 
elkaar in passie en enthousiasme voor het vak en jouw doel om immunotherapie naar 
de patiënt te brengen is voor mij heel inspirerend.
 Anniek, voortbordurend op jouw promotietraject heb ik mijn uiterste best gedaan 
om het AKT-project verder vooruit te helpen. Ik wil jou bedanken voor het aanleren 
van de kneepjes in het vak op gebied van experimenten doen en schrijven van we-
tenschappelijke artikelen. Dankzij jouw oog voor detail heb ik geleerd dat elke punt 
en komma ‘recht’ moet staan en ben ik er nu zelf ook van overtuigd dat deze details 
belangrijk zijn. Ik wens je veel succes in het onderwijs en ben blij dat je daarnaast ook 
een vervolg zal geven aan het AKT-project. Ik hoop dat hier nog veel mooie resultaten 
mee geboekt zullen worden.
 Willemijn, ik wil jou bedanken voor het meedenken over het AKT-project. Jouw 
kritische input is heel belangrijk geweest voor de voortgang van dit project. Daarnaast 
vond ik het prettig om onder jouw supervisie aan het PD-L1 silencing project te 
werken. Je stroomt over van de ideeën en zet deze snel om in actiepunten, en dit 
maakt dat ik in korte tijd veel van jou heb geleerd op gebied van onderzoek doen. 
Ik waardeer en respecteer jouw gedrevenheid in het vak en neem dit mee als inspiratie 
voor de toekomst.
 Ik wil ook mijn promotor Joop bedanken. Ik wil je bedanken voor de goede voort-
gangsgesprekken naar aanleiding van de diverse LH-retreats en jouw input op de 
verschillende projecten. Ik waardeer jouw leidinggevende capaciteiten met hart voor 
je medewerkers. Je ziet hierin echt de persoon, wat voor mijn onder andere bleek uit 
jouw inzet bij de afronding van mijn promotietraject zodat ik met mijn nieuwe baan in 
Amerika kan starten.
Collega’s, aan jullie heb ik heel veel te danken, in de eerste plaats veel gezelligheid. 
Hanny, dankjewel! De eerste jaren zaten we vaak samen in het kweeklab, en hoewel 
jij niet aan mijn papers kon meewerken was je toch mijn maatje op het AKT-project. 
We hebben het heel gezellig gehad en daarnaast ben jij een super steun geweest. 
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Even vragen hoe het met me gaat, op een drukke dag nog even langslopen voordat 
je naar huis gaat, toch nog even die DCs uit de stikstof halen etc. etc. Ja, de kleine 
dingetjes maken echt het verschil. Het geeft je het gevoel dat je er niet helemaal 
alleen voor staat en dat is zo fijn! Tim en Soley, jullie waren echt mijn matties tijdens 
de eerste 2,5 jaar. Veel gezelligheid, lekker discussiëren over het leven en vooral heel 
veel plezier. Ik kijk terug op een hele goede tijd en ik koester dat nog steeds. 
Jeannette, we shared the office for more than three years, where I appreciated you as 
colleague. Always busy busy busy but also interested in your colleagues. You do 
everything nicely in your own way and I think that’s cool. Jolien, ik vond het heel fijn 
jou als collega te hebben. Even een praatje over de stand van zaken, even lekker 
kletsen. Dat heeft mij echt geholpen in de laatste stressvolle tijden en daar wil ik je 
voor bedanken. Ralph, ik vond het gezellig met jou! Veel gelachen en daarnaast fijn 
dat jij er ook regelmatig was als ik na kantooruren nog druk was. Samen ploeteren is 
sowieso beter dan alleen. Diede, ik vind jou een heel fijn maatje op het PD-L1 silencing 
project. Je hebt een goed oog voor detail en ik laat het project met een gerust hart bij 
jou achter. Ik hoop dat we het artikel binnen niet al te lange tijd mooi kunnen afronden. 
Jesper, we delen toevalligerwijs veel overeenkomsten qua achtergrond maar zijn 
toch ook zo verschillend. Je bent heel goed bezig met de DCs, keep going! Paulien, 
ik vind jou gewoon een heel fijn persoon. Herken bij jou een stukje gedrevenheid en 
frustratie dat dingen niet snel genoeg gaan. Maar het komt sowieso goed! En als ik 
ooit een hematoloog nodig heb dan zou ik heel graag naar jou toe gaan. Paul, super 
sociaal, super gezellig, altijd vrolijk en optimistisch en in voor een biertje. Echt leuk! 
Jolanda, ik vind het heel leuk dat er een nieuwe enthousiasteling in het T cel 
differentiatie veld bij is gekomen op de afdeling. Ik ben benieuwd wat voor interessante 
bevindingen je nog allemaal gaat doen en hou je publicaties zeker in de gaten. Aafke, 
ik vind jou echt een bikkel! Ik vind het heel leuk dat jij tijdens mijn laatste jaar het 
AKT-team bent komen versterken en wil je bedanken voor je inzet bij de revisie van 
het CD4 paper. Daarnaast heb ik me dankzij jou meer in het CAR-T-cel veld kunnen 
verdiepen en hebben we veel van elkaar kunnen leren. Denise, even lekker kletsen, 
dan ben je bij Denise aan het goede adres. Maar ook heel behulpzaam op het lab, 
dankjewel daarvoor. Lisanne, altijd in voor een kletspraatje, en even vragen hoe het 
gaat. Bedankt voor al je interesse op werk maar ook privégebied, je ben een super 
goede collega. Rob, jou wil ik logischerwijs bedanken voor al je hulp op gebied van 
flow cytometry, maar daarnaast ook voor de collegialiteit en niet vergeten voor het 
verzamelen van alle nieuwe roddels. Marij, ik wil jou bedanken voor je betrokkenheid 
en gezelligheid, en het was heerlijk om soms even lekker samen te klagen toen we 
beiden met onze laatste loodjes bezig waren. Daarnaast ben je altijd heel behulpzaam 
geweest, dit maakte echt het verschil op de momenten dat ik (te)veel werk te doen 
had. Dankjewel!
 Ik wil ook alle andere groepen binnen lab Hematologie bedanken. Allereerst wil 
ik iedereen bedanken voor de vriendelijkheid en behulpzaamheid op het lab. Ik vond 
de sfeer en gemoedelijkheid heel prettig. De beenmerg transplantatie unit wil ik 
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me to continue my research career in immunotherapy in this institute. Your enthusiasm 
and joy in doing research is very inspirational. I also want to thank Yun, Jessica, 
Sanjivan, Neal and Nga for all their help and kindness. 
 Ik wil Thorbald van Hall bedanken voor onze samenwerking in hoofdstuk 5. Het was 
me een genoegen om ongeveer 4 jaar na het afronden van mijn laatste masterstage 
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maar dankzij jullie voelde ik me snel thuis in Nijmegen, kon ik lekker mijn hoofd 
leegmaken tijdens het spelen en daarnaast zijn jullie gewoon heel lief en gezellig. 
Mijn lieve vriendinnetjes uit Amsterdam Karima, Nadine, Christa, Daniëlle en Mieke, 
dank jullie wel voor de vriendschap en de vele hele gezellige avondjes! Jullie zijn altijd 
zo geïnteresseerd en ik voelde me door jullie echt gesteund tijdens dit promotie 
avontuur. Cindy en Lian, wat is het leuk dat we elkaar al zo lang kennen, dat schept 
een speciale band. Allemaal totaal wat anders gaan doen, maar blij voor elkaars 
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alles te kletsen wat vooral niet met de wetenschap te maken heeft.
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